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Abstract 
i 
 
ABSTRACT 
 
Inherited platelet disorders vary in their associated bleeding risk.  Individuals in families with 
known platelet gene mutations often have variable bleeding, suggesting that bleeding risk is 
multifactorial. 
Inherited platelet disorders are difficult to diagnose due to the absence of a gold standard 
laboratory technique and their variable bleeding phenotype, which often only manifests after 
haemostatic challenges. 
The work in this thesis furthers the previous studies in the genotyping and phenotyping of 
platelets project by significantly increasing the number of participants, allowing further 
characterisation of inherited platelet disorders in those with a normal platelet count.  A 
bleeding assessment tool score was also recorded in all newly recruited adults. 
Two specific groups of patients are also studied: 
 Those with unexplained menorrhagia, in whom the hypothesis was that some have an 
undiagnosed platelet defect. 
 Those with inherited thrombocytopenia, in whom I sought to develop an assay to 
assess platelet function, as bleeding risk can not be predicted by platelet count alone, 
suggesting that qualitative defects may contribute. 
The genetic basis of platelet defects was investigated in many of the patients, leading to 
identification of mutations in genes known to be critical in platelet biology, and identification 
of several possible novel variants. 
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CHAPTER ONE: GENERAL INTRODUCTION 
 
1.1 Basics of platelet function, signalling and role of platelets in haemostasis and 
thrombosis 
Human platelets are small, anucleated cells that circulate in blood and play a critical role in 
haemostasis and thrombosis.  Their lifespan is approximately 10 days (1), and during this time 
they constantly survey the integrity of the vessel wall.  Normal human platelets are small and 
discoid in shape (0.5 × 3.0 µm), have a mean volume of 7–11 fL, and circulate in relatively 
high numbers (between 150-400 × 10
9
/L) (2-4).  Their small disc shape enables the platelets 
to be marginated towards the edge of vessels so that the majority circulate adjacent to the 
vascular endothelial cells that line all blood vessels (5).  Upon detection of vessel wall 
damage, they undergo rapid and controlled adhesion, activation, and aggregation to form a 
hemostatic plug and thus rapidly prevent blood loss (2, 3).  They also provide a phospholipid 
surface for initiation of the coagulation cascade (6, 7).  Endothelial cells produce a number of 
potent anti-platelet substances (e.g. nitric oxide, prostacyclin, and CD39) that normally inhibit 
vessel wall-platelet interactions (8-10).  Vessel wall damage exposes highly adhesive 
substrates [e.g. P selectin, Von Willebrand factor (VWF), collagen, and many other 
extracellular matrix components], which overcome these inhibitory factors and result in a 
sequence of stepwise events resulting in the formation of a hemostatic plug (11, 12): 
 Initial adhesion, transient rolling of platelets along the vessel wall, and slowing of the 
cells.  Consequently, platelets are more likely to undergo stable adhesion. 
 Platelet activation (if there is more extensive damage or stimuli-promoting platelet 
activation). 
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 Stable adhesion through additional receptor-ligand interactions and integrin activation. 
 Platelet aggregation. 
 Generation of platelet procoagulant activity and stabilization of the hemostatic plug 
via interaction with coagulation factors. 
 Clot retraction 
The process of platelet adhesion, activation and aggregation is depicted in Figure 1.1.. 
 
 
Figure 1.1   Platelet adhesion, activation, and aggregation. (A) Normal endothelium releases anti-
aggregant molecules promoting haemostasis and nonthrombogenic state. (B) Injured endothelium 
exposes platelets to thrombogenic subendothelium. Activated platelets release pro-aggregant 
molecules. (C) Clot formation at site of injury. Endothelium releases factors that stabilize the clot and 
limit the haemostatic process to the site of injury. ADP, adenosine diphosphate; NO, nitric oxide; 
PGI2, prostacyclin; t-PA, tissue plasminogen activator; TxA2, thromboxane A2.  Figure reproduced 
with permission from (13). 
 
The platelets interact with and sense the environment through many types of surface receptors 
(12).  The net balance between activating or inhibitory stimuli thus controls whether platelets 
continue to circulate, begin to reversibly interact with the vessel wall, or become irreversibly 
adherent to either the vessel wall or to each other (2, 3). 
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During adhesion, platelets become activated through signal transduction pathways, which 
mediate shape change, degranulation and spreading upon areas of exposed subendothelium 
(11).  Activated platelets recruit additional platelets into the growing platelet aggregate or 
thrombus via a number of positive feedback pathways, including release of dense granular 
adenosine diphosphate (ADP) and generation of thromboxane A2 (11).  Activated platelets 
also express negatively charged phospholipids on their surface and release microvesicles, 
facilitating the local generation of high amounts of thrombin, which not only further activates 
other platelets, but also stabilizes the platelet plug through fibrin formation via the 
coagulation cascade (6, 7).  In this manner, platelets rapidly seal any areas of vessel wall 
damage and provide a catalytic surface for coagulation to occur, resulting in the formation of 
a stable hemostatic plug. 
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1.2  Platelet receptors, agonists and signalling pathways 
Platelets interact with and sense the environment through numerous surface receptors. These 
receptors are activated by corresponding agonists (or ligands).  Major platelet receptors and 
their agonists are summarized in Table 1.1 overleaf. 
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AGONIST RECEPTOR EFFECT AND PHYSIOLOGICAL ROLE 
Adhesion molecules 
Collagen GP VI Major signalling receptor for collagen 
 21 Supports adhesion by collagen 
Fibrinogen IIb3 Aggregation, spreading and clot retraction 
Fibronectin 51, IIb3 Adhesion through α5β1 
Laminin 61 Adhesion 
von Willebrand factor GP Ib-IX-V, 
IIb3 
Platelet tethering (also fibrinogen) 
Amines 
Adrenaline 2 Positive feedback agonist 
5-HT 5-HT2A Mediates vasoconstriction, positive feedback 
agonist 
Cytokines 
TPO c-Mpl Maturation of megakaryocytes, control of platelet 
number in circulation 
Immune complexes 
Fc portion of antibodies FcRIIA Immune- and bacteria-induced platelet activation 
Lipids 
PAF PAF Positive feedback agonist 
Prostacyclin (PGI2) IP Inhibition of platelet activation 
Thromboxane A2 TP Major positive feedback agonist 
Prostaglandin E2 (PGE2) EP3 Inhibition of platelet activation 
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AGONIST RECEPTOR EFFECT AND PHYSIOLOGICAL ROLE 
Nucleotides   
Adenosine A2a Inhibition of platelet activation 
ADP P2Y1 Early role in platelet activation 
 P2Y12 Major positive feedback receptor 
ATP P2X1 Possible early role in platelet activation 
Proteases 
Thrombin PAR1, PAR4 Coagulation-dependent platelet activation 
Surface molecules   
CD40 ligand CD40 and αIIbβ3 Interaction with other blood cells, role in immune 
response and inflammation 
P-selectin glycoprotein 
ligand 1 (PSGL-1) 
P-selectin Interaction with other blood cells 
Tyrosine kinase receptors 
Podoplanin / possible 
other unknown ligand 
CLEC-2 Role in foetal vascular development 
Possible role in platelet activation in atherosclerosis 
and cancer progression(?) 
EphrinB1 EphA4 and EphB1 Late events in platelet activation(?) 
Vitamin K-dependent 
Gas6 Sky, Axl and Mer Supports platelet activation(?) 
Table 1.1 Major platelet agonists and their surface receptors.  Platelets express a remarkable number 
and variety of receptors for a wide range of ligands. For many of these receptor–ligand combinations, 
however, the effect on platelet activation is weak and of uncertain significance. (?) indicates a putative 
role /effect. 
Originally published in (14).  Adapted version reproduced from (4)) 
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Platelet signalling is a complex process involving many biochemical pathways.  Specific 
types of receptor and their signalling pathways are described below (15): 
 
1.2.1  G protein-coupled receptors (GPCRs) 
These are composed of seven transmembrane domains (and are therefore referred to as 
heptahelical).  They activate heterotrimeric G proteins which are made up of α, β and γ 
subunits.  There are four classes of α subunit (Gαs, Gαq, Gαi and Gα12/13), each of which 
mediate different signalling effects.   When these receptors are activated GDP dissociates 
from the α subunit and allows GTP to bind.  This then allows the α subunit to dissociate from 
the remainder of the complex, allowing it to bind to effector proteins, such as adenylyl cyclase 
and phospholipase C β. 
 
1.2.1.1 Gi proteins 
Gi proteins are abundantly expressed in platelets, and are so named as they inhibit adenylyl 
cyclase (in contrast, Gs proteins stimulate it).  They also have several other effector proteins, 
such as phosphoinositide 3-kinase.  The main Gi coupled receptors in platelets are the P2Y12 
ADP receptor and the α2-adrenoceptor.  Neither of these receptors can mediate activation of 
washed platelets on their own, and both require the presence of feedback mediators to fully 
activate platelets in platelet rich plasma.  In synergy with calcium mobilising receptors they 
can mediate powerful platelet activation, and this effect renders ADP a key feedback agonist 
in regulating in vivo platelet activation. 
The P2Y12 receptor is the target for several drugs (eg ticlodipine, clopidogrel, prasugrel, 
ticagrelor) used in the treatment of cardiovascular disease.  The receptor was cloned in 2001 
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by two separate groups working on human and rat isoforms (16, 17).  Clopidogrel had been 
identified prior to this molecular cloning being reported (18).   Mouse knockout models show 
evidence of increased bleeding (19), and there are now several cases reported in patients 
where increased clinical bleeding is accompanied by a P2Y12 receptor mutation (20-22), as 
discussed in section 1.3. 
Mice deficient in the α2-adrenoceptor are observed to have an increase in tail bleeding time 
(23), however it is generally believed that the P2Y12 receptor has a more significant role than 
the α2-adrenoceptor in positive feedback activating the Gi family of G proteins in platelets 
(24). 
 
1.2.1.2 Gq proteins 
There are two forms of Gq protein, Gq and G11.  Platelets express only the Gq form.  Gq 
deficient mice have been shown to have prolonged bleeding times and platelets that are 
unresponsive to multiple agonists (25).  Gq-coupled receptors activate platelets via a pathway 
that regulates isoforms of phospholipase C β, generating inositol 1,4,5-trisphosphate and 1,2-
diacylglycerol as secondary messengers.  These compounds then mobilise intracellular 
calcium and activate protein kinase C.  The Gq receptors in human platelets that are important 
in physiological platelet activation are the P2Y1 ADP receptor, the thromboxane A2 (TxA2) 
receptor, and the two thrombin receptors, PAR1 and PAR4. 
The P2Y1 receptor synergises with the P2Y12 receptor to mediate full aggregation of platelets 
exposed to ADP as an agonist (26).  It is present in relatively low numbers on platelets 
(approximately 150 copies per platelet).  The P2Y12 receptor is also able to synergise with 
other calcium mobilising receptors. No patients have been reported with a P2Y1 receptor 
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mutation that results in excessive bleeding.  Work in mouse platelets suggests that this 
receptor may be important in thrombus formation (27), suggesting that pharmacological 
agents that antagonise this receptor may represent a novel form of antithrombotic agents (28). 
The thromboxane A2 receptor has two isoforms, although only the α isoform is reported to be 
expressed on the platelet surface (29).  The receptor is activated by thromboxane A2 which is 
a metabolite of arachidonic acid.  Arachidonic acid is liberated by cytosolic phospholipase A2, 
which is activated by elevation of intracellular calcium downstream of Gq coupled receptors 
and tyrosine kinase linked surface receptors.  The thromboxane receptor is a powerful platelet 
activator in synergy with the P2Y12 receptor, and as such is a critical feedback receptor in the 
control of platelet activation.  Aspirin targets this pathway, by inhbiting platelet 
cyclooxygenase-1 and thereby preventing thromboxane formation.  This is of very high 
clinical relevance as aspirin is one of the most commonly taken drugs worldwide, and has a 
very important role in treating and preventing cardiovascular disease.  Half of all adults aged 
45-75 in the United States are reported to take low dose aspirin as a preventative measure 
(30).  A number of patients with bleeding tendencies have been reported to have thromboxane 
receptor mutations (31-34), and studies show prolonged bleeding times in mice who do not 
express the receptor (35). 
The PAR1 and PAR4 thrombin receptors are activated by thrombin, a soluble serine protease.  
The PAR1 receptor plays the major role in activation (36).  Mouse platelets do not express 
PAR1, but do express PAR4 and in addition PAR3.  Thrombin cleaves the N-terminal of the 
PAR1 and PAR4 receptors to expose a tethered peptide ligand.  Receptor activation can be 
replicated by using short thrombin receptor activating peptides, which activate the receptor 
without the need for cleavage.  These peptides can be used to induce aggregation in platelet 
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rich plasma, but thrombin can not (in the absence of GPRP to block fibrin polymerisation) as 
it cleaves fibrinogen to form fibrin and consequently forms a clot rich in platelets.  Thrombin 
is a very powerful agonist and plays a critical role in platelet activation and also in positive 
feedback in the coagulation cascade which takes place on the platelet’s phospholipid surface.  
Once the PAR1 and PAR4 receptors have been cleaved by thrombin they activate Gq and G13 
proteins, leading to regulation of phospholipase C β and Rho kinase.  There are no reports of 
patients with mutations in the PAR1 or PAR4 receptors leading to excessive bleeding, but 
there is evidence that PAR1 and PAR4 polymorphisms alter platelet responses to thrombin 
(37-40). 
Figure 1.2 (overleaf) shows the signalling pathways of GPCR coupled receptors in platelets. 
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Figure 1.2   GPCR-coupled platelet activation signalling. PDE3, phosphodiesterase 3; p115RhoGEF, 
p115 Rho guanine nucleotide exchange factor.  Figure and legend reproduced with permission from 
(41)    
 
Additional abbreviations: 5HT=5-hydroxytryptamine, AC=Adenylyl cyclase, ADP= Adenosine 
diphosphate, Akt= Serine–threonine kinase, also termed protein kinase B [PKB], cAMP= cyclic 
adenosine monophosphate, cGMP= cyclic guanosine monophosphate, DAG=diacylglycerol, IP= 
Inositol phosphate, IP3=Inositol Trisphosphate, MAPKs= Mitogen-activated protein kinases, 
NO=nitric oxide, NOS=nitric oxide synthase, PAR= Protease-activated receptor, PGI2= Prostaglandin 
I2, PI3K = Phosphoinositide 3-kinase, PKC=Protein Kinase C, PKG= Protein Kinase G (cGMP-
dependent protein kinase), PLA2= Phospholipase A2, PLCβ= Phospholipase Cβ, Rap1= Ras-related 
protein 1, RhoA= Ras homolog gene family A, RIAM= Rap1-GTP-interacting adaptor molecule, 
SFK=Src family kinases, sGC= soluble guanylyl cyclase, TP= Thromboxane receptor, TXA2= 
Thromboxane A2. 
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1.2.2 Glycoprotein receptors 
Numerous platelet membrane receptors are glycoproteins.   Amongst these are the           
GPVI-FcR γ chain complex which is the major collagen signalling receptor, GPIb-IX-V 
which is the tethering receptor for von Willebrand Factor (VWF), and αIIbβ3 which is a 
critical platelet integrin and a receptor for a number of proteins including fibrinogen and 
VWF. 
GPVI was recognised as the major platelet collagen receptor after it was demonstrated to 
associate with the FcR γ chain in the platelet membrane (42).  An earlier report had shown 
that a case of autoimmune thrombocytopenia was due to a GPVI autoantibody which 
diminished platelet aggregatory response to collagen (43).  The FcRγ chain contains an 
immunotyrosine based activation motif  (ITAM) that is essential in the signalling process 
after GPVI clusters following collagen stimulation(44).  Src-kinase mediated phosphorylation 
of this ITAM allows binding of Syk and initiation of a pathway which results in powerful 
activation of phospholipase C γ2.   GPVI is a member of the immunoglobulin (Ig) family of 
surface receptors and has two extracellular Ig domains (45).  GPVI levels on the platelet 
surface are believed to be tightly regulated (46).  The interaction between collagen and the 
GPVI receptor is strengthened by the integrin α2β1 in a two step process(47).  The synthetic 
collagen, CRP can activate GPVI independently of the association with α2β1(48).  Both GPVI 
and FcRγ chain deficient mice demonstrate an increase in tail bleeding time (49, 50), and 
mice treated with an anti-GPVI antibody are protected from lethal thrombogenic injections of 
collagen and adrenaline (51).  A small number of mutations in the GPVI receptor in humans 
associated with a bleeding phenotype have been described (52-54). 
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The VWF receptor GPIb-IX-V is highly expressed on the platelet surface, and is composed of 
two units each of GPIbα, GP1bβ and GPIX and one subunit of GPV.  It tethers platelets to 
VWF at intermediate and high shear rates.  Additionally, the GP1bα subunit binds to 
thrombin, allowing it to activate the PAR1 and PAR4 receptors.  When VWF binds to GPIb-
IX-V, weak intracellular signalling events lead to activation of the integrin αIIbβ3.  Patients 
with reductions in or qualitative abnormalities in GPIb (both subunits) and GPIX suffer from 
Bernard Soulier syndrome, a macrothrombocytopenia associated with relatively severe 
bleeding.  A variety of mutations are responsible for this disorder. (55, 56). 
The integrin αIIbβ3 is very highly expressed on platelets, being the most abundant protein on 
them.  It binds to several proteins including VWF and fibrinogen.  These proteins mediate 
formation of a platelet aggregate by cross linking platelets.  αIIbβ3 activation at the platelet 
surface is referred to as inside-out signalling, as opposed to outside-in signalling which results 
from αIIbβ3 clustering and supports several components in platelet activation.  Patients with 
mutations in either of the two subunits suffer from Glanzmann’s thrombasthenia, which is 
characterised by severe bleeding with a normal platelet count.  In a similar fashion to Bernard 
Soulier disease, this condition is also associated with numerous mutations (57, 58).    
Figure 1.3 (overleaf) shows the signalling pathways of glycoprotein receptors in platelets. 
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Figure 1.3.  Signalling pathways of three major platelet adhesion receptors.  sGC, soluble guanylyl 
cyclase; eNOS, endothelial NO synthase.  Figure and legend reproduced with permission from (41) 
 
Additional abbreviations:   Akt= Serine–threonine kinase, also termed protein kinase B [PKB], Btk= 
Bruton's tyrosine kinase, cAMP=, DAG=diacylglycerol, FcγRIIa= FcγRIIa receptor, 
GPVI=Glycoprotein VI, GPCR= G protein-coupled receptors, IP= Inositol phosphate, IP3=Inositol 
Trisphosphate, LAT=Linker for activation of T cells, MAPKs= Mitogen-activated protein kinases, 
NO=nitric oxide, NOS=nitric oxide synthase, PI3K = Phosphoinositide 3-kinase, PKC=Protein Kinase 
C, , PLCγ= Phospholipase Cγ, Rap1= Ras-related protein 1, RhoA= Ras homolog gene family A, 
RIAM= Rap1-GTP-interacting adaptor molecule, SFK=Src family kinases, SLP76=adapter protein 
SLP76, Vav=Vav family proteins, VWF=von Willebrand Factor. 
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1.2.3 Other platelet receptors 
There are a large number of other receptors that are expressed on platelets.  In some cases 
their physiological role is not defined.  Examples of additional receptors include CLEC-2, 
P2X1 and c-Mpl as outlined in Table 1.1.  Mutations in c-Mpl and its signalling molecule 
JAK2 cause congenital amegakaryocytic thrombocytopenia and essential thrombocythaemia 
(a myeloproliferative disorder) respectively (59, 60).  JAK2 inhibitors are currently being 
researched as a treatment option in essential thrombocythaemia (61). 
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1.3  Platelet-based bleeding disorders 
The study of patients with bleeding problems is a powerful approach in determining the 
function and regulation of important proteins in human platelets. The identification of patients 
with defects in the major platelet integrin, αIIbβ3 (57, 62), the leucine rich receptor, the GPIb-
IX-V complex (56, 63, 64) and the immunoglobulin receptor, GPVI (65), played a pivotal role 
in their identification as platelet receptors for fibrinogen, VWF and collagen respectively.   
More recently identification of patients with defects in kindlin-3 (66) and the ADP P2Y12 
receptors (67) have contributed to our understanding of their roles in platelet regulation.  A 
brief reference guide to platelet disorders is outlined in Table 1.2 overleaf. 
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Platelet 
abnormality 
 
Disease Inheritance Defective gene Laboratory and other findings 
 
Platelet adhesion 
 
 
Platelet type von 
Willebrand disease 
 
 
 
 
autosomal 
dominant 
 
 
 
 
GP1BA (17p13.2)  
 
 
 
  
Thrombocytopenia 
Diminished or absent large VWF multimers 
Enhanced ristocetin agglutination (occurs at 
low concentrations), which corrects when 
donor platelets and patient plasma are used 
in mixing studies 
Bernard-Soulier 
syndrome  
 
autosomal 
recessive 
GP9  (3q21.3)  
GP1BA (17p13.2)  
GP1BB (22q11.21) 
Thrombocytopenia with increased MPV 
Anomalies in components of the GPIb-V-IX 
complex 
Platelet aggregation: absent ristocetin-
induced agglutination  
 
Platelet receptor 
defects 
 
P2Y12 ADP receptor  
 
autosomal 
recessive 
(mild phenotype 
in heterozygote) 
P2Y12 (3q25.1) 
 
Platelet count normal 
Platelet aggregation: normal P2Y1 receptor-
driven responses: shape change and transient 
aggregation 
GPVI Collagen receptor 
 
autosomal 
recessive 
 
GP6 (19q13.42)  
 
Platelet count normal  
Platelet aggregation: absent to GPVI-
specific agonists e.g. convulxin and 
collagen-related peptide; and marked 
reduction to collagen 
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Thromboxane A2 
receptor  
autosomal 
recessive 
(mild phenotype 
in heterozygote) 
TBXA2R (19p13.3)  
 
Platelet count normal 
Platelet aggregation reduced in 
heterozygotes to arachidonic acid and 
U44619 and presumed absent in 
homozygotes 
GPIIbIIIa (αIIbβ3) 
(Glanzmann’s 
thrombasthenia) 
 
autosomal 
recessive 
 
ITGA2B 
(17q21.32) 
ITGB3 (17q21.32) 
 
Normal platelet count, size and morphology 
Presents with severe bleeding symptoms in 
early life 
Absent platelet aggregation with all 
agonists; agglutination to ristocetin is 
normal. Flow cytometry with CD41 and 
CD61 antibodies may show reduced levels 
of either GPIIb or GPIIIa 
 
Platelet secretion Hermansky-Pudlak 
syndrome 
 
autosomal 
recessive 
 
HPS1 (10q24.2), 
HPS2/AP3B1 
(5q14.1), HPS3 
(3q24), HPS4 
(22q12.1), HPS5 
(11p14), HPS6 
(10q24.32), 
HPS7/dysbindin  
 (6p22.3), HPS8 
(19q13.32), HPS9 
(15q21.1) 
Platelet count normal 
Skin and hair hypopigmentation  
Reduced/absent δ-granules on electron 
microscopy 
Lumiaggregometry: reduced/absent ATP 
release  
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Chediak-Higashi 
syndrome 
 
 
autosomal 
recessive 
 
CHS1/LYST (1q42) 
 
Platelet count normal 
Skin and hair hypopigmentation 
Immunodeficiency 
Giant inclusions in granulocytes and their 
precursors, reduced or irregular α-granules 
Grey platelet syndrome
  
 
autosomal 
recessive 
 
NBEAL2 (3p21.31)  
 
Thrombocytopenia 
Increased MPV with platelet anisocytosis  
Platelets grey in colour on blood film 
Absent α-granules 
X-linked 
dyserythropoietic anemia 
and thrombocytopenia 
X-linked 
 
GATA1 (Xp11.23) 
 
Thrombocytopenia with increased MPV 
Reduced α-granules 
Anaemia 
Arthrogryposis, Renal 
dysfunction and 
Cholestasis (ARC) 
syndrome 
autosomal 
recessive 
 
VPS33B (15q26.1) 
VIPAS39 (14q24.3) 
 
Thrombocytopenia with increased MPV 
Severe multisystem syndrome, leading to 
fatal complications very early in life 
Absent α-granules 
Paris-
Trousseau/Jacobsen 
syndrome 
 
autosomal 
dominant 
 
FLI1 (11q24.1-
24.3) 
 
Thrombocytopenia with increased MPV 
Developmental delay and facial 
abnormalities 
Quebec platelet disorder autosomal 
dominant 
PLAU (10q22.2) Platelet count at low end of normal range 
α granule protein degradation 
Increased urokinase-type plasminogen 
activator storage in platelets 
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Platelet 
cytoskeleton 
MYH9-related disorders 
(May-Hegglin anomaly, 
Sebastian, Fechtner, 
Epstein syndrome) 
autosomal 
dominant 
 
 
MYH9 (22q12-13) 
 
 
 
Thrombocytopenia with increased MPV 
Döhle-like inclusions in neutrophils 
Nephritis,  hearing loss and cataracts in 
some forms 
Wiskott-Aldrich 
syndrome (WAS) / X 
linked thrombocytopenia 
X-linked WAS (Xp11.23) Thrombocytopenia with small platelets 
Immune deficiency and eczema (in WAS) 
Filamin A disorders 
(Periventricular nodular 
heretotopia/ 
Otopalatodigital 
syndrome) 
X-linked FLNa (Xq28) Thrombocytopenia with raised MPV and 
abnormal platelet morphology 
Abnormal distribution of platelet filamin on 
confocal microscopy 
Actin disorders autosomal 
dominant 
ACTN1(14q24.1) Thrombocytopenia with raised MCV and 
platelet anisocytosis 
Patients either have moderate bleeding 
tendency or may be asymptomatic 
 
Platelet 
procoagulant 
activity 
Scott syndrome autosomal 
recessive 
TMEM16F (12q12-
13.11) 
Platelet count normal 
Anomalies in flippases translocating 
negatively charged phospholipids on the 
plasma membranes. Impaired annexin A5 
binding with flow cytometry 
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Other 
thrombocytopenias
  
Congenital 
amegakaryocytic 
thrombocytopenia 
(CAMT) 
autosomal 
recessive 
 
MPL (1p34) 
 
Severe thrombocytopenia 
Pancytopenia 
Absent megakaryocytes in bone marrow 
Increased plasma thrombopoietin levels 
Thrombocytopenia with 
absent radius (TAR) 
syndrome 
 
Co-inheritance of 
2 mutations 
(behaves as 
autosomal 
recessive) 
RBM8A (1q21.1) 
 
Severe thrombocytopenia 
Normal platelet morphology 
Shortened/absent radii in forearm 
THC2 
 
autosomal 
dominant 
 
MASTL, ACBD5, 
ANKRD26 (all 
10p12.1) 
 
Mild to moderate thrombocytopenia with 
normal MPV 
Platelets deficient in GPIa (subunit of 
collagen α2β1 receptor) and α-granules 
Possible dysmegakaryopoiesis 
Platelet aggregation normal 
Familial platelet disorder 
with predisposition to 
acute myelogenous 
leukaemia (FPD / AML) 
autosomal 
dominant 
RUNX1 (21q22.12) Mild thrombocytopenia, with possible raised 
MPV 
Abnormal aggregation to multiple agonists  
 
GFI1B mutation autosomal 
dominant 
GFI1B (single 
nucleotide insertion 
in exon 7, c880-
881insC – results 
in frameshift 
mutation) 
Red cell anisopoikilocytosis 
Moderate thrombocytopenia, raised MPV 
Decrease in platelet alpha granules 
Absent aggregation with collagen, +/- other 
agonists 
Table 1.2: Brief reference guide to inherited platelet disorders.  Adapted from (68).  ADP: adenosine diphosphate; ATP: adenosine 
triphosphate; GP: glycoprotein; MPV: mean platelet volume; VWF: von Willebrand Factor 
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Megakaryocytes transcribe many thousands of genes which suggests that there are many more 
genes that could potentially be involved in the pathogenesis of bleeding disorders. 
Surprisingly few inherited mutations have been identified in genes encoding proteins that are 
known to play important roles in regulating platelet activation, especially in patients with mild 
bleeding disorders.  Six patients with function disrupting mutations in the stimulatory receptor 
for collagen, GPVI, have been described (52-54).  Two of these are compound heterozygotes, 
and the remaining four unrelated individuals are homozygotes for a gene insertion resulting in 
a premature stop codon.   A small number of inherited mutations in the Gq-coupled 
thromboxane receptor have been reported, all of which are heterozygous for the mutation (31-
34). The number of patients with mutations in the Gi-coupled P2Y12 ADP receptor is now into 
double figures (20-22, 40), with several also being heterozygous. There are no patients with 
mutations in the two PAR receptors, PAR1 and PAR4.  Many of the patients with excessive 
bleeding and heterozygous mutations in the thromboxane and P2Y12 receptors are likely to 
have either a second abnormality or the presence of modifying genetic defects, as some of 
their relatives who also carry the heterozygous change do not have a history of bleeding. 
Further, inhibitors of these two pathways are used widely as prophylaxis and treatment for 
arterial thrombosis but only induce excessive bleeding in a minority of treated patients (69). It 
should also be borne in mind that the second abnormality may not necessarily be a platelet 
defect as illustrated by the presence of heterozygous P2Y12 mutations in patients with type 1 
von Willebrand disease (70). 
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Platelet function disorders are difficult to diagnose and are likely to be under diagnosed (71) 
and therefore under researched.  Several factors have contributed to this including: 
 The absence of a ‘gold standard’ point of care assay of platelet function. 
 The generally asymptomatic presentation of patients with mild defects in platelet 
function who only exhibit symptoms of excessive bleeding when subject to an 
appropriate challenge such as surgery or severe injury.  Women often tend to present 
earlier due to heavy periods (menorrhagia) or excessive bleeding associated with 
childbirth. 
 The considerable redundancy in the pathways underlying platelet activation such that a 
single gene defect may not be sufficient to give rise to excessive bleeding (but may 
become clinically important under challenging conditions e.g. administration of an 
antiplatelet agent). 
 The very limited amount of mRNA that can be recovered from the anucleate platelet 
which severely hampers many standard approaches in molecular biology including use 
of microarrays because of concerns over contamination.   
 The lack of standardisation and quality assurance in platelet function testing, (although 
this has been addressed in some recent publications (72, 73)), in addition to the fact 
that platelet function testing requires fresh blood samples and is labour intensive. 
   
Platelet disorders that give rise to abnormal bleeding may be of genetic origin or may be 
acquired in situations such as ingestion of an antiplatelet agent (e.g. aspirin), liver or renal 
failure or immune dysregulation such as in immune thrombocytopenia purpura.  Diagnosis is 
supported by the nature of the bleeding (with bleeding from mucous membranes being 
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particularly common), by a defect in platelet function (often aggregation), and by the absence 
of abnormal findings in basic coagulation testing (typically prothrombin time and activated 
partial thromboplastin time) and lack of evidence for von Willebrand disease, which is caused 
by a quantitative or qualitative defect in von Willebrand Factor.  In some cases, however, the 
diagnosis of a platelet disorder is based on clinical judgement.  As a result, insight into the 
pathophysiological mechanisms underlying most mild platelet disorders remains limited. 
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1.4 Diagnosis of inherited platelet function disorders 
While the first suspicion of a platelet function disorder (PFD) is made on the clinical history, 
a definitive diagnosis requires demonstration of a laboratory defect in platelet function.  
Historically, the most widely used test was the bleeding time, but not only is this invasive, it 
is poorly reproducible and no longer recommended (72, 74). The modern day ‘gold standard’ 
test for monitoring platelet activation is light transmission aggregometry (LTA), which was 
first described by Born (75). The basic principle has not changed in over 50 years, even 
though modern day aggregometers are much smaller and easier to use (76). The test uses 
anticoagulated (usually citrated) platelet-rich plasma (PRP) or washed platelets and monitors 
the change in light transmission upon agonist addition. The response can consist of several 
components, including an initial increase in optical density brought about by a change in 
platelet shape, followed by a primary, biphasic, sustained or reversible increase in light 
transmission, which is normally mediated by αIIbβ3-dependent aggregation (77). The nature 
of the response is dependent on the agonist, agonist concentration and the feedback action of 
ADP and thromboxane A2 (TxA2).  LTA does require an experienced operator and does not 
pick up many aspects of platelet activation including procoagulant activity and platelet 
spreading. 
A variation of LTA is the addition of luciferin-luciferase reagent to simultaneously monitor 
dense granule secretion (78).  The combination of LTA with assessment of secretion by this 
method is often called lumiaggregometry, and an example trace is shown in Figure 1.4.. 
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Figure 1.4: Example trace of lumiaggregometry.  Lumiaggregometry traces from a patient with a 
heterozygous ADP P2Y12 receptor mutation in the DRY motif predicted to be function disrupting 
(R122H) and from a healthy volunteer (control).   The agonist used in this trace was a high 
concentration of ADP (30µM).   Control aggregation is shown in blue, patient aggregation is shown in 
red.  Control ATP secretion is shown in black, patient ATP secretion is shown in green.  Secondary 
wave of aggregation is seen in the healthy volunteer and is labelled.  The patient shows minimal ATP 
secretion and no secondary wave of aggregation, with deaggregation noted after initial primary wave 
formation.  Addition of the ATP standard to allow calculation of secretion to normalized platelet count 
is also labelled. 
 
 
 
 
General Introduction 
 
Page | 27 
 
Diagnosis of Hermansky Pudlak Syndrome and other dense granule secretory disorders 
cannot be achieved on the basis of aggregation alone as all of the commonly used platelet 
agonists, including ADP and adrenaline, can elicit full aggregation in the absence of secretion 
(72, 79). It should also be borne in mind that a defect in ATP secretion could reflect either 
abnormal granule formation or defective trafficking of granules. Additional tests such as 
electron microscopy, serotonin uptake, and total ATP content, are therefore required to 
distinguish between these two possibilities. 
 
A wide range of other platelet function tests are also available, some of which focus on 
responses to specific agonists and some of which measure a global output of platelet 
activation.  Each places a differing emphasis on the role of primary and secondary 
aggregation and feedback pathways, which explains the subtle distinctions in their results.   
The PFA-200
®
 is a modern update of the original PFA-100
®
 device first released in the mid 
1990’s, based on the prototype instrument developed by Kratzer and Born (80).  All test 
components are within disposable cartridges that are loaded into the instrument at the start of 
the test.  Citrated whole blood is pipetted into the cartridge and, after a short incubation 
period, exposed to high shear (5000–6000/s) through a capillary tube before encountering a 
membrane with a central aperture of 150 m diameter.  The instrument monitors the drop in 
flow rate as platelets form a haemostatic plug that seals the aperture and stops blood flow.  
This parameter is recorded as the closure time (CT).  A number of studies suggest that the 
PFA-100/200

 is a potential in vitro replacement of the bleeding time (80).  The 
disadvantages are that, like the in vivo bleeding time, the test is sensitive to both the platelet 
count and hematocrit, and it is therefore crucial that a full blood count is performed to help 
General Introduction 
 
Page | 28 
 
interpret abnormal results (81).  False negative results are sometimes obtained in milder 
inherited platelet disorders; for example, in patients with Hermansky-Pudlak syndrome and 
the Quebec platelet disorder (80).  Diagnosis of these disorders could therefore be missed if 
relying solely on the PFA-100

 as a screening test (72).  In patients with apparently normal 
platelet function, the instrument has also been shown to occasionally give false-positive 
results, which then require further detailed testing.  Guidelines on the utility and practice of 
using the PFA-100/200
®
 for clinical assessment of platelet disorders have been provided by 
various international and national organizations (72, 80, 82).  The advantages of the test are 
that it is simple, rapid, and does not require specialist training (apart from training in the 
manipulation of blood samples).  It is a potential screening tool for assessing patients with 
many types of platelet abnormalities.  Given the high shear conditions to which platelets are 
exposed during the test, the test is highly VWF-dependent and is therefore abnormal in 
patients with von Willebrand disease (83, 84).  The instrument thus provides laboratories with 
a limited but optional screening tool that can give rapid and reliable data with a relatively high 
negative predictive value (72).  However, further confirmatory testing with light transmission 
aggregation or a von Willebrand profile would be required, and clinicians and researchers 
often opt to proceed directly to these assays (72). 
Whole blood aggregometry measures the change in resistance or impedance between two 
electrodes as platelets adhere and aggregate in response to classical agonists (85).  The 
significant advantage of this assay is that anticoagulated blood does not require further 
processing for analysis.  Commercial multichannel impedance-based aggregometers, such as 
the Chronolog
®
 or Multiplate
®
 aggregometers, provide the ability to characterize several 
pathways of platelet activation in parallel.  The use of these analyzers has seen a rise in 
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popularity in the last decade, but is held back by their dependency on platelet count.  They are 
better established in the monitoring of anti-platelet therapy with some reported associations 
between laboratory findings and clinical outcomes, although these are not robust at present 
and require further investigation (86-88).   At present, clinical guidelines advise against the 
use of platelet function testing for routine monitoring of antiplatelet therapy (89-91). The use 
of whole blood aggregometry analyzers in the diagnosis of inherited platelet defects is limited 
and is seen in specialized laboratories.  Specific guidelines for the use of whole blood 
aggregometry for the diagnosis of platelet disorders are required before this assay can be 
widely implemented. 
A number of platelet function assays have been developed over the years to be used at the 
patient’s bedside (85).  Most of these assays were specifically developed for monitoring of 
antiplatelet therapy, and the experience with these assays in identifying platelet defects is 
limited.  The VerifyNow
®
 device, a fully automated and near patient testing aggregation 
system, is available solely for the monitoring of the three major classes of anti-platelet drugs 
(e.g. GPIIb/IIIa inhibitors, aspirin, and P2Y12 receptor inhibitors/antagonists) using specific 
cartridges (92).  Plateletworks®, a standardized platelet counting ratio technique, based upon 
comparing platelet counts within a control EDTA tube and after aggregation with platelet 
agonists within citrated tubes, could theoretically also be applied to the diagnosis of platelet 
disorders, although experience with this assay is limited (93).   Thromboelastography
®
 (TEG) 
provides various data relating to clot formation and fibrinolysis (the lag time before the clot 
starts to form, the rate at which clotting occurs, the maximal amplitude of the trace or clot 
strength and the extent and rate of amplitude reduction) (94).  With the PlateletMapping
TM
 
system, arachidonic acid and ADP can be used as agonists to pre-activate platelets within the 
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TEG system, thus making the assay theoretically suitable to monitor antiplatelet drugs, 
although the test lacks sensitivity to detect moderate changes in platelet function (95).  Its use 
is currently mostly limited to the monitoring of surgical haemostasis.  A recent study within 
the GAPP group examined the utility of the 96 well plate aggregation assay (known as 
Optimul
®
) in diagnosing platelet defects and found it to have good correlation with 
lumiaggregometry (96).  Further studies within the group have looked at the feasibility of a 
flow cytometric whole blood platelet function test which can be performed remotely (after 
samples are fixed and posted to a central laboratory), and concluded that it may be a helpful 
screening test in determining who should go on to have extensive lumiaggregometry studies 
(97). 
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1.5 Genetic sequencing of patients with platelet disorders 
The Birmingham Platelet Group has previously identified several patients with function-
disrupting mutations in the P2Y12 ADP receptor and the TxA2 receptor (98). Strikingly, three 
of these mutations have been shown to be co-inherited with the most common forms of 
bleeding disorder, type 1 von Willebrand’s disease, which is caused by a quantitative defect in 
von Willebrand factor (70). Thus, mild bleeding may often be multifactorial and should be 
considered to be a complex trait, drawing comparisons with the multifactorial aetiology of 
thrombosis (Figure 1.5).  
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Figure 1.5 – The multifactorial aetiology of bleeding, encompassing genetic, acquired and 
environmental factors  
 
The success in identifying mutations was initially achieved by targetted sequencing of 
candidate genes identified by investigation of light transmission aggregation and ATP 
secretion, together with other testing methods such as flow cytometry and electron 
microscopy.  Sequencing of the relevant genes in a population enriched for bleeding (i.e. von 
Willebrand disease) was also used (70).   More recently, whole exome sequencing has been 
used to identify genes associated with an abnormal platelet phenotype (99-101). This 
approach to gene mapping of platelet disorders based on initial evaluation of clinical and 
laboratory phenotypes of patients with clinically diagnosed bleeding disorders and subsequent 
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targeted gene sequencing is referred to as the GAPP [genotyping and phenotyping of platelets 
(102)] approach and is summarised in Figure 1.6. 
 
Figure 1.6 – GAPP approach to investigating patients with platelet disorders showing initial sample 
collection and lumiaggregometry studies, in addition to examples of further testing methods.  
Modified from (98).  Figure courtesy of Professor Steve Watson. 
 
In cases where the location of the underlying mutation is strongly suspected direct Sanger 
sequencing of candidate genes can be used to identify the defect.  This is most applicable in 
the situation where there is selective loss of response to one agonist, suggesting an 
abnormality in its cell surface receptor.  However, the fact that some defects are partial 
(function disrupting rather than ablating) and the complicated feedback pathways in platelet 
signalling often complicate this interpretation.  Examples of mutations identified in this way 
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within GAPP include discovering a homozygous mutation in the ADP P2Y12 receptor (where 
deaggregation to high dose ADP was seen) (103) and a heterozygous function disrupting 
point mutation in the thromboxane receptor in a patient who had markedly reduced responses 
on testing with arachidonic acid and U46619, a direct stimulant of the thromboxane receptor 
(33). 
Next generation DNA sequencing (NGS) has led to major advances in the ability to sequence 
large amounts of genetic material (104), and has made sequencing of whole exomes 
financially viable (68).  However, expert interpretation of the data generated is required as 
huge amounts of information are returned, and comparison to datasets containing known 
candidate function disrupting mutations is required (105).  Confirmatory Sanger sequencing 
of the patient with the bleeding disorder and both affected and unaffected family members 
further supports genotype-phenotype association.   Limitations of this approach include the 
fact that several candidate disrupting mutations may be present, family members may be 
unavailable or unwilling to be tested, the sequencing methodology may not be fully optimised 
and reference databases may themselves not be completely contemporaneous (106).  In 
addition, mutations outside the exome (such as in regulatory regions) will not be identified, 
and GC rich regions can lead to incomplete coverage and failure to capture some mutations.  
When a candidate mutation is identified the role of the implicated protein in platelet function 
may not be known, and cell line expression models to evaluate its role are required.  This is 
important to attribute pathogenesis to the identified mutation, as healthy volunteers are known 
to be heterozygous for several function disrupting mutations which are not associated with 
any disease state (107). However, even if a functional defect can be related to the mutant 
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protein, it may be that the combination of additional, possibly heterozygous, mutations that 
give rise to the overall bleeding pathogenesis.   
In genetically related individuals, autozygosity mapping is one technique where NGS can be 
used to identify autosomal recessive mutations. The basis of this approach is that affected 
family members have common regions of autozygosity encompassing the disease-causing 
mutation. Restricting analysis of nonsense and missense single nucleotide polymorphisms to 
regions of autozygosity increases the speed of identifying causative genes in families with 
consanguineous marriages, which are commonly found amongst patients with inherited 
bleeding disorders.  Patients in these families will share thousands of nonsense and missense 
SNPs.  
This methodology has previously been used in identifying Hermansky Pudlak syndrome 8 
(108).  In cases with more than one candidate gene such as Hermansky Pudlak syndrome, use 
of microsatellite markers can further aid mapping of the causative mutation (109).  
Autozygosity mapping has also led to identification of ANKRD18A and NBEAL2 as causative 
genes in a families with thrombocytopenia associated with severely reduced platelet counts 
and platelet dysfunction, and grey platelet syndrome respectively (110-113). 
Next generation sequencing has also been used in investigating the mutations responsible for 
TAR (thrombocytopenia and absent radius) syndrome.  Patients with this condition have 
abnormal forearm development due to the absence of a radial bone in addition to a mild 
bleeding disorder with thrombocytopenia.   Gene mapping revealed a heterozygous 
microdeletion on the long arm of chromosome 1 in the gene RBM8A (114),  but some family 
members with this mutation did not have the disorder.  NGS was used to identify a second 
mutation in the regulatory region of RBM8A in individuals with this disease (115). This 
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mutation in the second allele was found in 53 out of 55 cases and was associated with reduced 
expression of the protein. 
NGS can be used in families with bleeding disorders suspected to be inherited in an 
autosomal dominant manner by sequencing affected and unaffected family members and 
examining novel variants which co-segregate with those individuals with excessive bleeding.  
There are relatively few autosomally dominant inherited bleeding disorders.   
The application of NGS to unrelated individuals is a challenge and requires large numbers of 
patients with similar clinical characteristics.  This is currently under study in both national 
and international studies (101, 116, 117).  The ability to clearly phenotype unrelated patients 
should assist in the search for a causative gene, as it narrows the number of possible causative 
candidate genes.  A similar approach has been successfully used in identifying mutations in 
GATA-2 as being responsible for causing an inherited immunodeficiency syndrome with 
predisposition to leukaemic transformation.  In this case four unrelated individuals were 
studied using whole exome sequencing (118). 
Clear phenotyping would also allow the use of targeted arrays in identifying the responsible 
gene, such as an array of 200 candidate genes for defective platelet activation that was 
generated within the GAPP project (119).  This was used to identify a novel HPS4 mutation 
in a patient with clinically suspected HPS and supporting laboratory changes in phenotype 
that demonstrated lack of dense granule secretion (119).  However, as whole exome 
sequencing comes down in cost this may be a more attractive option than using targeted 
arrays for initial screening, with confirmatory Sanger sequencing and use of cell line studies 
for further investigation of candidate mutations.  
Aims of PhD study 
 
Page | 37 
 
1.6  Aims of PhD study 
1. To create a multi-centre clinical network with coverage of haemophilia centres across 
the United Kingdom (three participating centres were registered at the start of my 
research fellowship in 2010).  The increase in centre numbers was necessary to allow 
the study of inherited platelet disorders, which are rare diseases with only small 
numbers of patients registered at each centre. 
2. To better define the normal range of platelet aggregation responses in healthy 
volunteers, including assessment of whether measuring secretion using Chronolume
®
 
during lumiaggregometry effects aggregation measurements. 
3.  To rationalise lumiaggregometry laboratory testing in platelet disorders with normal 
platelet number, producing a recommended testing algorithm for investigation of 
patients with a suspected platelet disorder. 
4. To classify platelet defects in patients with a normal platelet count included in the 
GAPP study. 
5. To assess bleeding scores in patients with and without platelet disorders to establish 
whether a raised score is indicative of an underlying defect. 
6. To undertake genotyping of selected patients found to have an abnormal phenotype to 
uncover genes involved in platelet function and megakaryopoiesis (using Sanger and 
second generation sequencing technology). 
7. To establish whether there is a significant prevalence of undiagnosed platelet function 
defects in patients with unexplained menorrhagia. 
8. To develop a new assay to allow for testing platelet function (ie presence of qualitative 
defects) in patients with thrombocytopenia.
Methods 
 
Page | 38 
 
CHAPTER TWO: METHODS 
2.1  NHS Permissions and patient recruitment 
2.1.1 NHS Permissions 
Retrospective approval for incorporation of the GAPP project into the National Institute of 
Health Research Portfolio (Non-Malignant Haematology subgroup, ID 9858) was obtained in 
February 2011, based on the fact that the study met a relevant clinical need.  This approval 
enabled access to support from the Comprehensive Local Research Networks (CLRNs), and 
Birmingham and the Black Country CLRN was elected as lead network for the study.  NHS 
Permissions were then obtained at over fifteen new centres using the Integrated Research 
Application System (IRAS), allowing coverage across most of the United Kingdom.  Testing 
continued to be performed at the three central laboratories in Birmingham, Bristol and 
Sheffield, with blood samples being sent by courier to the central laboratory in Birmingham 
for recruits from the newly approved centres. 
For centres at a travelling distance of more than four hours, recruitment and investigation was 
done in the local haemophilia unit and laboratory using on site testing, as the results obtained 
couriering blood may have been affected by the delay between venepuncture and PRP 
preparation.   
A secure portal was devised to allow data sharing across the three sites where the grant 
principal investigators were based (Birmingham, Bristol and Sheffield) using the National 
Institute of Health Research database. 
Numerous revisions to the study protocol, patient information sheets and consent forms were 
undertaken to allow for expansion in the scope of GAPP, all of which were reviewed and 
approved by the West Midlands Research Ethics Committee (reference 06/MRE07/36).  The 
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study was also registered with ISRCTN (reference 77951167).  An example patient 
information sheet and consent form are shown in Appendix 1.  Study reports containing a 
summary of bleeding history, laboratory findings and a conclusion on the platelet phenotype 
were produced on every recruited patient (as per the study protocol) and were returned to the 
referring consultant. 
 
2.1.2 Patient recruitment 
This section describes the patient recruitment procedure for patients with a normal platelet 
count and a suspected inherited platelet disorder.  Recruitment processes for patients with 
menorrhagia and inherited thrombocytopenia are discussed in Chapters 8 and 9 respectively. 
 
Potential participants with suspected platelet function defects were referred from UK 
Comprehensive Care Haemophilia Centres and were invited to participate if they satisfied all 
the following inclusion criteria: 
a. Aged 0 – 85 years 
b. Abnormal bleeding symptoms compatible with a possible inherited platelet 
function disorder (ranging from spontaneous bruising and easy bleeding to life 
threatening bleeding episodes requiring transfusion) 
c. Platelet count within the local laboratory reference range 
d. Results from coagulation factor tests within local laboratory reference intervals 
(minimum panel of prothrombin time, activated thromboplastin time, Clauss 
fibrinogen activity, von Willebrand factor antigen level, Ristocetin cofactor 
activity and FVIII:C activity)  
e. Willing to participate and able to provide informed consent 
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Exclusion criteria were as listed below: 
a. Patients with existing diagnoses of Glanzmann’s thrombasthenia, Bernard-Soulier 
syndrome, May Hegglin anomaly or Hermansky-Pudlak syndrome 
b. Patients taking drugs that are known to influence platelet function, including 
nonsteroidal anti-inflammatory drugs, aspirin, clopidogrel and dipyridamole within 7 
days of enrolment 
c. Patients having undergone a major surgical procedure within 1 month of enrolment. 
d. Patients with chronic renal failure requiring dialysis 
e. Patients with severe anaemia (Haemoglobin < 80g/l) 
 
After informed written consent (in accordance with the declaration of Helsinki), participants 
were interviewed to determine the distribution, frequency and severity of bleeding episodes.  
 
Healthy volunteers aged 18 years or older were also included in the study. Participants were 
considered healthy if they did not have a history of bleeding symptoms and did not require 
long-term medical therapy.  All healthy volunteers denied taking drugs known to influence 
platelet function in the 2 weeks prior to recruitment. 
 
The ISTH bleeding assessment tool (Appendix 2) was used for objective assessment of the 
participants’ bleeding history.  This score can range from 0-56 in women and 0-48 in men, 
based on a maximal score of 4 in fourteen separate categories assessing different types of 
bleeding. 
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The questionnaire was carried out in both patients and in healthy volunteers, and was 
conducted by a small number of key trained personnel (of which I was one) who regularly 
took bleeding histories in study participants.  The bleeding assessment scores were compiled 
prior to undertaking platelet function testing so that investigators were not influenced by 
lumiaggregometry results when assessing and quantifying the bleeding history. 
 
2.2 Platelet preparation and assessment of platelet function 
2.2.1 Platelet preparation 
Blood samples from participants and a simultaneous healthy volunteer (control, recruited 
from the same site as the patient) were taken into trisodium citrate (3.2-3.8%) with a 
trisodium citrate:whole blood ratio of 1:9.  Total volume of blood taken ranged from 15-60ml 
dependent on the age of the patient, their clinical status and the discretion of the referring 
clinician.  Blood drawing was performed using either a syringe or an evacuated test tube 
system (either Vacutainer or Sarstedt), and was undertaken with caution to avoid prolonged 
venous stasis, using a large-bore needle (between 19 and 21 gauge).   
The collected samples were then gently inverted to ensure complete mixing of the content.  
They were transported at ambient temperature (~20˚C) to the laboratory, using a courier 
service (DHL) for centres outside of the Midlands.  For centres in Newcastle and Edinburgh 
testing was performed in the local haematology laboratory due to the prohibitive travelling 
distance.   
Platelet rich plasma was prepared by transferring whole blood samples to 5ml polypropylene 
tubes using a Pasteur pipette, with subsequent centrifugation of whole blood at 200g for 20 
min. Autologous platelet-poor plasma was obtained by further centrifugation at 1000g for 10 
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min.  Buffy coat samples were aliquoted after removal of platelet poor plasma and were 
stored at -80ºC to allow for future genetic work. The platelet count in PRP and mean platelet 
volume were assessed with a Coulter Z2 analyser (Beckman Coulter (UK) Ltd).   
 
2.2.2  Assessment of platelet function 
Platelet aggregation and ATP secretion were measured in PRP using a dual Chronolog 
lumiaggregometer (Model 460 VS, Havertown, PA, USA). Autologous platelet poor plasma 
(PPP) was used to set the aggregation scale prior to each study according to the 
manufacturer’s instruction. All experimentation was performed within six hours of 
preparation of the PRP.    ADP and adrenaline responses were always tested first as their 
responses are the most time dependent.  PRP samples (400µl) were pre-warmed in siliconized 
glass cuvettes (Ladmedics, Manchester, UK) at 37˚C for 120s and stirred at 1200rpm for 60s 
prior to agonist addition.  Recording of aggregatory responses was undertaken for five 
minutes after agonist addition, with the exception of adrenaline responses which were 
recorded for up to ten minutes after agonist addition.  When a chart recorder was used, 
percentage aggregation was calculated by the observed change in optical density compared to 
the full scale deflection as set by the PPP control.  Latterly, responses were assessed using the 
AggroLink computer interface (ChronoLog / LabMedics UK) with the AggroLink for 
Windows software (version 5.2.3).  Parameters assessed using this software were maximal 
aggregation, final aggregation (to assess whether deaggregation occurred), and area under the 
aggregatory curve (to assess overall magnitude of aggregation response). 
Reagents used and their sources, stock and final concentrations are listed in Table 2.1.   
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Agonist Stock 
concentration 
Final concentrations 
tested (in cuvette) 
Source 
ADP 10 mM 3µM, 10µM, 30µM  Sigma-Aldrich 
A2754 
Adrenaline 100 mM 3µM. 10µM and 
30µM 
Sigma-Aldrich 
E-4375 
Arachidonic 
acid 
15 mM 0.5mM, 1mM and 
1.5mM 
Cayman Chemical 
10006607 
PAR1 peptide 
(TRAP - 
SFLLRN) 
10 mM 30µM and 100µM Commercial synthesis, e.g. 
Alta Biosciences, 
Birmingham 
PAR4 peptide 
(TRAP - 
AYPGKF) 
50 mM 250µM and 500µM Commercial synthesis, e.g. 
Richard Farndale, 
Cambridge 
Ristocetin 50 mg/ml 1.5mg/ml Helena Laboratories 
5372 
U46619 1 mM 1µM and 3µM Cayman Chemical 
CAY16450-5 mg 
Collagen 1 mg/ml 3µg/ml and 10µg/ml Nycomed- Austria 
NYAR 1130630 
Collagen-related 
peptide 
3 mg/ml 1µg/ml and 3µg/ml Commercial synthesis, e.g. 
Richard Farndale, 
Cambridge 
Table 2.1   Agonists used in platelet function testing, with their stock concentrations, final 
concentrations and source listed. 
 
 
All stock agonists apart from collagen and collagen-related peptide were kept at -80˚C and 
diluted with phosphate buffered saline.  Collagen and collagen related peptide were kept at 
4˚C and diluted with their specific diluents.  Reagents were kept on ice throughout the 
aggregation testing, and were diluted from stock concentrations during the platelet preparation 
time.  Each patient would not always have all concentrations of each agonist tested, dependent 
on available sample volume and responses to the lowest concentrations of each agonist.  In 
rare circumstances, with lack of response at the highest agonist concentration listed in the 
table, a higher concentration again was tried in order to attempt to elicit a response. 
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Measurement of secretion was carried out by adding 30µl of Chronolume
®  
(Chronolog 
corporation, Havertown, PA, USA / Labmedics, Manchester, UK - containing 0.2 mg 
luciferin, 22,000 units d-luciferase plus magnesium sulphate, human serum albumin, 
stabilizers and buffer) to the highest concentration of each agonist tested.  Chronolume
®
 was 
diluted according to the manufacturer’s instructions and added to the cuvette during the 
prewarming and stirring process (120s before agonist addition).  The ATP secreted was 
recorded using the Chronolog aggregometer (model 460VS), and was quantified by adding a 
known amount (4nmol) of ATP standard (Chronolog corporation, Havertown, PA, USA / 
Labmedics, Machester, UK).  Calculated secretion was normalised and expressed as 
nmol/1x10
8
 platelets.  Latterly, secretion responses were assessed using the AggroLink 
computer interface (ChronoLog / LabMedics UK) with the AggroLink for Windows software 
(version 5.2.3).  Parameters assessed using this software were time to secretion and 
standardised secretion. 
 
2.3  Statistical analyses 
Statistical analyses was carried out using Microsoft Excel 2007, GraphPad Prism 4 and IBM 
SPSS Statistics 19, with testing methodologies as specified in figure legends (dependent upon 
the data being interrogated).  P-values were considered to be significant if they were ≤0.05. 
 
2.4 Genetic and receptor expression studies 
Genetic and receptor expression studies were carried out by Neil Morgan and Stuart Mundell 
respectively (along with their laboratory teams), and are outlined in publications which they 
and I have co-authored (34, 40, 99, 109, 117).
Results – Creation of a multi-centre study 
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CHAPTER THREE: CREATION OF A MULTI-CENTRE NATIONAL STUDY 
ENABLING FURTHER GENOTYPING AND PHENOTYPING OF PLATELETS 
3.1 Introduction 
Prior to commencement of my research fellowship, the GAPP project had recruited 126 
participants (patients and healthy volunteers) over a four year period.  These recruits had 
come from three registered Haemophilia Comprehensive Care Centres in Birmingham, Bristol 
and Sheffield.  The target recruitment for the study was 600 participants, with a planned end 
date of December 2015. 
Several publications had arisen from this work, examining normal ranges for aggregation and 
secretion and describing phenotypic and novel genetic findings in recruited patients (15, 33, 
77). 
As inherited platelet disorders are rare, collaboration with more United Kingdom (UK) 
Haemophilia Centres was recognised as being critical to obtain sufficient numbers of patients.  
In addition, having good geographical coverage of Haemophilia Centres across the UK would 
ensure that the study was accessible to as many patients and clinicians as possible.   
 
3.2  Aim  
To create a multi-centre clinical network with coverage of haemophilia centres across the 
United Kingdom, allowing improved recruitment to the GAPP study. 
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3.3 Results 
Figure 3.1 shows the fifteen additional centres where NHS Permissions were received as a 
result of the multi centre expansion, with good geographical coverage of the United Kingdom 
achieved.  Figure 3.2 shows the improved accrual rates to the study as a result of this 
expansion, with actual recruitment exceeding projected target recruitment by September 2012.  
Participating centres (as of 2013) along with their local Principal Investigators are listed in 
Table 3.1. 
 
Figure 3.1  Map showing GAPP project collaborating centres (as of October 2013).  Red triangle 
with exclamation mark shows coordinating CLRN (Birmingham and the Black Country), and red map 
pins show central laboratories for phenotyping (Birmingham Platelet Group, Royal Hallamshire 
Hospital [Sheffield] and Bristol Royal Infirmary). Green markers show sites with approved NHS 
Permissions, and yellow markers show sites with NHS Permissions submitted but final approval 
pending. 
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Figure 3.2  Recruitment to the GAPP study over time. Black triangles show projected or target 
accrual. Red / amber / green line shows actual accrual, coded according to whether recruitment fell 
within the NIHR red (less than 65% target), amber (65-80% target) or green (over 80% target) zones.  
As of September 2012 the project was recruiting to over 100% of its time projected targets.  Dotted 
black line shows target total accrual (600 participants).  Dashed burgundy arrow shows time of 
incorporation into the National Institute of Health Research portfolio (Non Malignant Haematology 
Specialty Group) and dotted burgundy arrow shows time of adoption of the study into a lead network 
model by Birmingham and the Black Country CLRN. 
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Participating Centre Principal Investigator 
Birmingham Children’s Hospital NHS Foundation Trust Dr Mike Williams 
Birmingham Women’s NHS Foundation Trust Dr Will Lester 
Cardiff and Vale University Health Board Professor Peter Collins 
Central Manchester University Hospitals NHS Foundation Trust Dr Jecko Thachil 
Great Ormond Street Hospital for Children NHS Foundation 
Trust 
Dr Paul Gissen 
Guys’ and St Thomas’ NHS Foundation Trust Dr Steve Austin 
Hull and East Yorkshire Hospitals NHS Trust Dr David Allsup 
Imperial Healthcare NHS Trust (Hammersmith Hospital)* Dr Nichola Cooper 
Leeds Teaching Hospitals NHS Trust Dr Beki James 
Midlands Research Practices (General Practice) Consortium 
(MidReC) 
Professor David Fitzmaurice 
Newcastle Hospitals NHS Foundation Trust Dr Kate Talks 
NHS Lothian (Royal Infirmary Edinburgh and Royal Hospital for 
Sick Children) 
Dr Angela Thomas 
Nottingham University Hospitals NHS Trust Dr Gerry Dolan 
Oxford University Hospitals NHS Foundation Trust Dr David Keeling 
Royal Devon and Exeter NHS Foundation Trust Dr Jason Coppell 
Royal Liverpool and Broadgreen University Hospitals NHS 
Foundation Trust 
Professor Cheng Hock Toh 
Sheffield Children’s NHS Foundation Trust Dr Jeanette Payne 
Sheffield Teaching Hospitals NHS Foundation Trust Professor Mike Makris 
University College London Hospitals NHS Foundation Trust Dr Elaine Murphy 
University Hospital Birmingham NHS Foundation Trust Dr Jonathan Wilde 
University Hospitals Bristol NHS Foundation Trust Dr Andrew Mumford 
University Hospitals Coventry and Warwickshire NHS Trust Dr Peter Rose 
University Hospitals of Leicester NHS Trust Dr Sue Pavord 
Table 3.1 Centres participating in the GAPP study and their local principal investigators, as of 
October 2013.  Centres marked with a * had pending NHS Permissions, with the relevant documents 
submitted to the Trust Research and Development Departments. 
 
 
 
Results – Creation of a multi-centre study 
 
Page | 49 
 
3.4 Discussion 
The approach and resultant increase in recruitment reported in this chapter highlight the need 
to study rare diseases using a multi-centre approach, using national research networks to 
identify valuable support (120).  Sponsorship of the project by the Birmingham and the Black 
Country Comprehensive Local Research Network (as a “lead network”) aided the process of 
gaining NHS Permissions at new sites, and meant that the study was accessible to both 
patients and clinicians across the UK.  The processes described here and significant 
improvement in accrual rates led to the GAPP study being identified as “Study of the Month” 
in the October 2012 edition of “Specialty Group News”, a national publication circulated by 
the NIHR describing research in all clinical specialties (121). 
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CHAPTER FOUR: ASSESSMENT OF PLATELET AGGREGATION AND 
SECRETION IN HEALTHY VOLUNTEERS 
4.1  Introduction 
A major challenge in the use of lumiaggregometry in the investigation of PFDs is the wide 
variation observed in responses of healthy volunteers (77, 122). Thus, the common practice of 
comparing results in the patient to a healthy volunteer analysed at the same time can often be 
misleading in the absence of locally determined normal ranges (72). Other factors that can 
influence the response include the platelet count, although previous work in GAPP has shown 
that this is not significant in PRP over the range 1.5–6.0x106/ml (77).  This is in line with 
recent literature suggesting the use of native PRP to be superior to PRP diluted to a standard 
platelet count (123, 124). However, the level of ATP secretion is platelet count-dependent, 
thus making normalisation to platelet count necessary (103). Below a platelet count of 
1.5x10
8
/ml platelet function is hard to assess by aggregometry, and there is a paucity of data 
surrounding responses of control individuals at these platelet counts. 
Previous work in GAPP compiled response data to a minimum of three concentrations of 9 
platelet agonists and established normal ranges with cut-offs.  Readings for these ranges were 
obtained by using a chart recorder and manually measuring and calculating responses (77, 
103)) .  
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4.2  Aims 
 To define normal platelet aggregation and secretion responses in a new cohort of 
healthy volunteers recruited to the GAPP study using Aggrolink
®
 software. 
 To establish whether distance travelled by the sample has an impact upon aggregation 
findings in healthy volunteers. 
 
4.3  Results (125) 
The platelet aggregation and secretion responses [using the rationalized agonist panel with a 
minimum of twelve independent dose points (103)] of 68 healthy volunteers recruited to the 
GAPP study between December 2011 and March 2013 were characterized.    For further 
information on the rationalised agonist panel development and validation, see Chapter 5.  All 
participants had had their aggregation and secretion responses recorded using Aggrolink
®
 
software.  35 participants (51%) were female, 19 (28%) were male, and sex was not stated on 
the consent form for the remaining 14 (21%).  Age was available on 19 participants, with a 
median of 32 years and interquartile range of 3 years.   
 
The 5
th
 percentile for platelet count in PRP was 200x10
9
/l, with the 95
th
 percentile lying at 
556x10
9
/l. (Figure 4.1).  Mean platelet volume ranged from 8.2 to 10.3fl (5
th
 to 95
th
 
percentile), as shown in Figure 4.2.   
In general, higher concentrations of agonists resulted in narrow reference intervals, but lower 
agonist concentrations were significantly more variable, especially for ADP (Figure 4.3), 
Collagen (Figure 4.4) and Arachidonic Acid (Figure 4.5).   Approximately 10% of 
participants did not show secondary wave aggregation to Adrenaline (Figure 4.6).  A lack of 
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full response to ristocetin was seen in 6/61 individuals (10%), with a biphasic response in 
24/61 individuals (39%), as detailed in Table 4.6.  The impact of distance travelled by the 
sample on aggregation was examined, and transport over 100 miles did not alter platelet 
aggregation responses to the most variable dose points – ADP 3µM, adrenaline 10µM, 
collagen 1µg/ml and PAR-1 peptide 30µM.  There was no effect of distance travelled by the 
sample on deaggregation to ADP 3µM (Figure 4.7). 
The data obtained is summarised in numerical form in Tables 4.1 (ADP responses), 4.2 
(Adrenaline responses), 4.3 (Arachidonic Acid responses), 4.4 (PAR-1 peptide responses), 4.5 
(collagen responses) and 4.6 (ristocetin responses). 
A. 
 
B. 
 
 
Figure 4.1 Platelet count in PRP.  For panel A, bars represent median and interquartile range.  For 
panel B, box represents median and interquartile range, whiskers represent 5
th
 and 95
th
 percentiles, 
outlying points represented by dots.  
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A. 
 
B. 
 
 
Figure 4.2 Mean platelet volume.  For panel A, bars represent median and interquartile range.  For 
panel B, box represents median and interquartile range, whiskers represent 5
th
 and 95
th
 percentiles, 
outlying points represented by dots. 
 
 
 
 
 
 
 
 
A. 
 
B. 
 
 
Figure 4.3  ADP responses.  For panel A, bars represent median and interquartile range.  Black 
symbols represent maximal aggregation and grey symbols represent final aggregation 5 minutes after 
agonist addition. For panel B, boxes represent median and interquartile range, whiskers represent 5
th
 
and 95
th
 percentiles and outlying points are represented by dots. Black symbols represent maximal 
aggregation, grey symbols represent final aggregation 5 mins after agonist addition. 
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A. 
 
 
 
 
 
 
 
 
B. 
 
 
Figure 4.4 Collagen responses.  For panel A, bars represent median and interquartile range.  Black 
symbols represent maximal aggregation and grey symbols represent final aggregation 5 minutes after 
agonist addition. For panel B, boxes represent median and interquartile range, whiskers represent 5
th
 
and 95
th
 percentiles and outlying points are represented by dots. Black symbols represent maximal 
aggregation, grey symbols represent final aggregation 5 mins after agonist addition. 
 
 
 
 
 
 
A. 
 
 
 
 
 
 
 
 
B. 
 
                   AA concentration (mM)  AA concentration (mM) 
 
Figure 4.5  Arachidonic acid responses.  For panel A, bars represent median and interquartile range.  
For panel B, boxes represent median and interquartile range, whiskers represent 5
th
 and 95
th
 percentiles 
and outlying points are represented by dots.  Maximal aggregation only is shown (as no healthy 
volunteers showed deaggregation to arachidonic acid). 
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A. 
 
B. 
 
 
Figure 4.6  Adrenaline responses.  For panel A, bars represent median and interquartile range.  Black 
symbols represent maximal aggregation and grey symbols represent aggregation 5 minutes after 
agonist addition (aggregation was monitored for ten minutes in total for adrenaline). For panel B, 
boxes represent median and interquartile range, whiskers represent 5
th
 and 95
th
 percentiles and 
outlying points are represented by dots. Black symbols represent maximal aggregation and grey 
symbols represent aggregation 5 minutes after agonist addition (aggregation was monitored for ten 
minutes in total for adrenaline). 
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Figure 4.7  Effect of distance travelled by sample.  X axis for all panels shows all responses, and 
subcategories of local (testing and venepuncture performed in same city), intermediate (tested from a 
city less than 100 miles away) and distant (tested from a city 100 miles or more away) testing.  Bars 
represent median and interquartile range.  Panel A shows maximal aggregation to ADP 3µM, Panel B 
shows maximal aggregation to adrenaline 10µM, Panel C shows maximal aggregation to PAR-1 
peptide 30µM, Panel D shows maximal aggregation to collagen 1µg/ml, and Panel E shows final 
aggregation at 5 minutes post agonist addition (allowing for deaggregation) to ADP 3µM.  For all 
panels p > 0.05 using Kruskal Wallis test to compare local, intermediate and distant groups.  For all 
panels no p values ≤ 0.05 were obtained using Dunn’s multiple comparisons test. 
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 ADP 3µM ADP 10µM ADP 30µM 
Maximal aggregation (%) 17-92 56-92 72-98 
Final aggregation (%) 0-92 53-92 70-98 
Area under the curve (%.s) 12.9-361 234-365 274-395 
Time to secretion (s)   15-120 
Standardised secretion (nmol 
ATP/1x10
9 
platelets) 
  0.28-1.93 
Table 4.1 Normal responses to ADP.  Secretion data shown for highest concentration tested only, as 
secretion was not measured at lower concentrations.  Values stated represent 5
th
 percentile to 95
th
 
percentile.  Final aggregation measured at 5 minutes post agonist addition. 
 
 Adrenaline 
3µM 
Adrenaline 
10µM 
Adrenaline 
30µM 
Maximal aggregation (%) 13-91 18-93 16-98 
Aggregation at 5 minutes (%) 11-91 16-92 14-93 
Area under the curve (%.s) 40-305 45-302 30-302 
Time to secretion (s)  45-240 60-240 
Standardised secretion (nmol 
ATP/1x10
9 
platelets) 
 0.47-2.19 0.32-2.16 
Table 4.2 Normal responses to Adrenaline.  Secretion data shown for highest concentrations tested 
only, as secretion was not measured at lowest concentrations.  Values stated represent 5
th
 percentile to 
95
th
 percentile.  Aggregation to adrenaline was measured for ten minutes post agonist addition.  
Maximal aggregation reflects the highest percentage aggregation attained during this time. 
 
 
 Arachidonic acid 
0.5mM 
Arachidonic acid 
1mM 
Arachidonic 
acid 1.5mM 
Maximal aggregation (%) 0-94 70-96 70-922 
Final aggregation (%) 0-94 70-96 70-92 
Area under the curve (%.s) 0-372 235-382 218-362 
Time to secretion (s)  0-30 0-53 
Standardised secretion (nmol 
ATP/1x10
9 
platelets) 
 0.30-1.99 0.41-1.82 
Table 4.3 Normal responses to Arachidonic Acid.  Secretion data shown for highest concentrations 
tested only, as secretion was not measured at lower concentration.  Values stated represent 5
th
 
percentile to 95
th
 percentile.  Final aggregation measured at 5 minutes post agonist addition. 
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 PAR-1 peptide 30 
µM 
PAR-1 peptide 100 
µM 
Maximal aggregation (%) 31-94 77-98 
Final aggregation (%) 10-94 77-98 
Area under the curve (%.s) 51-409 298-414 
Time to secretion (s)  0-0 
Standardised secretion (nmol ATP/1x10
9 
platelets) 
 0.85-3.02 
Table 4.4 Normal responses to PAR-1 peptide.  Secretion data shown for highest concentration tested 
only, as secretion was not measured at lowest concentration.  Values stated represent 5
th
 percentile to 
95
th
 percentile.  Final aggregation measured at 5 minutes post agonist addition. 
 
 Collagen  1µg/ml Collagen  3µg/ml 
Maximal aggregation (%) 0-89 69-94 
Final aggregation (%) 0-89 69-94 
Area under the curve (%.s) 0-302 162-325 
Time to secretion (s)  30-60 
Standardised secretion (nmol ATP/1x10
9 
platelets) 
 0.37-2.09 
Table 4.5 Normal responses to Collagen.  Secretion data shown for highest concentration tested only, 
as secretion was not measured at lowest concentration.  Values stated represent 5
th
 percentile to 95
th
 
percentile.  Final aggregation measured at 5 minutes post agonist addition. 
 
 Ristocetin 1.5mg/ml 
Maximal agglutination (%) 25-100 
Agglutination at 5 minutes (%) 16-100 
Area under the curve (%.s) 60-424 
Table 4.6  Normal responses to Ristocetin.   Values stated represent 5
th
 percentile to 95
th
 percentile. 
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4.4  Discussion 
The work presented in this chapter defined normal responses to a panel of platelet agonists by 
lumiaggregometry in 68 healthy volunteers recruited to the GAPP study.  Use of Aggrolink
®
 
software allowed accurate characterisation of various parameters detailing aggregation and 
secretion responses.  This work builds on previously published data (77, 103) addressing 
normal ranges in lumiaggregometry.  Overall this is an under-researched field, with lack of 
guidelines on what constitutes a normal response.   
Whilst published guidelines recommend testing a parallel control sample when assessing 
platelet function in a patient (72), they do not comment on the range of normal responses 
expected in the control sample, thus complicating the interpretation of platelet 
lumiaggregometry studies in diagnosing a platelet function defect. 
My results show that higher concentrations of agonists resulted in narrow reference intervals, 
but lower agonist concentrations (including some routinely used in current laboratory 
practice, such as ADP 3 µM and collagen 1 µg/ml) were significantly more variable. 
Transporting samples over 100 miles was not found to alter platelet aggregation responses. 
This is supported by previous work within the GAPP study which found that storage of 
citrated blood at room temperature for up to 6 hours prior to platelet preparation had a 
minimal effect on responses to all agonists except for ADP, where a small reduction in 
aggregation (approximately 20%) was observed (77).  This finding is important from a 
practical viewpoint, as it supports the potential practice of undertaking lumiaggregometry in a 
relatively small number of specialised haemostasis laboratories, and validates multicentre 
recruitment to research studies in which lumiaggregometry is assessed. 
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The findings presented here are relevant in improving the interpretation of lumiaggregometry 
and in better defining the presence of a platelet defect in patients with excessive bleeding.  
Based on the pattern of responses observed in healthy volunteers and described here, caution 
should be exercised in labelling a platelet defect based on an isolated reduced response to a 
low dose of agonist. 
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CHAPTER FIVE: COMPILATION AND VALIDATION OF A RATIONALISED 
AGONIST PANEL FOR LUMIAGGREGOMETRY TESTING  (103) 
5.1  Introduction 
Platelet function testing has historically been poorly standardised, although this has been 
addressed in some recent publications (72, 73).  In addition, it is not subject to quality 
assurance schemes, is labour intensive and is time critical due to the need to work with fresh 
samples.  Recent documents (72, 73) make suggestions about the agonists and concentrations 
that should be used when performing aggregometry, but these are discrepant between studies 
and use concentrations of some agonists that I found to have a wide variation in response 
amongst healthy volunteers, such as ADP 2.0-2.5µM.   
We therefore compiled a “streamlined agonist panel” (Table 5.1), choosing dose points from 
previous work on healthy volunteers in GAPP including my work as described in Chapter 4 
(77, 125).  I compiled this panel along with Marie Lordkipanidzé and Ban Dawood.  The dose 
points included were chosen based on their ability to discriminate between normal and 
abnormal responses, meaning that dose points with a tight distribution of results in healthy 
volunteers were preferable, such as ADP 10µM rather than ADP 3µM, which displays a wide 
range of responses in healthy individuals (Figure 4.3). 
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Agonist Concentration Comments / further guidance 
ADP 10µM Maximal, sustained aggregation expected at this 
concentration. If reversible aggregation seen use 
30µM. 
Adrenaline  10µM Biphasic aggregation expected.  If aggregation 
absent or reduced use 30µM. 
Arachidonic acid 1mM Maximal, sustained aggregation expected.  If 
aggregation reduced or reversible use U46619 
3µM. 
PAR-1 receptor 
specific peptide 
(SFLLRN) 
100µM Maximal, sustained aggregation expected.  If 
aggregation reduced use PAR-4 receptor specific 
peptide (AYPGKF; 500µM). 
Collagen  1µg/ml If aggregation reduced use 3µg/ml.  If this 
concentration shows reduced aggregation, use 
collagen related peptide (CRP) 3 µg/ml. 
Ristocetin  1.5mg/ml Maximal, sustained agglutination (often biphasic) 
expected.  If reduced consider vWF profile and 
GPIb levels by flow cytometry. 
Table 5.1  A recommended streamlined panel of agonists for diagnosing platelet function defects.  
ATP secretion from dense granules should be measured with ADP 30µM, adrenaline 10µM, 
arachidonic acid 1mM, PAR1 – specific peptide 100µM and collagen 3µg/ml 
 
5.2  Aim 
We sought to develop and validate the streamlined agonist panel for platelet function testing 
by comparing it to an expanded (or original) agonist panel, which included a wider range of 
agonists and dose points, and had historically been used in the GAPP project.   
This work was carried out with Marie Lordkipanidzé and Ban Dawood. 
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5.3  Methods 
Platelet function testing methods are outlined in Section 2.2.2.  For the purpose of validation 
of the streamlined agonist panel I was one of two independent experts (along with Marie 
Lordkipanidzé) who were blinded to previous diagnoses and reviewed data that would have 
been created using the streamlined agonist panel.  A mutually acceptable consensus was 
reached following discussion for the cases where the independent experts had a difference of 
opinion.  The diagnoses from this process were then compared to the previous historical 
diagnoses which had been reached using expanded agonist testing. 
 
5.4  Results 
Data were available for 107 historical cases, out of which 94 were suitable for full analysis. 
Inter observer variation was minimal with an agreement of over 90% (kappa statistic 0.829, p 
value for significance <0.001).  There was a significant level of agreement between historical 
diagnoses and diagnoses reached via the streamlined agonist panel with a Cohen’s kappa 
statistic for agreement of 0.721 (p value for significance < 0.001). In addition, the sensitivity 
(87%, 95% Confidence Interval (CI) 74%-94%), specificity (86%, 95% CI 71% to 94%), 
negative predictive value (84%, 95% CI 67% to 93%) and positive predictive value (88%, 
95% CI 75% to 88%) of the streamlined agonist panel were all good (Table 5.2).  By way of 
comparison, published sensitivity and specificity values for the bleeding time in patients with 
congenital platelet disorders are 37% and 88% respectively (126).  Estimation of the 
sensitivity and specificity of the PFA-100 in diagnosing congenital platelet disorders varies 
widely, with sensitivity reports ranging from 24% to over 80% depending upon the population 
studied and the severity of the platelet defects that they suffer from (80). 
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 Expanded agonist 
panel positive  
Expanded agonist 
panel 
negative  
 
Streamlined agonist 
panel positive  
45  6  Positive  
predictive value  
88%  
Streamlined agonist 
panel negative  
7  36  Negative  
predictive value  
 84%  
 Sensitivity   87% Specificity 
86% 
 
Table 5.2  A comparison between the expanded agonist panel and streamlined agonist panel in 
diagnosing platelet function defects.  The data shows a comparison between diagnoses of platelet 
function defect using the expanded agonist panel and a recommended streamlined agonist panel, 
displaying sensitivity, specificity, negative predictive value and positive predictive value.  Cohen’s 
kappa statistic for agreement was 0.721 (p<0.001).   95% Confidence Intervals for Sensitivity, 
Specificity, Negative Predictive Value and Positive Predictive Value were 74-94%, 71-94%, 67-93% 
and 75-88% respectively. 
 
This data led to adoption of this panel for prospective platelet function testing in the GAPP 
study. 
 
 
 
 
 
 
 
 
Results – Compilation and validation of rationalised agonist panel 
 
Page | 66 
 
5.5  Discussion 
In the results presented in this chapter, the use of a rationalised panel of six platelet agonists 
(Table 5.1) has been validated by comparing the diagnoses that would have been created from 
this panel with the original extended agonist testing profile. The rationalised agonist panel 
could be used in nearly all clinical testing centres and would serve to guide further  
sub-typing of inherited platelet function disorders by a specialist laboratory or a clinical 
research study through functional investigations and targeted genotyping or analysis of whole 
exome sequencing data.   
This panel was devised based on discriminatory platelet aggregation responses in healthy 
volunteers (77, 103, 125), and may contribute to the published guidelines (72, 73) in assisting 
clinical laboratories who perform platelet function testing in patients.  
Additional functional tests following the rationalised agonist panel application could include 
an expanded range of platelet agonists and more specialised tests, such as measurement of 
second messengers (cAMP and Ca
2+
 elevation), TxA2 formation, shear-based assays of 
platelet adhesion and aggregation, and flow cytometric measurements of α-granule secretion 
and glycoprotein receptor levels.  
The rationalised agonist panel would also identify nearly all of the 40% of patients in whom a 
platelet defect was not identifiable by extended agonist testing and where additional testing 
would appear to have limited value.  Identifying patients in whom additional time consuming 
testing is not of benefit is an important area, and has been further addressed in studies within 
GAPP looking at the use of 96 well plate testing and remote flow cytometric based testing in 
identifying which patients should go on to have formal assessment of platelet function by 
lumiaggregometry (96, 97).  Coupling laboratory testing with clinical bleeding history, 
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including assessment of a bleeding score such as the ISTH BAT score, is clinically important 
in identifying which patients should have further investigation (127). 
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CHAPTER SIX:  CLASSIFICATION OF PLATELET DEFECTS IN PATIENTS 
WITH A NORMAL PLATELET COUNT 
6.1 Introduction 
Even when locally determined normal ranges are available, diagnosing a defect in platelet 
function often remains a challenge because of overlap with the response of healthy volunteers. 
There is also the further challenge of interpreting the likely mechanism of the defect because 
of the feedback effects of ADP and TxA2 and the fact that many PFDs are associated with a 
partial rather than a complete loss of a particular receptor or signalling pathway (103). 
Assessment of the overall pattern of response by an experienced investigator is therefore 
essential in concluding whether there is a defect in platelet activation, in addition to looking at 
responses to several agonists.  Interpreting defects based on responses to a single agonist 
(especially those with wide variation in response in the normal population, such as ADP or 
adrenaline) may lead to an over diagnosis of platelet abnormalities. 
Table 6.1 describes typical aggregation and secretion findings in the main categories of 
inherited platelet disorders. 
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DISORDER AGGREGATION FINDINGS SECRETION FINDINGS 
Bernard–Soulier syndrome 
 
Absence of agglutination to high dose 
ristocetin with preserved responses to 
other platelet agonists 
 
Unaffected 
 
Type IIB VWD / Platelet-
type von Willebrand’s 
disease 
Presence of agglutination to low dose 
ristocetin with preserved responses to 
other platelet agonists.  Exact diagnosis 
can be established by platelet and plasma 
mixing studies. 
Unaffected 
Glanzmann’s 
thrombasthenia 
 
Absence of sustained aggregation to all 
agonists except ristocetin 
Shape change and primary wave of 
aggregation can be seen 
 
Can be reduced as a result 
of reduced positive 
feedback from GPIIbIIIa 
outside-in signalling  
Secretion defects Commonly, absence of secondary wave 
aggregation to most agonists used in low 
concentrations, and epinephrine at all 
concentrations 
 
Significantly reduced 
levels of ATP secretion, 
when normalized for 
platelet count 
 
Thromboxane pathway 
defects 
Absence/severe reduction of aggregation 
in response to arachidonic acid while 
response to thromboxane mimetics is 
preserved (for cyclooxygenase defects) or 
absence of aggregation response to both 
arachidonic acid and thromboxane 
mimetics (for thromboxane receptor 
defects)  
Commonly, absence of secondary wave 
aggregation to most agonists used in low 
concentrations, and epinephrine at all 
concentrations 
Unaffected 
Gi-coupled receptor defects Reduced aggregation to ADP with notable 
deaggregation even at high concentrations 
of agonist 
Reduced primary wave response to 
epinephrine and absence of secondary 
wave 
Unaffected 
Table 6.1  Typical lumi-aggregometry findings in commonly encountered platelet defects.  
Reproduced from (4) 
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At the start of my research fellowship 80 patients had been studied in the GAPP project, of 
whom 17 (21%) were found to have a secretion defect, 15 (19%) were found to have a Gi-
coupled receptor defect, 11 (14%) were found to have a thromboxane pathway defect, and 6 
(7%) had other categories of defects including GPVI receptor defects and complex defects.  
31 patients (39%) did not have a platelet function defect based on the testing performed.   
 
6.2 Aim 
To recruit, test and classify patients with a suspected platelet function defect and normal 
platelet count within the GAPP project. 
 
6.3 Results 
Between October 2010 and March 2013 I tested and reported 88 patients from 10 centres with 
a normal platelet count and clinical suspicion of an inherited platelet disorder, in addition to 
testing many other patients whose reports were compiled by other members of the GAPP 
team. The 88 patients that I tested and reported were enrolled into the “clinically suspected 
platelet disorder” arm of the GAPP study.  Amongst the 88 patients tested, 39 (44%) were not 
found to have a platelet defect using the modalities available for testing.  Of the 49 (56%) 
who were found to have a defect, most (43/49, 88%) could be classified as having either a 
dense granule secretion defect, an abnormality in Gi pathway signalling or an abnormality in 
the cyclooxygenase pathway.  The distribution of defects amongst these patients is shown in 
Figure 6.1.  By means of comparison, the distribution of defects amongst 111 patients 
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recruited to the same arm of GAPP had previously been analysed and described (68) and is 
shown in Figure 6.2.  Overall this showed very similar findings, with 42% not having a 
demonstrable platelet defect, and the patients with a defect mostly falling into the categories 
of dense granule secretion defect, Gi pathway signalling defect and cyclooxygenase pathway 
defect. 
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Figure 6.1  Distribution of platelet defects amongst 88 patients I recruited into the “clinically 
diagnosed platelet disorder” arm of the GAPP project.  Segment labels show (absolute number, 
percentage).  COX = cyclooxygenase, Gi = Gi signalling pathway. 
 
 
Figure 6.2  Distribution of platelet defects amongst 111 previously studied patients recruited into the 
“clinically diagnosed platelet disorder” arm of the GAPP project. .  Reproduced from (103).   δ 
granule = platelet dense granules. 
  
39, 44% 
12, 14% 
20, 23% 
11, 12% 
6, 7% No platelet defect 
identified 
Secretion defect 
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Example traces from patients found to have the three main categories of defects are shown in 
Figures 6.3 (dense granule secretion defect), 6.4 (Gi signalling defect) and 6.5 
(cyclooxygenase pathway defect). 
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A. 
 
B. 
 
C. 
 
D. 
 
E. 
 
  
Figure 6.3  Representative images from a patient with a dense granule secretion defect.  Horizontal 
bars represent 2 minutes time.   Y axes show percentage aggregation.   For all traces patient 
aggregation is shown in blue, healthy volunteer aggregation is shown in red, patient secretion is shown 
in black and healthy volunteer secretion is shown in green.  Panel A shows response to ADP 30µM, 
Panel B shows response to adrenaline 30µM, Panel C shows response to arachidonic acid 1.5mM, 
Panel D shows response to collagen 10µg/ml and Panel E shows response to PAR-1 peptide 100µM.  
Responses to all agonists are reduced, with deaggregation to high dose ADP and no secondary wave of 
aggregation seen with high dose adrenaline.  Normalised secretion to PAR-1 peptide is 
0.34nmol/1x10
8
 platelets (5
th
 centile in healthy volunteers = 0.84 nmol/1x10
8
 platelets) 
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A. 
 
B. 
 
C. 
 
D. 
 
E. 
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Figure 6.4 Representative images from a patient with a Gi signalling defect.  Horizontal bars represent 
2 minutes time.   Y axes show percentage aggregation.   For panels B, C, E and F patient aggregation 
is shown in blue, healthy volunteer aggregation is shown in red, patient secretion is shown in black 
and healthy volunteer secretion is shown in green.   For panels A and D patient aggregation is shown 
in blue and healthy volunteer aggregation is shown in black.   Panel A shows response to ADP 10µM, 
Panel B shows response to adrenaline 30µM, Panel C shows response to collagen 3µg/ml, Panel D 
shows response to arachidonic acid 0.5mM, Panel E shows response to arachidonic acid 1mM and 
Panel F shows response to PAR-1 peptide 100µM.  Deaggregation is seen to high dose ADP, with no 
secondary wave of aggregation with high dose adrenaline.  Response to high dose collagen is reduced 
with some deaggregation.  No aggregation is seen with low dose arachidonic acid, although this 
normalises at a higher concentration.  Response to high dose PAR-1 peptide is normal.  Normalised 
secretion to PAR-1 peptide is within the normal range at 1.40nmol/1x10
8
 platelets (5
th
 centile in 
healthy volunteers = 0.84 nmol/1x10
8
 platelets) 
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Figure 6.5 Representative images from a patient with a cyclooxygenase pathway defect.  Horizontal 
bars represent 2 minutes time.   Y axes show percentage aggregation.   For panels B, C, D and E 
patient aggregation is shown in red, healthy volunteer aggregation is shown in blue, patient secretion 
is shown in green and healthy volunteer secretion is shown in black.   For panels A patient aggregation 
is shown in black and healthy volunteer aggregation is shown in blue.   Panel A shows response to 
ADP 10µM, Panel B shows response to adrenaline 30µM, Panel C shows response to arachidonic acid 
1mM, Panel D shows response to collagen 3µg/ml and Panel F shows response to PAR-1 peptide 
100µM.  Deaggregation is seen to high dose ADP, with no secondary wave of aggregation with high 
dose adrenaline.  Response to high dose collagen is reduced.  No aggregation is seen with high dose 
arachidonic acid, and this was confirmed on a repeat experiment using arachidonic acid 1.5mM (data 
not shown).  Response to high dose PAR-1 peptide is normal.  Normalised secretion to PAR-1 peptide 
is within the normal range at 0.86nmol/1x10
8
 platelets (5
th
 centile in healthy volunteers = 0.84 
nmol/1x10
8
 platelets).  Response to U46619 was not tested by lumiaggregometry due to sample 
constraints, but was tested using the 96 well plate Optimul assay (96) and this demonstrated a normal 
dose response curve, suggesting that the defect lies above the level of the thromboxane A2 receptor. 
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6.4 Discussion 
My work examining patients with a suspected platelet function disorder and a normal platelet 
count found similar results to those that had previously been studied within the GAPP project 
(103).  In both datasets a defect could not be identified in approximately 40% of recruited 
patients.  In the patients where a defect was seen, three main categories of defect were 
observed – Gi defect, dense granule secretion defect and cyclooxygenase pathway defect, 
constituting 41%, 24% and 22% of patients with an identified platelet defect respectively.  
These categories of defect and their basic laboratory features are also included in national 
guidelines for the laboratory investigation of suspected platelet function disorders (72).  
Whilst accurate classification of an inherited platelet function defect does not necessarily 
change haemostatic management, correct diagnosis per se of an inherited platelet function 
defect enables appropriate surveillance and management of periods of heightened bleeding 
risk, and ensures appropriate family counselling. 
It is interesting to consider the reason for excessive bleeding in the 40% of patients in whom a 
platelet defect was not identified.  It is possible that the testing undertaken within GAPP is not 
comprehensive enough to capture all inherited platelet defects – for example, defects in 
procoagulant activity or alpha granule function may not be detected.  The work presented in 
Chapter 5 suggests that a small number of patients may be labelled with a platelet defect 
when using extended lumiaggregometry agonist testing who would not have been diagnosed 
using the rationalised agonist method (7/52 [13%] in our experience).   
It is also possible that the patients in whom a platelet defect was not identified have an 
abnormality in another part of the haemostatic process which is difficult to test, such as vessel 
wall function and collagen exposure, or fibrinolysis.  Clinical noting of excessive bleeding in 
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patients with connective tissue disorders is well reported, with an example being increased 
incidence of menorrhagia in patients with Ehlers-Danlos syndrome (128). As bleeding is 
likely to be a multifactorial trait (Figure 1.5), genetic variants in several parts of the 
haemostatic cascade may also contribute to an individual’s overall bleeding risk when 
exposed to suitable challenges. 
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CHAPTER SEVEN: ASSESSMENT OF WHETHER SIMULATANEOUS 
MEASUREMENT OF LIGHT TRANSMISSION AGGREGATION AND SECRETION 
POTENTIATES ADRENALINE RESPONSES (129) 
7.1  Introduction 
A previous report (130) concluded that using lumiaggregometry for simultaneous 
measurement of LTA and platelet secretion / ATP release (as was our standard practice within 
GAPP) could potentiate platelet responses to adrenaline.  This resulted in the presence of a 
secondary wave of aggregation to adrenaline in subjects in whom it would not have been 
expected (such as those with Quebec platelet disorder), and was reported to have a possible 
impact on incorrect classification of whether a patient has a platelet defect, and on labelling 
the category of defect.   
 
7.2  Aim  
To establish whether simultaneous assessment of secretion using Chronolume
®
 during 
lumiaggregometry effects aggregation measurements. 
 
7.3  Methods 
Platelet aggregation measurement without and with Chronolume
®
 was carried out 
simultaneously in response to adrenaline 10 µM with recording left for up to 10 min.  The 
effect of addition of vehicle (Phosphate buffered saline, PBS) or Chronolume
®
 alone in 
inducing aggregation was also measured.  General methods were as described in Section 
2.2.2.  This work was carried out in conjunction with Marie Lordkipanidzé. 
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7.4  Results 
100 participants were studied, of whom 27 were healthy volunteers and 73 were patients 
suspected to have a platelet function defect.  The median age of healthy volunteers and 
participants with bleeding symptoms was 29 (interquartile range from 28 to 30 years) and 38 
years (interquartile range from 12 to 47 years), respectively.  The majority of recruited 
participants were female (75% among participants with suspected platelet function defects 
and 74% among healthy volunteers).   
A platelet defect was found on platelet function testing in 38% of participants with bleeding 
symptoms (62% had no demonstrable platelet defect, 16% had a Gi-like defect, 11% had a 
dense granule secretion defect, 4% had a defect in the thromboxane pathway and 7% had a 
complex phenotype).  As shown in Figure 7.1, addition of the vehicle (PBS) or Chronolume
®
 
alone did not induce aggregation in 10 healthy volunteers.  Moreover, addition of 
Chronolume
®
 did not result in a significant increase in maximal platelet aggregation or 
platelet aggregation 5 minutes after addition of adrenaline in healthy volunteers (n=27) or in 
participants with bleeding symptoms (n=57, 78%) who had a sustained and biphasic response 
to adrenaline 10 µM. In 16 (22%) participants with bleeding symptoms, there was no 
secondary wave in response to adrenaline 10 µM. Addition of Chronolume
®
 in this group had 
no significant effect on maximal platelet aggregation in response to adrenaline 10 µM (mean 
difference between aggregation levels with vs. without Chronolume
®
 = 10.6%, 95%CI -1.8% 
to 23.1%, p=0.09).  Addition of Chronolume
®
 induced a secondary wave of aggregation in 4 
out of 16 participants who had no secondary wave in response to adrenaline in the absence of 
Chronolume
®
.  However, addition of Chronolume
®
 resulted in abrogation of a secondary 
wave in 3 out of 57 participants with biphasic aggregation.  Overall, the McNemar test 
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showed no impact of adding Chronolume
®
 on induction of a secondary wave in response to 
adrenaline 10 µM (Figure 7.1, p=0.625 in healthy volunteers and p=1.0 in patients with 
bleeding symptoms). 
Results – Assessment of simultaneous measurement of aggregation and secretion 
 
Page | 82 
 
Results – Assessment of simultaneous measurement of aggregation and secretion 
 
Page | 83 
 
Figure 7.1  Effect of adding Chronolume
®
 on platelet responses to adrenaline 10 µM in healthy 
volunteers (n=27), in participants with bleeding symptoms who had a sustained and biphasic response 
to adrenaline 10 µM (n=57, “normal response”), and in participants with bleeding symptoms who 
displayed no secondary wave in response to adrenaline 10 µM (n=16, “abnormal response”).  A.  
Maximal aggregation.  Open symbols without Chronolume
®
, closed symbols with Chronolume
®.  Δ 
(95% CI) represents the mean difference between aggregation levels with vs. without Chronolume
®
. 
B.  Aggregation at 5 minutes after addition of adrenaline 10 µM. Open symbols without Chronolume
®
, 
closed symbols with Chronolume
®.  Δ (95% CI) represents the mean difference between aggregation 
levels with vs. without Chronolume
®
.  C.  Cross-comparison of the presence of a secondary wave in 
response to adrenaline 10 µM in healthy volunteers. McNemar test, p=0.625  D.  Cross-comparison of 
the presence of a secondary wave in response to adrenaline 10 µM in participants with bleeding 
symptoms. McNemar test, p=1.0 
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7.5  Discussion 
The findings reported above do not support the previously reported observation that 
Chronolume
®
 consistently induces a secondary wave of aggregation in response to adrenaline 
10 µM in patients with an aberrant response to this agonist in the absence of Chronolume
® 
(130).  This is in agreement with other findings where no effect of Chronolume
®
 on human 
platelets was demonstrated, whereas it was shown to potentiate aggregation in response to 
ADP and collagen in canine, feline, bovine and equine platelets (131). Potentiation of platelet 
aggregation by Chronolume
®
 had been suggested by previous studies which used a slightly 
different formulation of the reagent (132, 133); however, absence of effect and even the 
opposite effect (i.e. inhibition of platelet responses when luciferin:luciferase-containing 
reagents [including Chronolume
®
] were used) have also been reported (134, 135). 
Closer examination of the patients whose results were discrepant in the presence of 
Chronolume
®
 in the findings in this chapter revealed that the final diagnosis of the presence 
of a platelet function defect would not have been affected by using Chronolume
®
 to 
simultaneously assess ATP secretion alongside aggregation to adrenaline 10µM.  In the cases 
where a secondary wave of adrenaline was induced in the presence of Chronolume
®
, it was 
either significantly delayed (>300 sec, which represents the 95
th
 percentile of locally-derived 
normal ranges) or was accompanied by abnormalities in ADP-induced aggregation (also 
dependent on appropriate activity of the Gi-coupled P2Y12 receptor) (136).  The opposite 
effect, i.e. abrogation of a secondary wave when Chronolume
®
 was added, was seen in one 
participant labelled as having a Gi-like defect.  The interpretation was not affected as 
abnormalities in ADP-induced aggregation were also noted in the same participant, alongside 
a shift in dose-response to adrenaline.  It is noteworthy that similar differences in the presence 
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of Chronolume
®
 were seen in healthy volunteers, with either induction or abrogation of a 
secondary wave in response to adrenaline 10 µM, which suggests that the variation seen in the 
patients with bleeding symptoms is within the variability of the assay in the normal 
population, consistent with previous literature (72).   
Overall, the results presented above suggest that the presence of Chronolume
® 
may 
occasionally induce or abrogate the secondary wave of aggregation in response to adrenaline 
10µM, but that this effect does not have an impact on either diagnosis of an underlying 
platelet function defect, or classification of such a defect in participants with a history of 
excessive bleeding.  This supports the practice of using adrenaline in the presence of 
Chronolume
®
 in the assessment of lumiaggregometry as part of a rationalised agonist panel, 
as detailed previously (136). 
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CHAPTER EIGHT:  STUDY OF THE ISTH BLEEDING ASSESSMENT TOOL 
SCORE IN HEALTHY VOLUNTEERS AND IN PATIENTS SUSPECTED TO HAVE 
A PLATELET DISORDER  
8.1 Introduction 
Assessing and recording mild bleeding symptoms can be difficult, and several bleeding 
assessment tools (BATs) have been developed for this purpose, with the aim of standardising 
the documentation of symptoms of excessive bleeding in patients, allowing comparison 
between patients and selecting patients in whom further investigations are appropriate (137).  
This is further compounded by the fact that mucocutaneous bleeding symptoms are reported 
in a significant proportion of the healthy population, which makes determination of the 
threshold that constitutes excessive bleeding difficult (138).  Initially BATs focussed on 
patients with von Willebrand disease (139, 140) as it is the commonest inherited bleeding 
disorder, and later scoring systems were designed for specific patient populations on some 
occasions, such as children (141-143) or women with menorrhagia (144, 145).  The 
International Society on Thrombosis and Haemostasis Bleeding Assessment Tool was 
developed specifically to also detect recurrent milder bleeding symptoms (146), and is 
therefore applicable to patients with some types of inherited platelet disorder.  The full 
questionnaire is included in Appendix 2.  It is designed to be conducted by a physician, and 
takes approximately fifteen to twenty minutes to complete.  It has been shown to be helpful in 
assessing children and parents in routine clinical practice, and found to be equally 
discriminative as a BAT specifically designed for paediatric patients with regard to the 
prevalence of an underlying bleeding disorder (147).  Data is currently being collected into an 
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ISTH registry to examine bleeding scores using this assessment tool in patients with inherited 
platelet disorders (127). 
 
8.2 Aims 
To assess ISTH bleeding assessment tool scores in patients with and without platelet 
disorders, and to establish whether a raised score is indicative of an underlying defect. 
 
This work was carried out in conjuction with Marie Lordkipanidzé. 
 
8.3 Results 
ISTH Bleeding Assessment Tool (BAT) scores were analysed in 100 participants in GAPP 
(148).  
5.3.1  Participant characteristics 
Of the 100 participants studied, 21 were healthy volunteers and 79 were recruited from UK 
Comprehensive Care Haemophilia Centres with suspected inherited platelet function 
disorders.  The median age of participants with bleeding symptoms was 39 years 
(Interquartile range [IQR] from 31 to 53 years), while it was 32 years (IQR from 30 to 35 
years) in healthy volunteers.  The majority of recruited participants were female (81% among 
participants with bleeding symptoms and 67% among healthy volunteers). 
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5.3.2  Association of scores with platelet function testing results 
A platelet defect was found on lumiaggregometry in 52% of participants with bleeding 
symptoms, in accordance with our previously published findings (103).  The score obtained 
through the ISTH BAT in participants referred by UK Comprehensive Care Haemophilia 
Centres with bleeding symptoms (12; IQR 8 to 16) was significantly higher than in healthy 
volunteers (0; IQR 0 to 0), consistent with the clinical diagnosis of a bleeding disorder.  
However, there was no significant difference between participants in whom a platelet defect 
was detected by lumiaggregometry (11; IQR 8 to 16) and in whom platelet function was 
deemed normal (12; IQR 8 to 14) (Figure 8.1). 
 
 
Figure 8.1  Association between presence of a platelet function defect on lumiaggregometry and the 
ISTH bleeding assessment tool score  95
th
 percentile (score of 4) calculated from healthy volunteers 
and represented by horizontal dotted line.  For the data points the line represents the median and the 
whiskers represent the interquartile range.  Statistical analysis performed by the non-parametric 
Kruskall-Wallis test, with Dunn’s adjustment for multiple comparisons.   
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There was no association between the type of platelet defect detected by lumiaggregometry 
(as defined in (103)) and the ISTH BAT score, although the numbers of patients in some 
diagnostic classification subgroups was relatively small (Figure 8.2). 
 
Figure 8.2  Association between type of platelet function defect on lumiaggregometry and the ISTH 
bleeding assessment tool score  95
th
 percentile (score of 4) calculated from healthy volunteers and 
represented by horizontal dotted line.  For the data points the line represents the median and the 
whiskers represent the interquartile range.  Statistical analysis performed by the non-parametric 
Kruskall-Wallis test, with Dunn’s adjustment for multiple comparisons.   COX: cyclooxygenase.  For 
description of types of defects, refer to (103). 
 
A receiver-operator curve (ROC) analysis was carried out to evaluate whether the ISTH 
bleeding assessment tool could discriminate between patients with and without a 
demonstrable platelet defect on lumiaggregometry (Figure 8.3).  The area under the curve 
was 0.50 (95% CI 0.37 to 0.63, p=0.98) thus demonstrating a lack of discriminative ability.  
Moreover, the ISTH BAT score was not associated with a demonstrable platelet defect on 
platelet function testing in a simple logistic regression model (OR 1.01 [95% CI 0.93 – 1.09], 
p=0.91). 
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Figure 8.3  Receiver-operator curve for the presence of a platelet function defect on 
lumiaggregometry and the ISTH bleeding assessment tool score.  Area under the curve: 0.50 (95% CI 
0.372 to 0.63), p=0.98 
   
Subgroup analyses were performed to examine whether certain bleeding symptoms were 
predictive of the presence of a platelet defect on lumiaggregometry.  ISTH BAT scores for 
epistaxis, cutaneous bleeding, post operative (including post dental work) bleeding and 
menorrhagia in women were assessed (Table 8.1).  No statistical significance was found for 
any of these subgroups.  
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Bleeding symptom Patients with 
platelet defect 
(Median, 
Interquartile range) 
Patients without 
platelet defect 
(Median, 
Interquartile range) 
p value 
Epistaxis 1, 0-3 1, 0-2 0.67 
Cutaneous bleeding 1, 0-2 1, 0-1 0.17 
Post operative 
bleeding (including 
post dental work) 
4, 2-6 4, 2-6 0.89 
Menorrhagia 3, 1-4 3, 2-4 0.27 
Table 8.1  Subgroup analyses for ISTH bleeding assessment tool score in patients with and without a 
platelet defect.  Symptoms assessed were epistaxis (maximum score 4), cutaneous bleeding (maximum 
score 4), post operative bleeding (including post dental work, maximum score 8) and menorrhagia (in 
female participants only, maximal score 4).  Statistical analyses performed by the non-parametric 
Mann Whitney U test. 
 
Sensitivity, specificity, positive predictive value and negative predictive value of the ISTH 
BAT in predicting the presence of a platelet defect on lumiaggregometry was assessed (Table 
8.2).  A cut off value of 12 was used for the ISTH BAT score as this represented the 50
th
 
centile of ISTH BAT score in all patients.  This analysis confirmed the absence of association 
between a high ISTH BAT score and the likelihood of having a platelet defect (κ=-0.04, [95% 
CI -0.26 to 0.18]).   
 Defect present on 
lumiaggregometry 
Defect absent on 
lumiaggregometry 
 
BAT score ≥ 12 20 20 Positive predictive 
value = 50% 
BAT score < 12 21 18 Negative predictive 
value = 54% 
 Sensitivity = 49% Specificity = 53%  
Table 8.2  2x2 analysis of the predictive value of a ISTH BAT score of 12 and over in predicting the 
presence of a platelet defect on lumiaggregometry. ISTH BAT score of 12 represents the 50
th
 centile in 
all patients studied.  Sensitivity, specificity, positive predictive value and negative predictive value are 
shown.  Kappa statistic for concordance = -0.04 (95% CI  -0.26 to 0.18), demonstrating a lack of 
significance. 
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8.4 Discussion 
 
The findings presented in this chapter confirm that the ISTH BAT score is raised in patients 
with clinical evidence of excessive bleeding and a suspected platelet function disorder.  The 
results also show that healthy volunteers have a low score (≤4) in keeping with the absence of 
a history of bleeding episodes.  However, the score is unable to discriminate between patients 
with clinically diagnosed bleeding disorders subsequently shown to have a platelet defect on 
lumiaggregometry and those in whom an underlying platelet defect was not detected.  This 
suggests that the ISTH BAT is powerful in documenting bleeding symptoms, but that its level 
per se is not predictive of the likelihood of diagnosing an inherited platelet disorder in 
patients with excessive bleeding.   
It is possible that some patients classified as not having a platelet defect do have a mild defect 
which is below the limit of sensitivity of our current testing assays, or have a defect in other 
aspects of platelet function (such as procoagulant activity) which was not tested for in the 
GAPP project.  Given the history of excessive bleeding in all patients, abnormalities in other 
untested parts of the haemostatic pathway may also account for the clinical presentation of a 
proportion of the patients in whom a platelet defect was not detected. 
The healthy volunteer group included in this study is small (n=21).  The 95
th
 centile for BAT 
score in this group is 4, although defining a more precise upper limit of normal range for the 
BAT score requires larger studies that ideally examine heterogenous populations.  In addition, 
the median age in the healthy volunteer group was slightly lower than in the patient group.  
This may have reduced the BAT score in healthy volunteers due to fewer cumulative 
challenges to the haemostatic system such as surgery or pregnancy and childbirth in women.  
Previous work has shown that platelet aggregability slightly increases with age (149), 
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meaning that the aggregation ranges observed in the healthy volunteer group may be lower 
than that expected in the patients if platelet function was normal.  However, this would have 
biased the results in the patient group towards increased platelet reactivity and therefore 
should not have led to mislabeling of patients with normal responses as having a platelet 
defect.   
The documentation of bleeding risk in mild bleeding disorders is challenging.  
Mucocutaneous bleeding symptoms are reported in a significant proportion of the healthy 
population, which makes determination of the threshold that constitutes excessive bleeding 
difficult (138).  Mild bleeding disorders are prevalent in the general population, reaching up 
to 1%, but both the clinical diagnosis and laboratory characterization remain complicated 
(150).  The presence of a laboratory phenotype does not necessarily lead to bleeding 
especially in the absence of a hemostatic challenge and as a consequence most mild bleeding 
disorders, particularly inherited platelet disorders, remain clinically and biochemically ill 
defined (150, 151).  There is an important clinical need for an assessment tool that would 
allow clinical characterisation of this population in order to stratify which patients require 
further investigation. 
Numerous scores for bleeding assessment have been proposed over the years (reviewed in 
(137, 151)).  The strength of the ISTH BAT tool is to specifically capture the frequency of 
mild bleeding symptoms, which are often missed in traditional BATs (152).  As such, the 
ISTH BAT is particularly relevant to patients with recurrent and mild bleeding symptoms, 
which are a key feature of inherited platelet disorders (150, 151).   
There is little prior experience with this tool in mild bleeding disorders.  Using a previous 
version of a BAT based on the European MCMDM-1 VWD study (140) the BAT’s clinical 
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utility in 215 patients with mild bleeding disorders was analysed (153).  The findings 
supported the use of the BAT instrument, as a low bleeding score could reasonably exclude 
the presence of a mild bleeding disorder in an unselected population, and the utility increased 
when the BAT score was used in conjunction with laboratory testing (153).  The results 
presented in this chapter agree with these findings, as patients with clinical evidence of 
excessive bleeding in our study did have significantly higher ISTH BAT scores than healthy 
volunteers.  A further study looked at the clinical utility of the ISTH BAT questionnaire in a 
routine pediatric setting (147).  In this study on 100 children presenting with a mild bleeding 
diathesis, a low ISTH BAT score made a bleeding disorder diagnosis unlikely, consistent with 
findings in this study and those of others (147, 153).  However, only 5 children were 
diagnosed with a possible platelet disorder in this study, thus reducing the generalisability to a 
large cohort of patients with suspected inherited platelet function disorders.  Also, given that 
the ISTH BAT assesses responses to haemostatic challenges, including menorrhagia, 
childbirth, dental procedures and surgery, the applicability of the scores obtained in children 
to an adult population is uncertain, as many children will not yet have been exposed to these 
challenges.   
The findings presented here were the first to report on the utility of the ISTH BAT in a large 
cohort of patients with suspected inherited platelet function disorders.  The results supported 
the use of the ISTH BAT to document recurrent bleeding symptoms in this population (148).  
However, in this work, the ISTH BAT score was not found to be predictive of which patients 
have a platelet function defect by laboratory investigation using lumiaggregometry. 
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CHAPTER NINE: GENETIC TESTING OF PATIENTS IDENTIFIED TO HAVE A 
PLATELET DEFECT 
9.1  Introduction 
As outlined in Section 1.5, previous work in the GAPP project has identified the genetic cause 
of some of the platelet defects phenotyped in patients recruited to the study (33, 103).  
Identification of the underlying genetic defect responsible for a change in platelet phenotype 
and a bleeding tendency in the patient helps with both appropriate diagnosis and possible 
screening of other family members.  Use of newer sequencing techniques such as next 
generation sequencing and whole exome sequencing approaches has increased the 
opportunities available to identify these underlying defects (as compared to direct Sanger 
sequencing of possible candidate genes) (154).  One of the fundamental aims of GAPP was to 
identify genetic defects responsible for inherited platelet disorders, and examples of this 
approach in two patients recruited to the project are outlined here. 
9.2  Aim 
To undertake genotyping of selected patients found to have an abnormal phenotype to 
uncover genes involved in platelet function and megakaryopoiesis (using Sanger and second 
generation sequencing technology). 
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9.3  Results 
9.3.1  Hermansky Pudlak syndrome – identification of second novel mutation in HPS7 gene 
(109) 
A 77 year old Caucasian female was referred to the bleeding disorder clinic with a lifelong 
bleeding tendency (family tree shown in Figure 9.1A).  There was no history of a bleeding 
disorder in this participant’s half siblings, parents or children.  Her parents were first cousins. 
She had pale skin and hair and had reduced visual acuity and nystagmus throughout life. She 
also had spontaneous epistaxes as a teenager which lasted for several hours and required 
medical attention, and several episodes of prolonged bleeding from minor injuries that 
required surgical haemostasis.  She bled for several days after dental extractions in her 
twenties and thirties and required packing of the tooth sockets to control the bleeding.  She 
had menorrhagia from menarche which eventually necessitated a hysterectomy at the age of 
37. She experienced heavy post partum bleeding after all of her three vaginal deliveries. 
Surgical procedures in this patient, including surgery for an ectopic pregnancy in the 1960s, 
abdominal hysterectomy and salpingo-oophrectomy in 1971 and excision of a lipoma from 
her back in 2002, were followed by prolonged bleeding requiring blood product transfusion. 
She had two episodes of severe per-rectal bleeding.  The first one occurred in 1979 and was 
attributed to a rectal polyp which was surgically removed.  She bled significantly after this 
procedure and required a platelet transfusion.  A further episode occurred in 2009 which was 
attributed to Crohn’s disease. During this episode the patient required red cell and platelet 
transfusions and tranexamic acid and was being considered for a right hemicolectomy at the 
time of her haematology referral.  
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Colonic biopsies showed florid granulomatous inflammation with no co-existing infection 
(Figure 9.1B). Acid fast bacilli were absent. She was reviewed by a respiratory physician in 
2010 and had no evidence of any respiratory disease, with normal lung function tests (FEV1 
100% predicted, FVC 95% predicted, TLC 80% predicted and KCO 105% predicted, all 
within normal ranges). A chest X ray showed no active lung disease, and a CT thorax with 
contrast showed no convincing features of fibrosis. 
I recruited the patient to the GAPP study, and performed platelet function testing by 
lumiaggregometry using Chronolume
®
 to assess secretion. The responses to intermediate 
concentrations of PAR-1 peptide (30 µM) and collagen (1 µg/ml) were reduced relative to the 
control tested on the day and also a panel of over 70 healthy volunteers. Normal aggregation 
was observed at higher concentrations of these agonists (not shown). A lack of dense granule 
secretion with the entire panel of agonists tested (rationalised agonist panel described in 
(103))  was noted, as illustrated for PAR-1 and PAR-4 peptides (Figures 9.1C and 9.1D). 
The lack of platelet ATP secretion was consistent with an absence of platelet dense granules, 
and in combination with the patient’s clinical features was diagnostic of Hermansky Pudlak 
syndrome (HPS).  
DNA was extracted from peripheral blood and genetic studies were undertaken by Neil 
Morgan and Isabel Sanchez Guiu.  As the patient’s parents were related by blood, they were 
able to apply autozygosity linkage mapping by genotyping several microsatellite markers 
flanking all of the known human HPS genes.  This was carried out to prioritize a limited 
number of HPS genes for direct sequencing. Strikingly the only HPS locus that displayed 
autozygosity for both flanking markers and over an extended region of genetic distance was 
the HPS7 locus. Therefore the most likely candidate HPS gene was HPS7/Dysbindin on 
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chromosome 6p22.3. The 10 coding exons of DTNBP1 (encoding dysbindin) including exon-
intron boundaries were PCR-amplified and sequenced. Sequencing of DTNBP1 revealed a 
homozygous nonsense mutation in exon 4 (c.177 G>A; p.Trp59Stop) confirming a diagnosis 
of HPS type 7 (Figure 9.1E).  
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Figure 9.1 Identification of the second HPS7 mutation in a patient with Hermansky-Pudlak syndrome.  
(Panel A) Pedigree of a consanguineous family with Hermansky-Pudlak syndrome. The affected 
individual is represented by a solid symbol.   (Panel B) Images of a colonic biopsy from the patient in 
low power (upper panel) and high power (lower panel). Both images show inflammatory infiltrates 
and granulomata with numerous giant cells, alongside normal bowel mucinous glands.  No caseous 
necrosis is seen, and special stains showed no evidence of micro-organisms (including mycobacteria).  
(Panels C and D) Absence of secretion (black trace) to high doses of PAR-1 peptide 100µM (Panel C) 
and PAR-4 peptide 500µM (Panel D) in this patient.  Left sided Y axis depicts percentage aggregation, 
and right sided Y axis represents platelet ATP secretion assessed using Chronolume
®
. 1.6nmol of ATP 
standard were added to each cuvette in order to calculate absolute secretion and secretion normalised 
to platelet count in PRP for both patient and control.  
(Panel E) Identification of a homozygous single base substitution (c.177 G>A) in Dysbindin leading to 
a premature stop codon (p.Trp59Stop). Sanger sequencing showing wild-type and mutant DTNBP1 
sequence traces. The position of the mutation is indicated by the boxed regions. 
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9.3.2  Identification of a PAR1 receptor polymorphism associated with reduced surface 
receptor expression in combination with an ADP P2Y12 receptor mutation in a family with a 
history of excessive bleeding (40) 
A 44 year old woman (P1) was investigated in the GAPP project.  In order to allow her to be 
recruited I had liaised with her treating physicians and sought NHS Permissions for her 
treating comprehensive care haemophilia centre.  She had a lifelong history of haemorrhagic 
symptoms dominated by spontaneous epistaxis and recurrent limb bruising, in addition to 
haemorrhage after surgical challenges and menorrhagia. She had not experienced any life-
threatening bleeding episodes and she had no co-morbidities. Her ISTH bleeding assessment 
tool score was high at 17 (upper limit of normal in healthy volunteers 4).  The patient had two 
sisters with a similar bleeding history. Initial laboratory assessment in her referring hospital 
revealed a normal platelet count and normal basic coagulation parameters (prothrombin time 
and activated partial thromboplastin time).    
Aggregation testing in this patient was undertaken by Marie Lordkipanidzé.  I contributed to 
interpretation of the aggregation findings, production of the patient’s report and reports of 
other family members, planning further investigation and compiling the findings for 
publication.  Aggregation responses to ADP (Figures 9.2A and 9.2D), adrenaline and PAR1 
peptide (Figures 9.2C and 9.2D) were significantly reduced whilst aggregation responses to 
arachidonic acid (Figures 9.2B and 9.2D), PAR-4 peptide, collagen, collagen-related peptide 
and ristocetin were normal.  Only shape change was seen in response to ADP, even at supra-
physiological concentrations as high as 300 µM, which was accompanied by an absence of 
aggregation in response to a high concentration of adrenaline (30 µM).  These results were 
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indicative of a loss of ADP P2Y12 receptor function, but with more a pronounced reduction in 
PAR-1 peptide aggregation than expected for this type of defect.   
 
Figure 9.2 Agonist-induced platelet activation in homozygous carrier of the P2Y12 R122C mutation.  
(A-C) Representative traces showing platelet aggregation in response to (A) ADP (100 µM) (B) 
Arachidonic acid (1 mM) and (C) PAR-1 peptide (100 µM) (D) Maximal platelet aggregation in 
response to ADP (10, 30, 100 and 300 µM), arachidonic acid (A.A; 1 mM), PAR-1 peptide (100 and 
250 µM), PAR-4 peptide (250 and 500 µM) and collagen (3 and 10 µg/ml). All experiments were in 
citrated PRP from a healthy volunteer (HD) and from the homozygous carrier of the P2Y12 R122C 
mutation (P1) and are representative of two independent experiments.  
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Genetic analysis was subsequently undertaken by Neil Morgan to examine both the P2Y12 and 
PAR1 genes.   All 3 exons of P2RY12 were PCR amplified and sequenced, covering the entire 
342 amino acid coding region. The patient was found to be homozygous for a novel missense 
mutation p.Arg122Cys, the result of a c.364C>T substitution. The p.Arg122Cys mutation was 
found at the start of the 2
nd
 intracellular loop of the receptor found within the DRY motif of 
this receptor.  The exonic and flanking intronic sequences of the F2R gene encoding for PAR-
1 were amplified from genomic DNA and sequenced on an automated ABI 3730 DNA 
capillary sequencer. Sequencing of all coding exons and flanking regions did not reveal any 
novel variations in any of the participants.  However the patient was homozygous for the 
rs168753 single nucleotide polymorphism (SNP). The rs168753 polymorphism is an A>T 
transversion located in the intervening sequence, 14 nucleotides upstream of the exon 2 start 
site (IVSn – 14 A/T).  The T allele (allelic frequency of 0.14) has previously been associated 
with decreased expression of PAR1 receptor on platelets, lower aggregation and secretion 
response to the PAR1 activating peptide, and decreased procoagulant activity (38).    
Platelets from three carriers of the R122C mutation, P1 and her sons P2 and P3 were 
subsequently tested (Figure 9.3).  Both P2 and P3 were heterozygous for the novel missense 
mutation p.Arg122Cys in their P2RY12 gene.  Surprisingly, while ADP response was reduced 
in P3, it was within the normal range in P2 when high ADP concentrations were used (Figure 
9.3B).  At a lower concentration of ADP (10 µM) however, aggregation responses were 
clearly biphasic (data not shown), whereas this concentration induces maximal sustained 
aggregation of platelets in control subjects studied previously (as shown in healthy volunteers 
results section) and is therefore believed to be discriminatory for the presence of an ADP 
defect.  All participants also showed reduced responsiveness to PAR1 peptide (100 µM; 
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Figure 9.3A), which was disproportionate to their impairment of ADP-induced aggregation 
(particularly in P2 who had a preserved ADP response).  Further genetic analysis by Neil 
Morgan revealed that all participants were carriers of the rs168753 polymorphism which 
likely explained their reduced PAR1 receptor responsiveness. This data is summarized in 
Figure 9.3C. 
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Figure 9.3 Agonist-induced platelet activation in index case and family members. Aggregation of 
platelets in PRP from a healthy volunteer (HD), index case (P1) or family members (P2 and P3)  in 
response to (A) PAR-1 peptide (100 µM) or (B) ADP (100 µM). Data are expressed as maximal 
platelet aggregation and aggregation after 5 minutes agonist- stimulation.  (C) Inheritance of ADP 
P2Y12 receptor mutation and PAR-1 defects in family of index case P1. Males are represented by 
squares and females by circles. The index case is arrowed with summary of platelet phenotyping for 
P1-P3.  Homozygosity for the P2RY12 364C>T (R122C) mutation is indicated by black filling on the 
left side of the symbols, while shading of the right indicates homozygosity for the rs168753 (SNP) 
mutation in the PAR-1 gene. Patient ISTH bleeding assessment tool scores, if available, are in 
brackets. 
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Further work by Stuart Mundell and colleagues in Bristol (a central GAPP laboratory) 
examined if there were any significant changes in receptor expression as a result of the R122C 
mutation (40).    These results are shown in Appendix 3.  This shows reduced cell surface 
expression of the mutant R122C receptor, with resultant intracellular pooling and impaired 
ability to recycle to the cell surface.  As a result of this, the R122C receptor was found to be 
associated with lysosomal markers, and is therefore rendered a target for degradation. 
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9.4  Discussion 
The cases discussed in this chapter show the potential applicability of autozygosity mapping 
and phenotype guided direct gene sequencing in determining the genetic cause of platelet 
defects in patients recruited to the GAPP study.  Whole exome sequencing has also been used 
to look for genetic defects in recruited patients, as discussed in Section 11.4.3 and published 
elsewhere (68, 99, 155). 
In the first patient discussed in this chapter, a novel mutation in the HPS7 (Dysbindin) gene 
causing a premature stop codon was rapidly identified following autozygosity mapping using 
microsatellite markers. This high-speed technique provided a rapid approach to identify 
candidate genes for Sanger sequencing. An alternative method to identify the genetic defect in 
this patient would have been to utilise second generation sequencing strategies such as whole 
exome sequencing or custom built arrays; however, this would have been far more costly and 
time consuming given the consanguinity in this family which we exploited to narrow down 
the culprit gene. Despite having had numerous hospital visits and lifelong excessive bleeding, 
the cause of this patient’s bleeding was not elucidated until she was aged in her eighth decade. 
Mild inherited platelet disorders should therefore be considered in patients presenting with 
excessive bleeding later in life. 
When mutations have been identified verification of their effect is necessary to establish their 
functional consequence and to demonstrate causality.  An example of this work by Stuart 
Mundell and colleagues (in the patient discussed in this chapter with an ADP P2Y12 mutation) 
is shown in Appendix 3, and shows reduced cell surface expression of the mutant receptor, 
with impaired recycling to the cell surface and a resultant increase in lysosomal association, 
increasing the chance of receptor degradation. The co-inheritance of the F2R (PAR1) 
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rs168753 single nucleotide polymorphism (SNP) in this patient and her recruited relatives 
may explain her disproportionate deaggregation with high dose PAR1 peptide and could 
contribute to her overall bleeding risk, in keeping with the multifactorial theory of bleeding 
(Figure 1.5). 
Both cases presented here demonstrate the importance of using information obtained from 
taking a clinical history and from laboratory assessment of platelet phenotype in guiding 
genetic investigation.  Establishing the underlying genetic cause of the increased bleeding 
seen in the patients described is important in ensuring correct treatment is given for any future 
periods of high risk of bleeding (such as peri-operatively or after injury) and in family 
counselling, particularly in families where consanguinuity is common. 
 
Investigation of patients with unexplained menorrhagia 
 
Page | 108 
 
CHAPTER TEN: STUDY OF PATIENTS WITH UNEXPLAINED MENORRHAGIA 
AND INVESTIGATION OF THE CONTRIBUTION OF AN UNDERLYING 
PLATELET DEFECT 
10.1  Introduction 
Diagnosing an underlying platelet disorder may be important is those with unexplained 
menorrhagia (heavy menstrual bleeding), and may significantly change medical management. 
Menorrhagia is defined as menstrual bleeding lasting more than seven days or with a total 
blood loss of greater than eighty millilitres (156).  Initial secondary care investigations 
include a coagulation and von Willebrand factor screen and an ultrasound scan of the uterus to 
exclude fibroids (which are very common and increase in prevalence with age (157)) or other 
anatomical abnormalities.  In a significant number of patients this testing does not reveal an 
underlying cause.   
The World Health Organisation estimates that 18 million women worldwide suffer from 
menorrhagia (158) and it is perceived as a public health challenge (159). It is common in 
women of reproductive age, and is most prevalent in those aged 30-49.  One in every twenty 
women in this age group will consult their general practitioner each year due to excessive 
menstrual bleeding (160).  Iron deficiency anaemia is very common in women with 
menorrhagia and leads to the need for oral iron replacement and reduced quality of life due to 
lethargy (161).  A  reduction in work productivity and ability to conduct activities of daily 
living has also been documented in patients with heavy menstrual bleeding (162). 
Assessment of menorrhagia is difficult as blood loss is hard to quantify.  The alkaline 
haematin method of assessing blood loss (156) is impractical and an alternative is now 
assessment of blood loss using pictorial charts such as the Pictorial Blood Assessment Chart 
(144).  Menorrhagia is often a taboo subject for discussion, especially in some cultural 
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groups, and patients can therefore present after many months or years of troublesome 
symptoms.  Many women prefer to consult a female doctor with regard to menorrhagia, and in 
some areas and practices this may not always be an option. 
Abnormalities of haemostasis have emerged as an important contributor to the pathology of 
menorrhagia over the last ten to fifteen years.  There is a very wide variation in the estimate of 
the prevalence of menorrhagia in women with inherited bleeding disorders with an estimate of 
5-98% of women with known platelet disorders developing this complication (163).  A 
reduction in quality of life due to menorrhagia is found in these patients (164).  Over two 
thirds of adolescents with known platelet function disorders experience menorrhagia which 
can result in hospitalisation and blood transfusion (165). 
Undiagnosed abnormalities of haemostasis can be an underlying cause in a significant 
proportion of women with menorrhagia.  Amongst newly diagnosed patients. 11-15% are 
believed to have von Willebrand disease, the commonest inherited bleeding disorder (166).  
When examining adolescents with menorrhagia the proportion of underlying haemostatic 
abnormalities may be higher, with one study demonstrating an underlying haemostatic 
abnormality in over half of young females referred for assessment (167).   The original 
description of von Willebrand disease came from a family where the index case died due to 
excessive and unstoppable menstrual bleeding (translated and discussed in (168)).  
Some studies suggest that as high as 80% of patients have impaired platelet aggregation as a 
contributing pathology (169). There is a huge variation on the estimated prevalence of 
abnormal platelet function in this group which may be explained by the fact that studies have 
taken place across many centres using variable techniques and non standardised classification 
of what constitutes a platelet defect. Significant variation between hospital sites and racial 
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origin of patients have been described within studies (170).  Menorrhagia has been 
documented as the presenting symptom in several patients subsequently found to have an 
inherited platelet disorder (171-173). When focussing on adolescents with menorrhagia, 
laboratory platelet function abnormalities have been shown in a significant proportion, 
although the difficulty of non standardised methodology rendering comparison difficult 
persists (174, 175).  
There are no formal guidelines addressing the utility of platelet function testing in this 
condition and it is therefore not routinely undertaken in investigating patients, although some 
recent publications have suggested that investigating a possible platelet defect in patients with 
unexplained menorrhagia may be worthwhile (176, 177).  Therefore, the contribution of mild 
platelet disorders to the pathophysiology of menorrhagia remains unclear.  The recommended 
therapy for women who have failed hormonal treatment of this condition is hysterectomy, 
which can sometimes take place at a relatively young age (178).  In 2012-13, 30 000 
hysterectomies were carried out in England, most commonly in women aged between 40 and 
50 (179).   
A better understanding of the implication of platelet function disorders in the aetiology of 
menorrhagia and the potential development of platelet targetted therapies may offer an 
important therapeutic avenue in the treatment of this disease, and could prevent unnecessary 
early surgical intervention with its associated comorbidities. 
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10.2  Aim 
1. To establish whether there is a significant prevalence of undiagnosed platelet function 
defects in patients with unexplained menorrhagia. 
 
10.3  Methods 
Patients with menorrhagia were studied from two distinct referral pathways: 
1. Those who had seen a tertiary gynaecology service (at Birmingham Women’s 
Hospital) due to menorrhagia and had no structural uterine abnormality or 
coagulopathy on local testing (referred to as having “primary menorrhagia”, n=20).   
 
2. Those who had excessive clinical bleeding with menorrhagia as a predominant feature 
and were referred to UK Comprehensive Care Haemophilia Centres for further 
investigation (referred to as having “clinically diagnosed” menorrhagia, n=21).  Post 
menopausal women were included in this group when menorrhagia had been their 
historical predominant bleeding feature. 
 
Inclusion and exclusion criteria are listed below 
Inclusion criteria 
 Female adult patients, aged ≥ 16 years 
 Willing to participate and able to provide informed consent 
 Diagnosed with menorrhagia and reviewed in secondary care 
 Platelet count within the local laboratory reference range. 
 No evidence of structural abnormalities such as fibroids on ultrasound scanning of 
the pelvis (for primary menorrhagia group) 
 
Exclusion criteria 
 Patients taking drugs that are known to influence platelet function, including 
nonsteroidal anti-inflammatory drugs, aspirin, clopidogrel and dipyridamole within 
7 days of enrolment 
 Patients known to have a platelet disorder, coagulopathy or von Willebrand 
disease 
 Patients having undergone a major surgical procedure within 1 month of enrolment 
 Patients with chronic renal failure requiring dialysis 
 Patients with severe anaemia (Haemoglobin < 80g/l) 
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As some of the patients recruited to the primary menorrhagia arm did not require clinical 
follow up, recruitment into the trial and blood sampling within patients’ homes was offered as 
an alternative.  A risk assessment pertaining to this was completed and assessed by the ethics 
committee.  This option significantly improved accrual to the study following its introduction. 
Local coagulopathy screening comprised basic coagulation screens (prothrombin time and 
activated partial thromboplastin time) and a von Willebrand profile in the clinically diagnosed 
group (von Willebrand factor levels, von Willebrand factor activity – ristocetin co-factor 
assay (Ricof) and FVIII:C levels).  Von Willebrand profiles were not pre-tested but were 
checked in the primary menorrhagia group as part of my studies (testing carried out by 
haemostasis laboratory, University Hospitals Birmingham).  A ferritin level was also 
measured in the local biochemistry laboratory in all patients from the primary menorrhagia 
group. 
An ISTH bleeding assessment tool score was recorded in participants (patients only), and a 
sample from a healthy volunteer (recruited from the same site as the patient) was studied 
alongside each patient sample.  Further information about ISTH bleeding assessment tool 
analysis and healthy volunteer recruitment is given in Section 2.1.2. 
Platelet preparation and platelet function testing was carried out as detailed in Section 2.2.2, 
using the rationalised agonist panel described in Chapter 5 and detailed in Table 5.1.  
Statistical analyses was carried out using Microsoft Excel 2007 and GraphPad Prism 4, with 
testing methodologies as specified in figure legends (dependent upon the data being 
interrogated).  P-values were considered to be significant if they were ≤0.05. 
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Genetic studies were carried out by Neil Morgan and his laboratory team, as detailed in 
Section 2.4. 
 
10.4  Results 
10.4.1 Patient cohort 
Median age in the primary menorrhagia group was 44 years, with an interquartile range of 38 
to 47 years.  In the clinically diagnosed group median age was 44.5 years, with an 
interquartile range of 33 to 56 years (p=0.62 for age difference between the two groups using 
Mann Whitney U test).  There was a wider spread of ages in the clinically diagnosed group as 
some women were referred later in life, in some cases when they were post menopausal, but 
gave a clear history of troublesome menorrhagia throughout their reproductive years.  The 
spread of ages in both groups is shown in Figure 10.1. 
In the primary menorrhagia referral group 19/20 (95%) of patients reported significant 
impairment in activities of daily living (such as work, housework, exercise and social 
activities) with most menses.  In addition, 6/16 (38%) who had previously had normal vaginal 
deliveries had experienced post partum haemorrhage.  One participant in this group was 
suspected to have Type 1 von Willebrand’s disease, although on repeat testing her von 
Willebrand profile results were within the normal range.  The prevalence of von Willebrand’s 
disease in this group was therefore much lower than that previously reported in the literature 
(166). 
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ISTH Bleeding Assessment Tool (BAT) scores were recorded in both groups.  The local 95
th
 
centile score in healthy volunteers was 4.  In patients with primary menorrhagia, the median 
score was 4.5, with an interquartile range of 3.75 to 7.25.   This group had a median score of 3 
for the segment of the ISTH BAT specifically relating to menorrhagia (maximum score 4), 
with an interquartile range of 2.75-3.25.  In patients with clinically diagnosed menorrhagia, 
the median score was 13 with an interquartile range of 10 to 16 (Figure 10.2).  The higher 
score in the clinically diagnosed group was statistically significant (p<0.0001 using Mann 
Whitney U test), and was explained by the presence of other bleeding symptoms in this group. 
The ISTH BAT score was not predictive of the presence of an underlying platelet defect in 
either of the referral groups (Figure 10.3A and 10.3B, p=0.54 and 0.23 for primary 
menorrhagia and clinically diagnosed groups respectively when comparing BAT score in 
those with and without a platelet defect, using Mann Whitney U test).  
 
Figure 10.1  Age of patients with menorrhagia by referral group.  Bars represent median and 
interquartile range.  p=0.62 using Mann Whitney U test. 
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Figure 10.2  ISTH Bleeding Assessment Tool score by referral group.  Bars represent median and 
interquartile range.  Horizontal dotted line represents 95
th
 centile of normal BAT score (score of 4) in 
healthy volunteers.  p<0.0001 using Mann Whitney U test. 
 
A 
 
B 
 
Figure 10.3  ISTH Bleeding Assessment Tool scores in patients with and without a platelet defect on 
laboratory testing.  Panel A shows patients with primary menorrhagia, Panel B shows patients with 
clinically diagnosed menorrhagia.  Bars represent median and interquartile range.  Horizontal dotted 
line represents 95
th
 centile of normal BAT score (score of 4) in healthy volunteers.  p<0.0001 using 
Mann Whitney U test.  p=0.54 for Panel A and 0.23 for Panel B when comparing groups with and 
without a platelet defect using the Mann Whitney U test.  
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10.4.2  Lumiaggregometry responses 
6 participants (30%) in the primary menorrhagia group were found to have platelet defects – 
one with a dense granule secretion defect, and five with a defect in Gi pathway signalling 
(with predominantly reduced responses in ADP and adrenaline mediated aggregation).   Their 
aggregation responses are quantified and compared to normal ranges in healthy volunteers in 
Tables 10.1, 10.2, 10.3 and 10.4. 
By contrast, 11 participants in the clinically diagnosed menorrhagia group were found to have 
a platelet defect (52%).  These comprised 4 dense granule secretion defects, 4 defects in Gi 
pathway signalling and 3 cyclooxygenase pathway defects.  Their aggregation responses are 
quantified and compared to normal ranges in healthy volunteers in Tables 10.5, 10.6, 10.7, 
10.8 and 10.9.  
Example clinical histories and laboratory findings from two recruited patients are shown in 
Figures 10.4 and 10.5.  The patient described in Figure 10.4 was recruited to the primary 
menorrhagia arm of the study, and was diagnosed with a Gi defect based on deaggregation to 
ADP 10µM (resulting in a right shift in the ADP dose response curve) and the presence of 
only a primary wave of aggregation to adrenaline 30µM.  The patient described in Figure 
10.5 was recruited to the clinically diagnosed arm of the study and was found to have 
deaggregation to ADP 10µM, a small amount of deaggregation to ADP 30µM, primary wave 
only aggregation to adrenaline 10µM and deaggregation with intermediate dose (30µM) PAR-
1 peptide.  On the basis of this she was diagnosed with a Gi defect, and genetic sequencing 
revealed a P2Y12 polymorphism located in exon 3A (c.36T>G [GGT>GGG], G12G) in this 
patient and her recruited relatives, with a minor allele frequency of 0.11.  No variants were 
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identified in F2R (thrombin receptor gene) in this participant or any of her recruited family 
members. 
The difference in defect rate between the primary menorrhagia and clinically diagnosed 
menorrhagia groups was statistically significant (p=0.003) using a χ2 test. 
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Patient code ADP 
3µM 
max 
agg 
(%) 
ADP 
3µM 
final 
agg (%) 
ADP 
3µM 
AUC 
(%.s) 
ADP 
10µM 
max agg 
(%) 
ADP 
10µM 
final agg 
(%) 
ADP 
10µM 
AUC 
(%.s) 
ADP 
30µM 
max 
agg (%) 
ADP 
30µM 
final 
agg 
(%) 
ADP 
30µM 
AUC 
(%.s) 
ADP 
30µM 
time to 
secretion 
(s) 
ADP 30µM 
standardised 
secretion 
(nmol 
ATP/1x10
9 
platelets) 
Normal 
range (n=68 
healthy 
volunteers, 
5
th– 95th 
centile) 
17-92 0-92 12.9-
361 
56-92 53-92 234-365 72-98 70-98 274-
395 
15-120 0.28-1.93 
Birm-JC-
140512 
60 60 238 81 81 307 72 72 219 60 0.69 
Birm-JC-
170512 
60 60 226 78 78 291 86 86 322 60 0.51 
Birm-JC-
151012 
45 42 189 74 74 297 69 69 285 105 0.31 
Birm-JC-
280113 
9 9 29 58 58 212 73 73 235 90 0.98 
Birm-JC-
040313 
38 32 152 48 45 199 76 76 283 120 0.43 
Table 10.1 Gi defects in patients with primary menorrhagia – ADP response.  Abnormal values are depicted in red and bold text. Agg = aggregation, 
AUC = area under the curve 
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Patient code Adr 
3µM 
max 
agg 
(%) 
Adr 
3µM 
final 
agg 
(%) 
Adr 
3µM 
AUC 
(%.s) 
Adr 
10µM 
max 
agg 
(%) 
Adr 
10µM 
final 
agg 
(%) 
Adr 
10µM 
AUC 
(%.s) 
Adr 
30µM 
max 
agg 
(%) 
Adr 
30µM 
final 
agg 
(%) 
Adr 
30µ
M 
AU
C 
(%.s
) 
Adr 
10µM 
time to 
sec.  (s) 
Adr 
10µM 
stand. sec. 
(nmol 
ATP/ 
1x10
9 
platelets) 
Adr 
30µM 
time 
to sec. 
(s) 
Adr 
30µM 
stand. sec. 
(nmol 
ATP/ 
1x10
9 
platelets) 
Normal 
range (n=68 
healthy 
volunteers, 
5
th
 – 95th 
centile) 
13-91 11-91 40-
305 
18-93 16-92 45-302 16-98 14-93 30-
302 
45-240 0.47-2.19 60-
240 
0.32-2.16 
Birm-JC-
140512 
Not 
done 
Not 
done 
Not 
done 
11 11 38.9 69 75 142 No sec. No sec. 180 0.90 
Birm-JC-
170512 
Not 
done 
Not 
done 
Not 
done 
7 7 21.3 7 7 26.2 No sec. No sec. No 
sec. 
No sec. 
Birm-JC-
151012 
Not 
done 
Not 
done 
Not 
done 
35 23 69.5 20 17 59.2 No sec. No sec. No 
sec. 
No sec. 
Birm-JC-
280113 
Not 
done 
Not 
done 
Not 
done 
32 32 82.6 63 55 111 No sec. No sec. 210 0.59 
Birm-JC-
040313 
Not 
done 
Not 
done 
Not 
done 
16 16 52 19 19 61.6 No sec. No sec. No 
sec. 
No sec. 
Table 10.2 Gi defects in patients with primary menorrhagia – Adrenaline response.  Abnormal values are depicted in red and bold text. Agg = 
aggregation, AUC = area under the curve, Sec. = secretion, Stand. Sec = standardised secretion. 
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Patient code PAR-1 
30µM max 
aggregation 
(%) 
PAR-1 
30µM final 
aggregation 
(%) 
PAR-1 
30µM 
AUC 
(%.s) 
PAR-1 
100µM max 
aggregation 
(%) 
PAR-1 
100µM final 
aggregation 
(%) 
PAR-1 100µM 
AUC (%.s) 
PAR-1 
100µM 
time to 
secretion 
(s) 
PAR-1 100µM 
standardised 
secretion (nmol 
ATP/1x10
9 
platelets) 
Normal 
range (n=68 
healthy 
volunteers, 
5
th
 centile – 
95
th
 centile) 
31-94 10-94 51-409 77-98 77-98 298-414 0-0 0.85-3.02 
Birm-JC-
211212 
62 62 278 66 66 272 0 0.71 
Table 10.3 Dense granule secretion defects in patients with primary menorrhagia – PAR-1 peptide response.  Abnormal values are depicted in red and 
bold text.  AUC = area under the curve. 
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Patient code ADP 10µM 
max 
aggregation 
(%) 
ADP 10µM 
final 
aggregation 
(%) 
ADP 
10µM 
AUC 
(%.s) 
Adr 10µM 
max 
aggregation 
(%) 
Adr 10µM 
final 
aggregation 
(%) 
Adr 
10µM 
AUC  
(%.s) 
Coll 3µg/ml 
max 
aggregation 
(%) 
Coll 3µg/ml 
final 
aggregation 
(%) 
Coll 
3µg/
ml 
AUC 
(%.s) 
Normal 
range (n=68 
healthy 
volunteers, 
5
th
 centile – 
95
th
 centile) 
56-92 53-92 234-
365 
18-93 16-92 45-302 69-94 69-94 162-
325 
Birm-JC-
211212 
64 64 236 13 13 42.6 61 61 157 
Table 10.4 Dense granule secretion defects in patients with primary menorrhagia –other agonist responses.  Abnormal values are depicted in red and 
bold text.  AUC = area under the curve. 
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Patient code ADP 
3µM 
max 
agg 
(%) 
ADP 
3µM 
final 
agg 
(%) 
ADP 
3µM 
AUC 
(%.s) 
ADP 
10µM 
max agg 
(%) 
ADP 
10µM 
final agg 
(%) 
ADP 
10µM 
AUC  
(%.s) 
ADP 
30µM 
max 
agg 
(%) 
ADP 
30µM 
final agg 
(%) 
ADP 
30µM 
AUC 
(%.s) 
ADP 
30µM 
time 
to sec. 
(s) 
ADP 30µM 
stand. sec. 
(nmol 
ATP/1x10
9 
platelets) 
Normal range 
(n=68 healthy 
volunteers, 5
th
 
centile – 95th 
centile) 
17-92 0-92 12.9-
361 
56-92 53-92 234-365 72-98 70-98 274-
395 
15-
120 
0.28-1.93 
Leic-SP-
210512.1 
Not 
done 
Not 
done 
Not 
done 
45 42 179 73 73 280 120 0.15 
Newc-KT-
030812.1* 
68 68 264 80 80 319 70 70 263 120 0.47 
Hull-DA-
061212.2 
36 28 141 50 45 191 59 59 245 No 
sec. 
No sec. 
Hull-DA-
220313.1 
12 8 21 28 16 90 57 55 241 No 
sec. 
No sec. 
Table 10.5 Gi defects in patients with clinically diagnosed bleeding and menorrhagia – ADP response.  Abnormal values are depicted in red and bold 
text. Agg = aggregation, AUC = area under the curve, Sec. = secretion, Stand. Sec = standardised secretion.  Incomplete data set for Newc-KT-
030812.1 as analysis performed on chart recorder and PAP-8E (during remote testing in Newcastle) with no Aggrolink software. 
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Patient code Adr 
3µM 
max 
agg 
(%) 
Adr 
3µM 
final 
agg 
(%) 
Adr 
3µM 
AUC 
(%.s) 
Adr 
10µ
M 
max 
agg 
(%) 
Adr 
10µ
M 
final 
agg 
(%) 
Adr 
10µM 
AUC 
(%.s) 
Adr 
30µM 
max 
agg 
(%) 
Adr 
30µ
M 
final 
agg 
(%) 
Adr 
30µM 
AUC 
(%.s) 
Adr 
10µM 
time 
to sec. 
(s) 
Adr 
10µM 
stand. sec. 
(nmol 
ATP/  
1x10
9 
platelets) 
Adr 
30µ
M 
time 
to 
sec. 
(s) 
Adr 
30µM 
stand. sec. 
(nmol 
ATP/  
1x10
9 
platelets) 
Normal range 
(n=68 healthy 
volunteers, 5
th
 
centile – 95th 
centile) 
13-91 11-91 40-
305 
18-
93 
16-
92 
45-302 16-98 14-
93 
30-302 45-
240 
0.47-2.19 60-
240 
0.32-2.16 
Leic-SP-
210512.1 
Not 
done 
Not 
done 
Not 
done 
10 10 32 13 13 41 No 
sec. 
No sec. No 
sec. 
No sec. 
Newc-KT-
030812.1* 
Not 
done 
Not 
done 
Not 
done 
25 25 Not 
available 
55 55 Not 
available 
No 
sec. 
No sec. No 
sec. 
No sec. 
Hull-DA-
061212.2 
Not 
done 
Not 
done 
Not 
done 
24 24 84 23 23 83 No 
sec. 
No sec. No 
sec. 
No sec. 
Hull-DA-
220313.1 
Not 
done 
Not 
done 
Not 
done 
29 29 91 50 43 121 No 
sec. 
No sec. No 
sec. 
No sec. 
Table 10.6 Gi defects in patients with clinically diagnosed bleeding and menorrhagia – Adrenaline response. Abnormal values are depicted in red and 
bold text.  Agg = aggregation, AUC = area under the curve, Sec. = secretion, Stand. Sec = standardised secretion.   
*Incomplete data set for Newc-KT-030812.1 as analysis performed on chart recorder and PAP-8E (during remote testing in Newcastle) with no 
Aggrolink software. 
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Patient code PAR-1 
30µM max 
aggregation 
(%) 
PAR-1 
30µM final 
aggregation 
(%) 
PAR-1 
30µM 
AUC 
(%.s) 
PAR-1 
100µM max 
aggregation 
(%) 
PAR-1 
100µM final 
aggregation 
(%) 
PAR-1 
100µM 
AUC  
(%.s) 
PAR-1 
100µM 
time to 
secretion 
(s) 
PAR-1 100µM 
standardised 
secretion (nmol 
ATP/1x10
9 
platelets) 
Normal range 
(n=68 healthy 
volunteers, 5
th
 
centile – 95th 
centile) 
31-94 10-94 51-409 77-98 77-98 298-414 0-0 0.85-3.02 
Card-PC-
100112.1 
84 84 364 89 89 387 0 0.57 
Leic-SP-
240112 
84 84 368 92 92 401 0 0.57 
Birm-JW-
050712 
53 46 240 74 74 327 No 
secretion 
0 
Nott-CG-
250313.3 
64 30 201 88 88 332 0 0.44 
Table 10.7 Dense granule secretion defects in patients with clinically diagnosed bleeding and menorrhagia –                                                                
PAR-1 peptide response.  Abnormal values are depicted in red and bold text.  AUC = area under the curve. 
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Patient code ADP 
10µM 
max agg 
(%) 
ADP 
10µM 
final 
agg 
(%) 
ADP 
10µM 
AUC 
(%.s) 
Adr 
10µM 
max agg 
(%) 
Adr 10µM 
final agg 
(%) 
Adr 10µM 
AUC  (%.s) 
Coll 3µg/ml 
max agg (%) 
Coll 
3µg/ml 
final agg 
(%) 
Coll 3µg/ml 
AUC  (%.s) 
Normal range 
(n=68 healthy 
volunteers, 5
th
 
centile – 95th 
centile) 
56-92 53-92 234-365 18-93 16-92 45-302 69-94 69-94 162-325 
Card-PC-
100112.1 
49 49 271 65 40 114 82 82 217 
Leic-SP-240112 82 82 320 85 78 159 89 89 340 
Birm-JW-
050712 
73 73 303 72 72 258 65 65 243 
Nott-CG-
250313.3 
71 71 305 20 20 76 63 63 220 
Table 10.8  Dense granule secretion defects in patients with clinically diagnosed bleeding and menorrhagia –other agonist responses. Abnormal values 
are depicted in red and bold text. Agg = aggregation, AUC = area under the curve. 
 
 
 
 
 
Investigation of patients with unexplained menorrhagia 
 
Page | 126 
 
Patient code AA 
0.5mM 
max 
agg 
(%) 
AA 
0.5mM 
final 
agg 
(%) 
AA 
0.5mM 
AUC 
(%.s) 
AA 
1mM 
max 
agg 
(%) 
AA 
1mM 
final 
agg 
(%) 
AA 
1mM 
AUC 
(%.s) 
AA 
1.5mM 
max 
agg 
(%) 
AA 
1.5mM 
final agg 
(%) 
AA 
1.5mM 
AUC 
(%.s) 
AA 1mM 
time to sec. 
(s) 
AA 1mM 
stand. sec. 
(nmol 
ATP/1x10
9 
platelets) 
Normal range 
(n=68 healthy 
volunteers, 5
th
 
centile – 95th 
centile) 
0-94 0-94 0-372 70-96 70-96 235-
382 
70-92 70-92 218-362 0-30 0.30-1.99 
Nott-CG-
291012.1 
0 0 0 68 68 300 Not 
done 
Not done Not 
done 
45 0.36 
Birm-JW-
180210 
Not 
done 
Not 
done 
Not 
done 
1 1 6.1 2 2 6.7 No 
secretion 
No secretion 
Nott-CG-
250313.1 
Not 
done 
Not 
done 
Not 
done 
1 1 49.4 77 77 321 No 
secretion 
No secretion 
Table 10.9  Cyclooxygenase defects in patients with clinically diagnosed bleeding and menorrhagia.  Abnormal values are depicted in red and bold 
text. Agg = aggregation, AUC = area under the curve, Sec. = secretion, Stand. Sec = standardised secretion.   
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Clinical History: Patient aged 38.  She had a 
history of easy skin bruising and oral cavity 
bleeding.  She bruised easily after 
venepuncture and had previously experienced 
ovulation bleeding. 
She had experienced menorrhagia for 
approximately six years at the time of entry to 
the study (since the delivery of her first child).  
She had been treated with the oral 
contraceptive pill and subsequently the 
levonorgestrel releasing intrauterine device in 
addition to oral iron therapy   She had no 
family history of excessive bruising and 
bleeding. 
A. 
 
B. 
 
C. 
 
Figure 10.4 Clinical history and lumiaggregometry findings from a patient (Birm-JC-040313) 
recruited to the primary menorrhagia arm of the study.  Horizontal bars represent 2 minutes time.   Y 
axes show percentage aggregation.   For Panel A patient aggregation is shown in blue and healthy 
volunteer aggregation is shown in black.  For panels B and C patient aggregation is shown in blue, 
healthy volunteer aggregation is shown in red, patient secretion is shown in black and healthy 
volunteer secretion is shown in green.    Panel A shows response to ADP 10µM, Panel B shows 
response to ADP 30µM and Panel C shows response to adrenaline 30µM.  Responses to PAR-1 
peptide 100µM, collagen 3µg/ml, arachidonic acid 1mM and ristocetin 1.5mg/ml were all normal 
(data not shown).  Normalised secretion to PAR-1 peptide was normal at 1.15 nmol/1x10
8
 platelets (5
th
 
centile in healthy volunteers = 0.84 nmol/1x10
8
 platelets).  The patient was diagnosed with a Gi defect 
based on a right shift in the ADP dose response curve with deaggregation to ADP 10µM, and lack of 
secondary wave aggregation to adrenaline at both 10µM and 30µM (10µM data not shown here). 
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Clinical History: Patient aged 65. She had a 
history of epistaxis, easy bruising, oral cavity 
bleeding and prolonged bleeding from minor 
wounds since birth.  She required resuturing, 
packing, and treatment with antifibrinolytics and 
desmopressin for excessive bleeding after a dental 
procedure, and experienced severe post-operative 
bleeding requiring antifibrinolytic treatment, 
wound packing and blood transfusion.  She 
suffered from menorrhagia since menarche, 
requiring iron and hormonal therapy, and had 
emergency hospital admissions on 2 occasions, 
eventually necessitating hysterectomy.  She had 
post partum haemorrhage after all of her three 
deliveries necessitating blood product treatment.    
Two of her daughters had excessive bleeding and 
were also recruited to the GAPP study. 
A. 
 
B. 
 
C. 
 
D. 
 
E. 
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Figure 10.5 Clinical history and lumiaggregometry findings from a patient (Hull-DA-220313.1) 
recruited to the clinically diagnosed arm of the study.  Horizontal bars represent 2 minutes time.   Y 
axes show percentage aggregation.   For Panels A and E patient aggregation is shown in blue and 
healthy volunteer aggregation is shown in black.  For panels B, C and D patient aggregation is shown 
in blue, healthy volunteer aggregation is shown in red, patient secretion is shown in black and healthy 
volunteer secretion is shown in green.    Panel A shows response to ADP 10µM, Panel B shows 
response to ADP 30µM, Panel C shows response to adrenaline 10µM, Panel D shows response to 
adrenaline 30µM and Panel E shows response to PAR-1 peptide 30µM.  Responses to PAR-1 peptide 
100µM, collagen 3µg/ml and arachidonic acid 1mM were all normal.  Partial agglutination was seen 
with ristocetin 1.5mg/ml (data not shown).  Normalised secretion to PAR-1 peptide was normal at 0.94 
nmol/1x10
8
 platelets (5
th
 centile in healthy volunteers = 0.84 nmol/1x10
8
 platelets).  The patient was 
diagnosed with a Gi defect based on deaggregation and absence of secretion in response to ADP (up to 
30 µM), absence of a secondary wave and secretion in response to adrenaline 10 µM, a delayed 
secondary wave with absent secretion in response to adrenaline 30 µM and complete deaggregation to 
PAR-1 peptide 30 µM.    Genetic sequencing (by Neil Morgan) revealed a P2Y12 polymorphism 
located in exon 3A (c.36T>G [GGT>GGG], G12G) in this patient and her recruited relatives, with a 
minor allele frequency of 0.11. No variants were identified in F2R (thrombin receptor gene) in this 
participant or any of her recruited family members.   
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10.4.3  Other laboratory assay findings 
Values for ferritin, von Willebrand factor antigen, von Willebrand factor activity (Ricof) and 
FVIII:C activity in the patients with primary menorrhagia are shown in Figure 10.6.  For all 
of these parameters no statistically significant difference was seen when comparing patients 
with and without a platelet defect on laboratory testing.  5/16 (31%) of the patients in the 
primary menorrhagia group were noted to have iron deficiency. 
A 
 
B 
 
C 
 
D 
 
Figure 10.6 Ferritin (Panel A), von Willebrand factor antigen (Panel B), von Willebrand factor 
activity (Panel C) and FVIII:C (Panel D) values for patients in the primary menorrhagia group.  Bars 
represent median and interquartile range, and horizontal dotted lines represent upper and lower limits 
of values in healthy volunteers for the laboratory where testing was performed (lower limit only 
displayed for ferritin).   For all parameters no statistically significant difference was seen between 
patients with and without a platelet defect on laboratory testing (p values 0.72, 0.63, 0.41 and 0.93 for 
Panels A, B, C and D respectively when using Mann Whitney U test).  Five participants were noted to 
have ferritin values below the lower limit of normal.   
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10.5 Discussion 
The work presented in this chapter supports the hypothesis that a proportion of patients with 
unexplained menorrhagia have an underlying platelet defect when assessed with 
lumiaggregometry.  In keeping with the previously discussed multifactorial nature of bleeding 
(Figure 1.5), these defects are likely to contribute to an individual’s overall bleeding risk and 
may be partly responsible for their symptoms. 
The prevalence of platelet defects is higher in patients who have other symptoms of excessive 
bleeding in addition to menorrhagia, and the likelihood of an underlying platelet defect can 
not be predicted by the ISTH Bleeding Assessment Tool score, supporting the data discussed 
in Chapter 8.  Almost all the patients in the primary menorrhagia group had experienced a 
significant impact on their activities of daily living as a result of their symptoms, highlighting 
the morbidity associated with heavy menstrual bleeding. 
These findings have important clinical implications and reinforce the previously published 
recommendations that platelet function testing should be part of the investigation pathway for 
patients with unexplained menorrhagia (176, 177).  An update to the clinical guidelines on 
investigation and treatment of menorrhagia (178) to incorporate this could potentially prevent 
unnecessary hysterectomy in a small but significant number of patients.  Due to the time 
consuming nature of platelet function testing it would need to be considered after other more 
basic investigations (such as uterine ultrasound and initial laboratory coagulation screening) 
had been performed.  This potential investigative pathway may avoid the peri- and 
postoperative complications associated with hysterectomy (180) and could prevent longer 
term problems such as an adverse effect on quality of life and sexual function in some patients 
who undergo this procedure (181).  Non-surgical management of menorrhagia in patients with 
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bleeding disorders is the subject of current research, and haemostatic treatment options are 
available (182). 
The low prevalence of von Willebrand’s disease in the primary menorrhagia group is an 
interesting finding and out of keeping with previous reports (166).  This may imply that, in 
those patients where mildly reduced von Willebrand levels and activity have historically been 
causally attributed to menorrhagia, additional unexplained haemostatic defects may also be 
present. 
One of the limitations of the work I undertook was that the age of patients recruited to both 
the primary menorrhagia and the clinically diagnosed groups was relatively high.  A small 
number of post menopausal women were included in the clinically diagnosed group, as they 
gave a clear history of menorrhagia throughout their reproductive years that had often not had 
an appropriate explanation and for which they had not always sought timely medical 
attention.  It could be hypothesised that younger patients who have consistently suffered from 
menorrhagia since menarche may have a higher chance of having an underlying platelet 
disorder, although larger studies would be required to confirm this. 
In summary, the work presented in this chapter shows that undiagnosed platelet defects may 
contribute to the pathology of menorrhagia not explained by conventional investigation, and 
supports the possibility of including platelet function testing in prospective investigation of 
this patient group.  Identifying an underlying platelet defect in these patients could have 
significant implications on the treatments offered to them, and would also ensure that they 
were appropriately managed for any future episodes with a high risk of bleeding, such as 
surgery or childbirth. 
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CHAPTER ELEVEN: STUDY OF PATIENTS WITH INHERITED 
THROMBOCYTOPENIA:  DEVELOPMENT OF AN ASSAY TO MEASURE 
QUALITATIVE PLATELET FUNCTION, AND APPLICATION OF THIS ASSAY TO 
CHARACTERISE BLEEDING PHENOTYPE IN PATIENTS WITH INHERITED 
THROMBOCYTOPENIA 
11.1  Introduction 
Haemophilia centres manage and treat patients with bleeding who have a lifelong inherited 
low platelet count (thrombocytopenia) with no attributable genetic diagnosis. Inherited 
thrombocytopenias ranging from moderate to severe are relatively rare but there are a number 
of patients and families enlisted at UK Haemophilia Centres classified as having these 
disorders.  In 2013-14, 1768 patients were registered as having a platelet defect not 
attributable to Glanzmann’s thrombasthenia or Bernard-Soulier syndrome, but this figure 
includes those with normal platelet counts and those with thrombocytopenia (183).  The 
number of patients with inherited thrombocytopenia is likely to be underestimated as some 
will be misdiagnosed as having immune thrombocytopenia purpura.  Misdiagnosis of 
conditions such as MYH9 disorders occurs in up to half of all cases (184).  This misdiagnosis 
may lead to unnecessary treatments such as steroids or splenectomy which pose their own 
unpleasant and occasionally potentially life threatening side effects.   Underestimation of the 
numbers in this patient group is also compounded by the fact that some will not be formally 
registered via a haemophilia centre.  In cases other than Bernard Soulier syndrome and the 
group of MYH9 disorders (caused by a mutation in myosin-II), the genetic cause is not 
normally known and a precise diagnosis can therefore not be made.  Furthermore, lack of 
knowledge of the genetic cause means that identification of the defect in family members has  
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to rely on platelet count and bleeding history. 
Much of the available data related to bleeding and platelet count has come from studies on 
patients with temporary chemotherapy induced thrombocytopenia or acquired autoimmune 
thrombocytopenia.  In many cases, the severity of bleeding cannot be predicted by the 
reduction in platelet count alone (185) suggesting additional qualitative platelet function 
defects as important contributors to bleeding in this patient group.  However, the assessment 
of platelet function in this population suffers from the limitation that the current functional 
testing procedures (namely light transmission aggregometry) do not work with such low 
platelet counts.  Percentage maximal aggregation falls as platelet counts drop below the 
normal (15, 186).  As a consequence, the understanding of the contribution of a functional 
defect in patients with low platelet numbers is limited, leaving the reason for the wide 
variability in individuals’ platelet counts at which bleeding is observed unexplained.   
Various aspects of platelet function can be tested using flow cytometry.  This is an attractive 
technique in thrombocytopenia, as it is independent of platelet count.  The principle of it is 
that the cytometer detects scattered fluorescent light (via use of fluorescently tagged 
antibodies) emitted by each individual platelet, with signal intensity being directly 
proportional to antigen density or the size/granularity of the platelet (4).  This technique is 
routinely used in the diagnosis of Bernard-Soulier syndrome and Glanzmann thrombasthenia 
to confirm absence of platelet surface glycoproteins (187-189).  Diagnostic assays are also 
available for quantifying copy number of any major glycoprotein, studying granular defects, 
diagnosing heparin-induced thrombocytopenia, and examining defects in platelet aggregation, 
secretion, or procoagulant activity.  When looking for activation markers it is important to 
choose a molecule not normally present on resting platelets such as CD62P (or P-selectin) 
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(expressed on the platelet surface following fusion of alpha granules upon stimulation).  Some 
applications of flow cytometry are currently limited to a research context, such as its use in 
monitoring antiplatelet therapy, but could become integrated into clinical practice in the future 
(190-192).   
Whole blood flow cytometry has previously been applied in a research context to patients 
with autoimmune thrombocytopenia (ITP) and patients with myelodysplasia to compare 
platelet function at similar levels of thrombocytopenia (193).  Platelet activation and 
microparticle formation have also been assessed using flow cytometry in patients with ITP, 
myelodysplasia and myeloproliferative disorders in addition to healthy volunteers (194).  
There is no standardisation on the use of flow cytometry to examine platelet function in 
patients with inherited thrombocytopenia.  
Identification of patients with a qualitative platelet defect as well as a low platelet count could 
lead to a reduction in the number of prophylactic platelet transfusions in patients with normal 
platelet function despite a low platelet count, which would therefore limit the risks associated 
with transfusions in this patient population. When compared with red cell transfusion there is 
approximately a four fold increased risk of adverse reactions with platelet transfusion.  These 
reactions can include transmission of life threatening infections and development of 
alloantibodies which can complicate and limit further options for platelet transfusion (195).  
On a health economic point, reduction in unnecessary platelet transfusion would also save 
money as platelet units are currently priced around £200 per unit (196). 
Current practice is to give prophylactic platelet transfusion to patients with chemotherapy 
induced thrombocytopenia below a platelet count of 10-20x10
9
/l as the risk of life threatening 
spontaneous bleeding increases below this threshold (197, 198).  A multicentre clinical trial 
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recently concluded that platelet transfusion prophylaxis was still indicated in patients with 
haematological malignancy, as more bleeding was demonstrated in the no prophylaxis arm 
that they studied (199).  Previous smaller studies looking at omitting prophylactic transfusion 
during induction chemotherapy for acute myeloid leukaemia and autologous bone marrow 
transplantation had demonstrated lack of prophylaxis to be a feasible approach (200, 201).  In 
patients with immune thrombocytopenia purpura current guidelines suggest platelet 
transfusion should be restricted to emergency situations, such as when major active bleeding 
is present, or when a surgical procedure is imminent (202, 203).  In patients with inherited 
platelet disorders published guidelines recommend platelet transfusion in severe disorders and 
where other agents have failed, but caution that a clear indication should be present because 
of the risks of allergy, transfusion transmitted infection and alloantibody formation (71). 
 
Patients with both impaired platelet function and thrombocytopenia may require closer 
clinical follow up and should be cautioned appropriately about the heightened risk of 
bleeding, with relevant lifestyle advice such as avoiding close contact sports or activities with 
a high risk of head injury.  Additional treatment options such as thrombopoietin mimetics 
could then be considered for groups at higher risk.  Evidence of patients who have reduced 
platelet numbers and function and have mild bleeding clinically would also support the idea 
that bleeding is a complex trait and is multifactorial.
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11.2  Aim 
To develop a new assay to allow for testing platelet function (ie presence of qualitative 
defects) in patients with thrombocytopenia. 
11.3  Methods 
Patients with inherited thrombocytopenia were recruited from Haemophila Centres around the 
United Kingdom.  Inclusion and exclusion criteria are listed below: 
Inclusion criteria 
 Adult patients, aged ≥ 18 years 
 Willing to participate and able to provide informed consent 
 Long term thrombocytopenia (platelet count less than 150x109/l) 
  
Exclusion criteria 
 
 Patients with a known additional platelet or coagulation disorder 
 Patients previously given treatment for immune thrombocytopenia purpura 
 Patients taking drugs that are known to influence platelet function, including 
nonsteroidal anti-inflammatory drugs, aspirin, clopidogrel, and dipyridamole within 7 
days of enrolment. 
 Patients having undergone a major surgical procedure within 1 month of enrolment 
 Patients with chronic renal failure requiring dialysis 
 Patients with severe anaemia (Haemoglobin <80g/l) 
 
An ISTH bleeding assessment tool score was recorded in participants (patients only), and a 
sample from a healthy volunteer (recruited from the same site as the patient) was studied 
alongside each patient sample.  Further information about ISTH bleeding assessment tool 
analysis and healthy volunteer recruitment is given in Section 2.1.2. 
 
Investigation of patients with inherited thrombocytopenia 
 
Page | 138 
 
11.3.1 Assay development 
Initial experiments focussed on assessing platelet response using flow cytometry to platelet P-
selectin (CD62P, marker of platelet α-granules) to a range of agonists.  P-selectin was chosen 
as it is stably expressed in platelets over time.  This was assessed by the following method: 
 
10ml of blood from a healthy volunteer (n=10) was taken into 10% by volume 3.2-3.8% 
trisodium citrate.  Platelet rich plasma was prepared as described in Section 2.2.1 then count 
adjusted platelets to produce 2x10
7
/ml were made by dilution with phosphate buffered saline 
(PBS).  This was then left for 30 minutes and 45µl of PRP was tested with a panel of agonists 
as shown overleaf (Table 11.1).  The PRP with added agonist was placed in a waterbath at 
37ºC for 2 minutes.  The reaction was terminated with 250µl ice cold PBS (a five-fold excess 
of PBS when compared with the total experimental reaction volume). 
 
Agonist Conc. Conc. Conc. Conc. 
0 (control) Nil (PBS vehicle)    
Adenosine diphosphate (ADP)
  
100µM 30µM 10µM 3µM 
 
Protease activated receptor 
(PAR)-1 peptide 
Sequence Ser-Phe-Leu-Leu-Arg-
Asn 
100µM 30µM 
 
10µM 
 
3µM 
 
Protease activated receptor 
(PAR)-4 peptide 
Sequence Ser-Phe-Leu-Leu-Arg-
Asn 
300µM 
 
100µM 
 
30µM  
U46619  10µM 3µM 1µM 0.3µM 
Adrenaline 30µM    
Arachidonic acid 1.5mM 1mM 0.5mM 0.1mM 
Collagen related peptide (CRP) 3µg/ml 1µ/ml 
 
0.3µg/ml 0.1µg/ml 
 
Table 11.1 – Agonist concentrations used in initial platelet flow cytometry experiments.  Conc. = 
concentration 
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5µl of P-selectin (mouse anti-human CD62 antibody, BD Pharmingen) was then added to 25 
FACS tubes.  300µl from each reaction volume (the total reaction volume) was added to a 
FACS tube and incubated in the dark for 45 minutes.  Flow cytometric analysis (Becton 
Dickinson FACS Calibur machine) was then undertaken to establish baselines and gating on 
the platelet population to record a total of 10000 events.  Geometric mean was recorded for 
each agonist and concentration. 
 
This method was subsequently modified to assess response at three dilutions of PRP (n=6) in 
the same way as described previously.  The concentrations of PRP assessed were neat 
(undiluted), and 1 in 3 and 1 in 10 diluted with PBS.  The reason for assessing several 
concentrations was to assess if dilution reduced the geometric mean fluorescence intensity.  
For each dilution the agonist concentrations listed below were assessed: 
ADP    0, 3, 10 and 30µM 
CRP    0, 0.3, 1 and 3 µg/ml 
PAR-1 peptide  0, 10, 30 and 100µM  
 
Responses to these agonists were chosen for assessment as they signal in different ways – 
CRP predominantly via tyrosine kinases, ADP predominantly via the P2Y12 receptor and Gi 
pathway, and PAR-1 peptide predominantly via the Gq pathway. 
 
At this stage a new Accuri C6 flow cytometer was obtained for future work and was dedicated 
solely to use with platelets.  Due to the nature of this instrument (digital with no logarithmic 
amplifiers), it was not possible to record geometric mean fluorescence intensity and median 
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fluorescence intensity was the most appropriate substitute measure.  However, it was still 
possible to compare trends of response between the two instruments. 
 
The PRP dilution experiments (n=4) outlined above were re-conducted using this equipment 
to check for reproducibility of results.  The agonists tested were the same as in the previous 
PRP dilution experiments.   An isotype control (mouse anti human-IgG1κ, BD Pharmingen) 
was also investigated alongside. 
 
The effects of inhibitors were investigated (n=5) by preparing PRP with DMSO (0.1% final 
concentration), indomethacin (cyclooxygenase inhibitor, Sigma-Aldrich, Poole, UK) in 
DMSO (10µM, 0.1% DMSO final concentration) and cangrelor (ADP P2Y12 receptor 
inhibitor, the Medicines Company, Abingdon, United Kingdom) in DMSO (1µM, 0.1% 
DMSO final concentration).  Each of these batches was tested neat and diluted 1 in 3 and 1 in 
10 with the agonists as per the original dilution experiments. 
 
This approach was extended to PAC-1 (activated glycoprotein αIIbβ3, Becton Dickinson) and 
fluorescent fibrinogen (DAKO cytomation polyclonal rabbit anti human fibrinogen-FITC).  
For each dilution 4 groups were studied: 
 PAC-1 added pre agonist 
 PAC-1 added post agonist 
 Fluorescent fibrinogen added pre-agonist 
 Fluorescent fibrinogen added post agonist 
The agonists studied for each dilution and group were ADP 30µM and PAR-1 100µM. 
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11.3.2 Investigation of patients with inherited thrombocytopenia   
10ml of blood from recruited patients was taken into 10% by volume 3.2-3.8% trisodium 
citrate, along with blood samples from a healthy volunteer recruited at the same site.  Platelet 
rich plasma was prepared as described in Section 2.2.1. 
 
11.3.2.1 Resting expression levels 
 
Surface receptor expression levels of CD42b (BD Pharmingen, FITC mouse anti-human 
CD42b) CD41 (DAKO, FITC mouse anti-human CD41) and GPVI (Gift from Elizabeth 
Gardiner, Monash University, Australia, PE conjugated) were assessed by incubating 45µl of 
PRP with 5µl of antibody and allowing to develop in the dark for 45 minutes. A zero value 
using 5µl of PBS alone and an isotype control (mouse anti human-IgG1κ, BD Pharmingen) 
were also recorded.  Reactions were terminated with 250µl ice cold PBS.  Flow cytometric 
analysis (Accuri C6 machine) was then undertaken to establish baselines and gating on the 
platelet population to record a total of 10000 events.  Median fluorescence intensity was 
recorded for each incubation. 
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11.3.2.2  P selectin responses 
 
P selectin responses were then assessed by testing aliquots of 45µl of PRP from both the 
recruited patient and healthy volunteer with a panel of agonists as listed below: 
Zero value  PBS alone 
Isotype control PBS alone 
ADP   3µM and 30µM 
CRP   0.3µg/ml and 3µg/ml 
PAR-1 peptide 10µM and 100µM 
The PRP with added agonist was placed in a waterbath at 37ºC for 2 minutes.  The reaction 
was terminated with 250µl ice cold PBS (a five-fold excess of PBS when compared with the 
total experimental reaction volume). 
5µl of P-selectin (mouse anti-human CD62 antibody, BD Pharmingen) was then added to 
FACS tubes.  300µl from each reaction volume (the total reaction volume) was added to a 
FACS tube and incubated in the dark for 45 minutes.  Flow cytometric analysis (Accuri C6 
machine) was then undertaken to establish baselines and gating on the platelet population to 
record a total of 10000 events.  Median fluorescence intensity was recorded for each agonist 
and concentration. 5µl of isotype control antibody (mouse anti human-IgG1κ, BD 
Pharmingen) was used for the isotype control assessment (in place of anti-CD62P). 
Median fluorescence intensities obtained were then compared to the platelet count equivalent 
healthy volunteers dilution experiments results in order to determine whether a possible 
qualitative platelet defect was present. 
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11.3.2.3  Fluorescent fibrinogen responses 
 
Fluorescent fibrinogen responses were assessed by testing aliquots of 45µl of PRP diluted 1 in 
10 with PBS from both the recruited patient and healthy volunteer with the same panel of 
agonists as listed for the P selectin response testing.  Isotype control values were not recorded 
for fluorescent fibrinogen.  As per the pilot experiment data, 5µl of fluorescent fibrinogen 
(DAKO cytomation polyclonal rabbit anti human fibrinogen-FITC) was added to the diluted 
PRP prior to agonist addition.  The diluted PRP with added fluorescent fibrinogen and agonist 
was placed in a waterbath at 37ºC for 2 minutes.  The reaction was terminated with 250µl ice 
cold PBS (a five-fold excess of PBS when compared with the total experimental reaction 
volume). The reaction volumes were incubated in the dark for 45 minutes.  Flow cytometric 
analysis (Accuri C6 machine) was then undertaken to establish baselines and gating on the 
platelet population to record a total of 10000 events.  Median fluorescence intensity was 
recorded for each agonist and concentration.  Median fluorescence intensities obtained were 
then compared to data accrued from all healthy volunteers in order to determine whether a 
possible qualitative platelet defect was present.  
 
11.3.2.4  Statistical analyses and genetic testing 
 
Statistical analyses was carried out using Microsoft Excel 2007, GraphPad Prism 4 and IBM 
SPSS Statistics 19, with testing methodologies as specified in figure legends (dependent upon 
the data being interrogated).  P-values were considered to be significant if they were ≤0.05. 
Genetic studies were carried out by Neil Morgan and his laboratory team, as detailed in 
Section 2.4. 
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11.4  Results 
11.4.1  Assay development 
11.4.1.1  Assessement of platelet rich plasma response to a variety of agonists using flow 
cytometry to P-selectin (mouse anti human-CD62P) 
A total of 10 healthy volunteers were assessed using methods as described above.  Results are 
shown in Figure 11.1. 
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Figure 11.1 Assessment of platelet rich plasma response using flow cytometry to P-selectin (mouse 
anti human-CD62P) on BD Facs Calibur machine.   Assessed at a platelet rich plasma count of 
2x10
7
/ml.  Results expressed as mean ± 1 standard deviation.  A = PAR-1 peptide 3-100µmol, B= 
ADP 3-30µmol, C= PAR-4 peptide 30-300µmol, D= U46619 0.1-10µmol, E= CRP 0.1-3µg/ml.  Mean 
PRP count prior to dilution = 3.5 x10
8
/ml, standard deviation 1.26x10
8
/ml.  Basal fluorescence 
intensity value was 15.8 (mean), with a standard deviation of 6.12.   
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Dose response curves were demonstrated to PAR-1 peptide, ADP, PAR-4 peptide and CRP.  
U46619 demonstrated a maximal (probable saturating) response at 1µM with overlapping 
standard deviations at all concentrations.   
Examples of dose response curves for individual participants are shown in Figure 11.2: 
  
Figure 11.2 Assessment of individual participant’s platelet rich plasma responses using flow 
cytometry to P-selectin (mouse anti human -CD62P) on BD Facs Calibur machine.   Assessed at a 
platelet rich plasma count of 2x10
7
/ml. A= Response to CRP 0.1-3µg/ml, B = Response to PAR-1 
peptide 3-100µM.   Mean PRP count prior to dilution = 3.5 x10
8
/ml, standard deviation 1.26x10
8
/ml 
  
As expected, there were significant differences in the magnitude of response between 
participants demonstrating a wide variety within the normal range.   
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11.4.1.2   Assessment of  platelet rich plasma response at three dilutions (neat, 1 in 
3 and 1 in 10) to ADP, CRP and PAR-1 peptide 
A total of six healthy volunteers were assessed using the BD Facs Calibur machine and 
responses are depicted in Figure 11.3: 
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Figure 11.3 Assessment of platelet rich plasma response at 3 dilutions (neat, 1 in 3 diluted with PBS 
and 1 in 10 diluted with PBS) using flow cytometry to P-selectin (mouse anti human -CD62P) on BD 
Facs Calibur.  Agonists tested – panel A = ADP 3-30µM, panel B=CRP 0.3-3µg/ml, panel C = PAR-1 
peptide 10-100µM.  Results expressed as mean ± 1 standard deviation.  n=5-6.   
  
For each graph, one way ANOVA was conducted for each concentration of agonist 
represented. The dependent variable was median fluorescence intensity and the varying 
dilutions of PRP were the independent variables.  For statistical significance bars,   * = p ≤ 
0.05 
 
These results show that for ADP and PAR-1 peptide measurement at 1 in 3 and 1 in 10 PRP 
dilutions show similar results to neat PRP.  The platelet count in these dilutions is similar to 
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the count we would expect in the PRP of patients with inherited thrombocytopenia and this 
technique is therefore potentially feasible as a way of assessing platelet function in this group 
of patients.  For CRP at low and intermediate concentrations, there is a significant difference 
in the values obtained with differing dilutions.  This may be because dilution also reduces the 
amount of important feedback mediators such as thromboxane A2.  This effect seems to be 
overcome at the highest CRP concentration. 
Initial work was then done to calibrate and establish familiarity with the Accuri C6 machine 
relative to the Becton Dickinson Flow Cytometer and examples of this are shown in Figure 
11.4: 
 
 
 
 
 
 
 
 
Investigation of patients with inherited thrombocytopenia 
 
Page | 150 
 
 
(10 000 events displayed on 
graph)
PRP count 5.6x108/ml, 
MPV 8.3 fl
SSC vs FSC Count vs FLI-H
0
CRP         
3µg/ml
 
Figure 11.4 Setting up Accuri C6.  Panel A shows a screen shot from the data collection and analysis 
software, and panel B shows example SSC vs FSC and count vs fluorescence plots for basal PRP 
samples and those activated with CRP 3μg/ml using an antibody to P selectin (mouse anti-human 
CD62P) 
 
A change in the shape of the SSC vs FSC plot was clearly visible on stimulation with high 
concentration CRP, as was a right hand shift in count vs FL1 plot indicating an increase in 
fluorescence and platelet activation. 
A total of nine healthy volunteers were then assessed and results are depicted in Figure 11.5. 
 
 
 
 
 
 
 
A. B. 
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Figure 11.5 Assessment of platelet rich plasma response at 3 dilutions (neat, 1 in 3 diluted with PBS 
and 1 in 10 diluted with PBS) using flow cytometry to P-selectin (mouse anti human -CD62P) on 
Accuri C6.  Agonists tested – panel A = ADP 3-30µM, panel B = CRP 0.3-3µg/ml, panel C = PAR-1 
peptide 10-100µM.  Results expressed as mean ± 1 standard deviation.  n=9.  For each graph, one way 
ANOVA was conducted for each concentration of agonist represented. The dependent variable was 
median fluorescence intensity and the varying dilutions of PRP were the independent variables.  For 
statistical significance bars,   * = p ≤ 0.05 
 
These results were not directly comparable to those obtained on the BD Facs Calibur because 
of the differing modes of analysis, however they were broadly in agreement with similar 
trends and feasibility of this technique at the 1 in 10 PRP dilution was shown again.  These 
results show that for all concentrations of ADP except the highest and for all concentrations of 
Investigation of patients with inherited thrombocytopenia 
 
Page | 152 
 
PAR-1 peptide measurement at 1 in 3 and 1 in 10 PRP dilutions show similar results to neat 
PRP. For CRP at intermediate and high concentrations, there is a significant difference in the 
values obtained with differing dilutions.   
Further analysis of these results including spread of data across individual participants and 
response according to PRP count in each dilution is shown in Figure 11.6 below.  As 
expected for any biological test, there is significant inter-individual variability within the 
normal range. 
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Figure 11.6  Assessment of platelet rich plasma response at 3 dilutions using flow cytometry to P-
selectin (mouse anti human -CD62P) assessed on Accuri C6 machine.  Panel A uses an example of 
response to intermediate concentration CRP (1µg/ml) and shows the spread of response over 
individual participants.  Panel B shows a scatter plot of platelet count per dilution and response to 
intermediate concentration CRP (1µg/ml) with a non-linear regression line of best fit. Panel C shows 
the dose response curves for CRP in neat PRP in individual subjects.  IC = isotype control. n=9. 
r value displayed in Panel B represents the calculated correlation coefficient. 
Panels A and C highlight the variability observed between individuals within the normal range in 
assessing response at various dilutions and at increasing concentrations of CRP respectively.  Panel B 
shows a line of best fit (non-linear regression) demonstrating the response between PRP count and 
response to CRP 1µg/ml. 
 
 
 
 
 
 
 
A) B) 
C) 
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11.4.1.3   Assessment of platelet rich plasma response dilutions to ADP, CRP and 
PAR-1 peptide using inhibitors. 
Five healthy volunteers were assessed yielding the results shown in Figure 11.7:  The effect 
of blockade of the major feedback pathways of platelet activation, namely thromboxane 
formation and ADP secretion, on the expression of P-selectin was investigated using the 
cyclooxygenase inhibitor, indomethacin, and P2Y12 receptor antagonist, cangrelor, 
respectively.   
Complete inhibition of the ADP response was demonstrated at all PRP dilutions (neat, 1 in 3 
and 1 in 10) and analysis of the ADP results shows a statistically significant difference in 
mean fluorescence intensity at all PRP dilutions with addition of inhibitors.  A significant 
difference on addition of inhibitors was only shown at the lowest concentrations of CRP and 
PAR-1 peptide. 
Post-hoc Tukey analysis (using IBM SPSS Statistics 19) showed the statistical significance on 
addition of inhibitors to be dependent on cangrelor.  For all dilutions of PRP tested with ADP 
30µM p values were less than 0.05 for comparison of no inhibitor versus cangrelor and 
indomethacin versus cangrelor.  P values for other comparisons did not show statistical 
significance. 
For neat PRP tested with CRP 3µg/ml the statistical significance on ANOVA was due to the 
difference between no inhibitor and the addition of cangrelor (p=0.045) with other 
comparisons not yielding statistical significance. 
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Lastly, for neat PRP tested with PAR-1 peptide 100µM the statistical significance on 
ANOVA was due to the differences between no inhibitor versus cangrelor (p=0.001) and 
indomethacin versus cangrelor (p=0.021).  Comparisons of other pairs within this group did 
not reach statistical significance. 
 
  
 
 
 
Figure 11.7 Assessment of PRP response at 3 dilutions (neat, 1 in 3 diluted with PBS and 1 in 10 
diluted with PBS) for high concentrations of ADP (Panel A), CRP (Panel B) and PAR-1 peptide 
(Panel C) using flow cytometry to P-selectin (mouse anti human -CD62P) and inhibitors, 
indomethacin 10µM final concentration and cangrelor 1µM final concentration.   Results expressed as 
mean + 1 standard deviation.  X-axes represent PRP dilutions. Y axes represent median fluorescence 
intensity as assessed on Accuri C6 machine. n=5.  For each graph, one way ANOVA was conducted 
for each PRP dilution represented. The dependent variable was median fluorescence intensity and the 
inhibitor added was the independent variable.  Basal values were excluded from the ANOVA analyses 
(each analysis examined data for no inhibitor, indomethacin and cangrelor).  For statistical 
significance bars,   * = p ≤ 0.05 
 
Investigation of patients with inherited thrombocytopenia 
 
Page | 156 
 
11.4.1.4  Pilot experiment assessing response to PAC-1 (activated glycoprotein IIbIIIa) 
and fluorescent fibrinogen 
A single experiment was carried out to determine which of these targets should be the next 
step in constructing standard curves for PRP response using flow cytometry and whether the 
flow cytometric active component (PAC-1 antibody or fluorescent fibrinogen) should be 
added prior to or after agonists.  Results are shown in Figure 11.8. 
  
Figure 11.8 Assessment of platelet rich plasma response (neat and 1 in10 dilutions) using flow 
cytometry to fluorescent fibrinogen (panel A) and PAC-1 (mouse anti-human activated glycoprotein 
IIbIIIa) (panel B).  X-axes agonist and concentration (0, ADP 30μmol and PAR-1 peptide 100μmol).  
Please note  logarithmic Y axis in panel i).  Y axes represent median fluorescence intensity as 
assessed on Accuri C6 machine. 
 
 
Using fibrinogen added prior to agonists at a 1 in 10 PRP dilution showed a dose response 
curve, which was not observed with neat PRP and fibrinogen added prior to incubation, or 
with fibrinogen added post incubation to either neat or 1 in 10 diluted PRP.  No dose response 
curve was seen with all combinations of neat and 1 in 10 diiluted PRP and PAC-1 added pre 
or post incubation.  On the basis of this, assessment of fibrinogen binding (adding fluorescent 
fibrinogen prior to incubation) using 1 in 10 diluted PRP was selected to be studied further 
and applied to investigation of patients.  
 
A. 
B. 
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11.4.2 Application to patients with inherited thrombocytopenia 
42 patients and 24 healthy volunteers were recruited to the inherited thrombocytopenia arm of 
the GAPP project between October 2010 and March 2013.  Analysis was performed on 37 
patients, as the remaining five were tested using a different flow cytometer and software and 
therefore did not have directly comparable results.  Amongst the 37 patients analysed, 13 
were male (35%). Median age in the patient group was 32 years, with an interquartile range 
(IQR) of 16 to 51 years. 
Patient’s responses were classified as normal (no qualitative defect) or abnormal (qualitative 
defect present) based upon responses to the assays outlined in the methods section.  23/36 
(64%) were classified as abnormal (qualitative defect present) based on this assay.  One 
patient (3%) had insufficient platelets in the sample received for the assay to be performed, 
and we suspect this to be an artefactual phenomenon related to venepuncture or sample 
processing. 
Median platelet count in platelet rich plasma (PRP) in the patients was 1.2x10
8
/ml 
(120x10
9
/l), with an IQR of 0.7-1.9x10
8
/ml (70-190 x10
9
/l).  In the healthy volunteers median 
platelet count in PRP was 3.65x10
8
/ml (365x10
9
/l), with an IQR of 2.85-4.9x10
8
/ml (285-
490x10
9
/l).  No significant difference was seen in PRP count between patients with and 
without a qualitative defect on laboratory testing (Figure 11.9A).   
Median mean platelet volume (MPV) in the patients was 9.3fl with an IQR of 8.6-10.7fl.  In 
the healthy volunteers median MPV was 9.0fl with an IQR of 8.6-9.3fl.  No significant 
difference was seen in MPV between healthy volunteers and patients, or in patients with and 
without a qualitative defect on laboratory testing (Figure 11.9B). 
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ISTH bleeding assessment tool score was available on 26 patients (it was not conducted in 
children), with a median score of 8, IQR 5-14.  No significant difference in score was seen 
between patients with and without a qualitative defect (Figure 11.9C).  The previously 
defined 95
th
 centile of the score in healthy volunteers was 4. 
Surface glycoprotein levels 
Surface levels of CD41 (Figure 11.10A), CD42b (Figure 11.10B) and GPVI (Figure 
11.10C) were studied.  For CD41 and GPVI, patients with a qualitative defect were found to 
have significantly lower levels of surface receptors (p≤0.05), however no significant 
difference was seen in CD42b expression.  For GPVI, data were available on 14 patients and 
14 healthy volunteers due to restricted availability of the PE-conjugated anti human GPVI 
antibody used. 
P selectin dose response curves 
Dose response curves assessed using FITC conjugated anti human P selectin antibody are 
shown in Figures 11.11 and 11.12.  No significant difference was found between responses of 
patients with and without a qualitative defect and healthy volunteers for baseline and isotype 
control values, but at all other dose points a significant (p≤0.05) difference was seen between 
patients with and without a qualitative defect. 
Fibrinogen dose response curves 
Dose response curves using FITC conjugated fibrinogen are shown in Figures 11.13 and 
11.14.  No significant difference was found between responses of patients with and without a 
qualitative defect and healthy volunteers for baseline.   Some dose points (ADP 3µM and 
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PAR-1 peptide 10µM) were non-discriminatory and did not show a significant difference 
(p>0.05) between all groups and specifically between patients with and without a qualitative 
defect.  However, high concentrations of each agonist did show a significant difference both 
overall amongst all groups and between patients with and without a qualitative defect.  Low 
dose C reactive peptide showed a non significant difference overall (p=0.06), but the 
difference between patients with and without a defect was significant (p<0.05).   
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Figure 11.9 Platelet count in PRP (Panel A), Mean Platelet Volume (Panel B) and 
ISTH Bleeding Assessment Tool Score (Panel C) in patients and healthy volunteers..  
In all panels, bars represent median and interquartile range.  For Panels A and B, X 
axis shows categories representing healthy volunteers, all patients, patients with a 
qualitative defect and patients without a qualitative defect.  For Panel C data for 
patients only is shown, split into those with and without qualitative defects.  The 
horizontal dotted line represents the 95
th
 centile (score of 4) in previously studied 
healthy volunteers.  For Panel A, p<0.0001 when comparing groups using Kruskal 
Wallis test with Dunn’s adjustment for multiple comparisons.  Significant differences 
(p≤0.05) were found for healthy volunteers versus patients, but no statistical 
significance (p>0.05) was seen between patients with and without a qualitative defect.  
For Panel B p=0.06 when comparing groups using Kruskal Wallis test with Dunn’s 
adjustment for multiple comparisons.   Comparison between pairs of groups was non 
significant (p>0.05) in all cases. For Panel C, p=0.42 using Mann Whitney U test. 
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Figure 11.10 Surface receptor expression of CD41 (Panel A), CD42b (Panel 
B) and GPVI (Panel C) in healthy volunteers and patients with and without a 
qualitative defect on laboratory testing.  In all panels, bars represent median and 
interquartile range.  X axis shows categories representing healthy volunteers, 
patients with a qualitative defect and patients without a qualitative defect.  For 
Panel A, surface expression was assessed using a FITC conjugated anti-human 
CD41 antibody.  p=0.0003 when comparing groups using Kruskal Wallis test 
with Dunn’s adjustment for multiple comparisons.  For Panel B surface 
expression was assessed using a FITC conjugated anti-human CD42b antibody.  
p=0.93 when comparing groups using Kruskal Wallis test with Dunn’s 
adjustment for multiple comparisons.  For Panel C, surface expression was 
assessed using a PE conjugated anti-human GPVI antibody.  p=0.0014 when 
comparing groups using Kruskal Wallis test with Dunn’s adjustment for 
multiple comparisons.   
Investigation of patients with inherited thrombocytopenia 
 
Page | 162 
 
   
A 
 
B 
 
C 
 
D 
 
 
Investigation of patients with inherited thrombocytopenia 
 
Page | 163 
 
Figure 11.11 Dose response curves assess using FITC conjugated anti-human P selectin antibody.  Baseline values (Panel A), IgGκ mouse anti-human 
isotype control antibody (Panel B), ADP 3µM (Panel C) and ADP 30µM (Panel D).  Bars represent median and interquartile ranges.  All X axes show 
responses for healthy volunteers, all patients, patients with a qualitative defect and patients without a qualitative defect.  Panels C and D also show data 
from the initial validation cohort relating to assay development.  For the validation cohort neat = neat platelet rich plasma (PRP), 1 in 3 = PRP diluted 1 
in 3 with phosphate buffered saline, 1 in 10 = PRP diluted 1 in 10 with phosphate buffered saline.   For panels A and B, p > 0.05 (0.08 and 0.25 
respectively) when comparing all groups using Kruskal Wallis Test with Dunn’s adjustment for multiple comparisons.  Comparison between groups 
was non significant (p>0.05) in all cases. For panels C and D, p<0.001 when comparing all groups using Kruskal Wallis Test with Dunn’s adjustment 
for multiple comparisons.  p < 0.01 when comparing patients with and without a qualitative defect. 
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Figure 11.12 Dose response curves assess using FITC conjugated anti-human P selectin antibody.  CRP 0.3µg/ml (Panel A), CRP 3µg/ml (Panel B), 
PAR-1 peptide 10µM (Panel C) and PAR-1 peptide 100µM (Panel D).  Bars represent median and interquartile ranges.  All X axes show responses for 
healthy volunteers, all patients, patients with a qualitative defect and patients without a qualitative defect.  Data from the initial validation cohort 
relating to assay development is also shown.  For the validation cohort neat = neat platelet rich plasma (PRP), 1 in 3 = PRP diluted 1 in 3 with 
phosphate buffered saline, 1 in 10 = PRP diluted 1 in 10 with phosphate buffered saline.   For panels A, B and D, p<0.0001 when comparing all groups 
using Kruskal Wallis Test with Dunn’s adjustment for multiple comparisons,  p < 0.001 when comparing patients with and without a qualitative defect.  
For panel C, p<0.0001 when comparing all groups using Kruskal Wallis Test with Dunn’s adjustment for multiple comparisons,  p < 0.05 when 
comparing patients with and without a qualitative defect. 
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Figure 11.13  Dose response curves assess using FITC conjugated 
fibrinogen.  Baseline values (Panel A), ADP 3µM (Panel B) and ADP 
30µM (Panel C) Bars represent median and interquartile ranges.  All X 
axes show responses for healthy volunteers, all patients, patients with a 
qualitative defect and patients without a qualitative defect.  PRP was 
diluted 1 in 10 with phosphate buffered saline prior to running the assay, 
as outlined in methods section.  For panels A and B, p>0.05 (0.56 and 
0.11 respectively) when comparing all groups using Kruskal Wallis Test 
with Dunn’s adjustment for multiple comparisons.  Comparison between 
pairs of groups was non significant (p>0.05) in all cases.   For panel C, 
p=0.047 when comparing all groups using Kruskal Wallis Test with 
Dunn’s adjustment for multiple comparisons, p < 0.05 when comparing 
patients with and without a qualitative defect. 
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Figure 11.14  Dose response curves assess using FITC conjugated fibrinogen.  CRP 0.3µg/ml (Panel A), CRP 3µg/ml (Panel B) , PAR-1 peptide 10µM 
(Panel C) and PAR-1 peptide 100µM (Panel D) Bars represent median and interquartile ranges.  All X axes show responses for healthy volunteers, all 
patients, patients with a qualitative defect and patients without a qualitative defect.  PRP was diluted 1 in 10 with phosphate buffered saline prior to 
running the assay, as outlined in methods section.  For panel A p = 0.06 when comparing all groups using Kruskal Wallis Test with Dunn’s adjustment 
for multiple comparisons, but p <0.05 when comparing patients with and without a qualitative defect.  For panel B, p = 0.007 when comparing all 
groups using Kruskal Wallis Test with Dunn’s adjustment for multiple comparisons, p <0.05 when comparing patients with and without a qualitative 
defect.     For panel C, p=0.08 when comparing all groups using Kruskal Wallis Test with Dunn’s adjustment for multiple comparisons, with non 
significant comparisons (p>0.05) between pairs of groups in all cases.  For panel D, p = 0.001 when comparing all groups using Kruskal Wallis Test 
with Dunn’s adjustment for multiple comparisons, p <0.01 when comparing patients with and without a qualitative defect.   
 
 
 
Investigation of patients with inherited thrombocytopenia 
 
Page | 169 
 
11.4.3 Genetic findings in patients with inherited thrombocytopenia  
11.4.3.1  ANKRD18A (110) 
A family with multiple consanguineous marriages and two affected children with severe 
thrombocytopenia were investigated.  One of the affected children suffered from intracerebral 
bleeding at birth and had a platelet count of 10x10
9
/l, and the other child had a platelet count 
of 20x10
9
/l with several serious epistaxes requiring hospitalisation.  Both children required 
HLA matched platelet transfusions on multiple occasions.   I recruited them and assessed their 
platelet function using the flow cytometry assay.  Sequencing the exomes of both patients was 
undertaken by Neil Morgan.  Comparisons with dbSNP build 135, the 1000 Genomes project 
database and our in-house database (composed of >250 exomes) identified 77 and 83 
homozygous novel variants, respectively. Of these only 2 homozygous non-synonymous 
variants and 1 non-frameshift deletion were found in both patients. The non-frameshift 
deletion was a homozygous single amino acid deletion (c.2401_2403delGAA; p.Glu801del) 
in exon 13 of ANKRD18A.  
Family studies confirmed that the mutation segregated with disease status and was not 
detected in 312 ethnically matched control chromosomes. ANKRD18A encodes the ankyrin 
repeat domain 18A protein and the mutation maps within a coiled-coil domain of the protein. 
ANKRD18A belongs to the same family of proteins that has recently been discovered to be a 
major cause of a dominant form of thrombocytopenia (THC2), which is attributable to 
mutations in the ANKRD26 gene (204).  The family tree, sequence traces and flow cytometry 
assessment of platelet function for these two patients are shown in Figure 11.15.  Further 
work examining ANKRD18A mRNA expression and the function of the ANKRD18A protein 
by Dr Morgan and colleagues is ongoing.  
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Figure 11.15 Identification of a homozygous in frame deletion mutation in ANKRD18A.  (A) Pedigree 
from a consanguineous family with severe thrombocytopenia. Text beneath each family member 
represents the genotype for the c.2401_2403del (p.Glu801del) mutation in ANKRD18A (affected 
individuals are shaded). (B) Wild-type and mutant ANKRD18A sequence traces. The boxed sequence 
shows the position of the c.2401_2403 deletion sequence change in affected patient II:3. (C) Flow 
cytometry response using anti-CD62P antibody. (D) Flow cytometry response using fluorescent 
fibrinogen (NB logarithmic Y axis).  Legends for (C) and (D) display PRP type.  Healthy volunteers 1 
in 10 = PRP from control individuals diluted 1 in 10 with PBS.   Data for healthy volunteers shown as 
mean + 1 s.d. (n= 9). Isotype control = IgGk1.  Incubation took place at 37ºC for 2 minutes and 
terminated by adding a fivefold excess of ice cold PBS. 
 
11.4.3.2  RUNX-1 and FLI-1 (205) 
NGS analysis of candidate PFD genes was undertaken in 13 families who I recruited to the 
GAPP project and who were found to have a secretion defect.  The genetic analysis was led 
by Neil Morgan and Jacqueline Stockley and identified a novel heterozygous alteration in 
either the FLI1 or RUNX1 gene in the index cases from 6 of the families studied (F1 to F6) 
(Table 11.2). Two nonsynonymous FLI1 alterations, c.1009C>T and c.1028A>G, predicting 
p.R337W and p.Y343C substitutions in the highly conserved DNA binding domain of FLI1 
were identified in affected members of F1 and F2, while a 4 bp frameshift deletion in FLI1 
(c.992-995del; p.Asn331Thrfs*4) was present in both affected members of F3. Three RUNX1 
variations predicted to cause RUNX1 haploinsufficiency were identified; donor splice site 
transversions, c.508+1G>T and c.351+1G>T, were detected in F4 and F5 respectively, and a 
nonsense mutation in codon 106 (c.317G>A; p.Trp106Stop) was detected in the index case 
from F6.  
The presence of a FLI1 or RUNX1 alteration was associated with symptoms of excessive 
bleeding in all index cases, and their affected family members, and with mild 
thrombocytopenia in five of the families (Table 11.2). Interestingly, the missense variations 
in FLI1 were also associated with alopecia, eczema or psoriasis, and recurrent viral infections 
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in affected individuals in F1, and with mild thrombocytopenia, alopecia and eczema in the 
affected individuals in F2 (Figure 11.16A and 11.16B).   
Examination of platelet secretion and aggregation in all subjects carrying FLI1 or RUNX1 
defects consistently revealed the predominant platelet abnormality to be a significant 
reduction in platelet ATP secretion in response to all agonists tested. (Figure 11.16C, Table 
11.2, and data not shown).  
 
Persistence of MYH10 in platelets from patients with FLI1 defects  
Persistence of MYH10 in platelets was recently proposed as a biomarker for RUNX1 
alterations in patients with familial thrombocytopenia with a predisposition to AML, and for 
FLI1 deletions in Paris Trousseau Syndrome (206). The detection of MYH10 in platelets from 
patients carrying the p.Tyr343Cys and the p.Asn331Thrfs*4 FLI1 variations confirms the use 
of MYH10 detection as a biomarker for FLI1 alterations (Figure 11.16F).  
 
The identification of RUNX1 or FLI1 alterations in 6/13 unrelated patients with the most 
profound dense granule secretion disorders in this study suggests that defects in these genes 
will account for a significant proportion of patients with defects in platelet dense granule 
secretion and excessive bleeding.  
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Figure 11.16 Mild bleeding symptoms and platelet dense granule secretion defects are associated with 
heterozygous mutations in FLI1 and RUNX1.  A and B: Pedigrees showing inheritance of mild 
bleeding, alopecia totalis and other clinical features in families 1 (A) and 2 (B). Individuals 
heterozygous for the c.1009C>T and c.1028A>G transitions in FLI1 are indicated. Lines through 
symbols indicate deceased individuals. In A, individuals with bleeding symptoms and alopecia, and 
confirmed platelet dense granule secretion are indicated by black filled symbols. An asterisk indicates 
the presence of eczema and a history of recurrent viral infections. The presence of psoriasis is 
indicated by a ‘+’ sign. In B, individuals with bleeding symptoms and alopecia are indicated by black 
or grey filled symbols. Black filled symbols indicate individuals with confirmed platelet dense granule 
secretion defect and mild thrombocytopenia. An asterisk indicates a history of infective endocarditis 
and the presence of eczema and colitis are indicated by a ‘+’ sign. C. ATP secretion in response to 
100µM PAR1 peptide in two members of F1 with the c.1009C>T transition in FLI1, and three 
members of F4 with the c.508+1G>T transversion in RUNX1 alongside controls. D. Schematic 
diagram of RUNX1 and FLI1 showing the regions of the proteins affected by mutations identified in 
this study. Intronic mutations, predicted to interfere with splicing of the RUNX1 RNA, are shown in 
italics. E. HEK293T cells were co-transfected with WT and variant FLI1 constructs, or combinations 
thereof, and pGL3.10-GP6-luciferase and pRLnull-Renilla reporters as shown, and firefly and Renilla 
luciferase expression assessed in cell lysates 48 hours later. Data represents the means (± SEM) of 3 
independent experiments; **p<0.01, ***p<0.001. F. MYH10 protein expression in platelets from 
patients with FLI1 mutations (F2.1 and F2.2 with p.Tyr343Cys FLI1 mutation; F3.1 and F3.2 with 
p.Asn331Thrfs*4 FLI1 mutation) and a healthy control. 
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Family (F)/ 
Patient ID 
Gene and nucleotide 
alteration¥ 
Effect Platelet count 
(x10
9
/L)^ 
Mean MPV 
(fL) 
ATP Secretion nmol/1x10
8
 
platelets* 
F1; II.1 FLI1; c.1009 C>T p.Arg337Trp 244 10.3 0.37 
F1; III.1 FLI1; c.1009 C>T p.Arg337Trp 150 10.5 0.07 
F2; II.5 FLI1; c.1028 A>G p.Tyr343Cys 92 8.8 ND ** 
F2; III.1 FLI1; c.1028 A>G p.Tyr343Cys 100 8.6 ND ** 
F3.1 FLI1; c.992-995del p.Asn331Thrfs*4 157 11.8 0.57 
F3.2 FLI1; c.992-995del p.Asn331Thrfs*4 142 11.4 0.38 
F4.1 RUNX1; c.508+1 G>T splicing Unavailable 7.3 0.32 
F4.2 RUNX1; c.508+1 G>T splicing 70 7.5 ND 
F4.3 RUNX1; c.508+1 G>T splicing 130 7.1 0.62 
F5 RUNX1; c.351+1G>T splicing 139 8.0 0.35 
F6.1 RUNX1; c.317 G>A p.Trp106Stop 100 8.0 0.25 
Table 11.2 Genotypic and phenotypic characteristics of subjects with platelet dense granule secretion defects.  Heterozygous nucleotide changes present 
in FLI1 and RUNX1 and their predicted effects on the resulting RNA or protein are shown. ¥ Alterations are numbered according to positions in the 
NM_002017.3 and NM_001754 transcripts for FLI1 and RUNX1 respectively; ^Mean platelet counts are shown; *ATP secreted in response to 100µM 
PAR-1 receptor specific peptide SFLLRN, 5
th
 centile in healthy volunteers is 0.82 nmol / 1x10
8
 platelets; **ATP secretion in response to 1U/ml 
thrombin. ND= not detectable; MPV=Mean platelet volume; NR= Normal range
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11.4.3.3  Whole exome sequencing of cohort of patients with inherited thrombocytopenia 
(117) 
Analysis of the genetic findings in the patients recruited to the thrombocytopenia arm of the 
GAPP project (including the patients who I recruited) has been undertaken by Neil Morgan 
and Ben Johnson.  Using the GAPP approach of combined platelet phenotyping with whole 
exome sequencing this work determined the possible genetic cause of disease in 73% (27/36) 
of index patients with thrombocytopenia. Genetic variations occurred in the 30 known genes 
associated with thrombocytopenia in 20 of 27 index cases (ACTN1, ANKRD26, CYCS, FLI1, 
GFI1B, GP1BA, MKL1, MYH9, NBEAL2, RUNX1, TPM4 and TUBB1). Seven cases were of 
suggested novel aetiology within previously unreported genes (ANKRD18A, MKL1, PF4 and 
SLFN14). 
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11.5  Discussion 
The work described in this chapter is based on the premise that patients with inherited 
thrombocytopenia have a wide spectrum of clinically observed bleeding, and that the platelet 
count threshold for developing clinical bleeding in patients with thrombocytopenia is 
observed to vary significantly (185).   
The variation in platelet count bleeding threshold may be explained by the presence of a 
qualitative platelet defect in addition to the numerical reduction in platelet count.  In 
accordance with the mulitfactorial aetiology of bleeding, an individual’s bleeding threshold 
may also be contributed to by changes in other parts of the haemostatic pathway, such as 
reduced von Willebrand factor levels which are not low enough to have a diagnostic label of 
von Willebrand disease (207).  The extent of the previous bleeding history is known to predict 
the risk of further bleeding events (208). 
My work on this patient cohort used flow cytometry in the assessment of platelet function, as 
this modality measures fluorescence emitted by individual platelets and is therefore 
independent of total platelet count.  Historically, assessing platelet function in this patient 
group has been difficult as lumiaggregometry becomes unreliable at low platelet counts (15, 
186). 
My findings have demonstrated the feasibility of the flow cytometry method that I developed 
in assessing platelet function in thrombocytopenia.  Dose response curves were demonstrated 
using this technique in healthy volunteers, with minimal effects observed after dilution of 
PRP from healthy volunteers to replicate platelet counts in PRP expected in patients with 
thrombocytopenia.  These dilution experiments allowed construction of reference ranges for 
expected values at differing platelet count in PRP ranges in order to allow comparison with 
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results obtained from patients.  Initial experiments focussed on assessing P-selectin 
expression after stimulation with a variety of agonists, and the testing procedure was 
subsequently modified to also examine fluorescent fibrinogen binding. 
This newly developed technique was then applied to patients with inherited thrombocytopenia 
and enabled categorisation of whether patients with thrombocytopenia may also have an 
additional qualitative defect.  The P-selectin assay was more discriminatory in this 
assessment, and was more reproducible in healthy volunteers.   The fluorescent fibrinogen 
assay occasionally showed pre-activation at baseline values, and appeared to be sensitive to 
handling and processing, which could limit future potential utility.  Future work is needed to 
validate these assays, which has not been possible so far due to the absence of a comparative 
gold standard in assessing platelet function in thrombocytopenia. 
The genetic findings that have arisen from investigation of the patient cohort that I recruited 
are interesting, and are a good example of clinical assessment and laboratory phenotyping 
driving advances in genetic understanding of a rare disorder.  In the cases described here, this 
process has led to the identification of a novel genetic defect (in ANKRD18A) and has 
identified mutations in FLI-1 and RUNX-1 as a relatively common and potentially significant 
cause in patients with inherited thrombocytopenia and secretion disorders.   Interestingly, 
several of these patients had a platelet count of over 100x10
9
/l and a small number had a 
platelet count in the normal range, which is out of keeping with the commonly reported 
finding that associates RUNX1 disorders with thrombocytopenia (209, 210). 
Cohort analysis of genetic findings was successful in identifying underlying mutations (in 
known and novel genes) in almost three quarters of recruited patients with inherited 
thrombocytopenia.   
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In summary, the work described in this chapter has developed a flow cytometric based 
technique to allow assessment of platelet function in thrombocytopenia.  This was then 
applied to patients with inherited thrombocytopenia to investigate whether they may have 
qualitative in addition to quantitative platelet defects.  An underlying genetic cause for 
inherited thrombocytopenia was identified in a significant number of the recruited patients.  
Although the flow cytometric technique remains a research tool at present and requires 
validation, it offers promise in extending the assessment of patients with thrombocytopenia to 
explain their individual bleeding thresholds and to personalise clinical management plans.  
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CHAPTER TWELVE: GENERAL DISCUSSION 
The work presented in this thesis has made the following contributions to the field of 
inherited platelet disorders: 
 Characterisation of normal aggregation and secretion responses in healthy volunteers, 
with resultant compilation and development of a rationalised agonist panel for 
laboratory testing of suspected inherited platelet disorders. 
 
 Confirmation that use of Chronolume® to assess secretion does not significantly 
impact on measured aggregation levels, suggesting that the practice of simultaneously 
measuring secretion and aggregation in lumiaggregometry is reliable. 
 
 Further characterisation of inherited platelet defects in patients with a suspected 
inherited platelet function disorder and a normal platelet count.  The majority of 
defects were in either dense granule secretion, Gi signalling or cycloxygenase pathway 
signalling, with a defect not identified in approximately 40% of recruited patients. 
 
 Assessment of ISTH BAT scores in patients with suspected inherited platelet function 
defects, with confirmation that this score is raised in this patient group, but that the 
score value is not discriminative for the presence of an underlying platelet defect.  
This supports the use of this tool in assessing and recording bleeding symptoms from a 
clinical and research perspective in patients with suspected platelet disorders. 
 
 Confirmation that some patients with unexplained menorrhagia are noted to have an 
underlying platelet disorder. 
 
 Development of an assay to assess platelet function in thrombocytopenia, with 
application of this assay to patients with thrombocytopenia to ascertain whether they 
have a qualitative platelet defect in addition to the numerical reduction in their platelet 
count. 
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The ultimate aim of GAPP was to identify mutations in known and novel platelet and 
megakaryocyte genes to explain inherited platelet defects, and to further understanding of 
basic platelet biology.  Use of phenotyping data to guide relevant genetic investigation has 
been vital in achieving this.   The nature of the search for mutations is governed by a number 
of factors, including the presence of consanguineous parents, evidence of autosomal dominant 
inheritance patterns, and the nature of the platelet function defect.  The greatest successes 
have been achieved in identifying mutations in patients with a clear pattern of inheritance 
such as thrombocytopenia (117) and conditions associated with characteristic laboratory 
findings (such as ADP P2Y12 receptor defects), or other phenotypic changes (as exemplified 
by HPS) (68). 
The use of next generation sequencing has facilitated the use of targeted arrays and whole 
exome approaches in identifying mutations to explain other gene defects in patients recruited 
to GAPP (99, 117, 155).  The whole exome approach allows for rapid generation of large 
amounts of data and is now financially viable, but does require expert interpretation and may 
not detect mutations in genes outside the coding region, or if unaffected family members are 
not available for comparative purposes.  It has the potential to identify genetic defects in large 
cohorts of unrelated patients and this is a very important future development (101, 116, 117).   
The need to further genetic understanding of platelet disorders is recognised by major 
stakeholder associations, including funders such as the NHLBI working group of the NIH in 
the USA (211).  The difficulty in unravelling genetic defects in a complex trait such as 
bleeding will be in linking mutations identified to the underlying bleeding disorder, and as 
such it is helpful to use platelet phenotyping to interpret and guide genetic investigations.  In 
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some cases, genetic mutations may represent a risk factor (rather than a solely causative 
agent) in giving rise to excessive bleeding (68). 
An improved ability to diagnose underlying platelet function disorders has important clinical 
implications, as it allows appropriate management of patients at times of high risk of bleeding 
(such as perioperatively, peripartum, during menstruation and after injury), prevents 
unnecessary treatment with immunosuppresion and allows appropriate family counselling.  
An awareness of the possibility of an underlying platelet function disorders in patients with 
excessive bleeding (such as patients with unexplained menorrhagia) is vital in directing 
patients towards the correct investigation and in making this diagnosis.  A more detailed 
assessment of bleeding risk than platelet count alone has potential importance in patients with 
inherited thrombocytopenia as it could change frequency of clinical assessment, lifestyle 
advice, treatment thresholds and consideration of newer agents (such as thrombopoietin 
mimetics) in treatment (212), thereby personalising management plans. 
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Appendix 1 – Example GAPP Patient Information Sheet (v8, 12/11/2012) and Consent 
Form (v5, 12/11/2012) 
 
 
                                                                                                    
 
Participant Information Sheet on ‘Mild Platelet Disorders’ 
 
PART 1  
1. Study title: Mild bleeding disorders caused by platelet defects 
 
2. Invitation paragraph:   
You are being invited to take part in a study. Before you decide it is important for you to 
understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends, relatives, your GP and your 
Consultant if you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
The UK Clinical Research Collaboration (UK CRC) publishes a leaflet entitled 
"Understanding Clinical Trials”. This leaflet gives more information about medical research 
and looks at some questions you may wish to ask. A copy may be obtained from the internet 
at http://www.ukcrc.org/publications/informationbooklets.  If you do not have access to the 
Internet, please let us know and we will print a copy off for you. 
 
3. What is the purpose of the study? 
This study aims to understand why some patients bleed excessively.  We are going to look at 
the following groups of patients: 
1. Patients with mild bleeding who have been seen by a blood specialist who feels their 
symptoms could be due to a problem in the platelets (“clinically diagnosed platelet 
defects”)  
2. Patients who have unexpectedly heavy periods with no obvious cause 
3. Patients with lifelong low platelet counts in the blood with no known cause 
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In addition, we will also include some “control” individuals who do not suffer from the above 
problems and are important to allow us to compare responses between those who bleed 
excessively and those who do not.  If we only examined affected patients it would be difficult 
to tell how their response compared to that expected in a normal individual. 
You will be included in the highlighted group above, if you choose to participate in this study. 
For all populations except the control group, we suspect that you have a problem in small 
cells in the blood, known as platelets, but we are not certain that this is the case.    This study 
will use new and more specialist tests in an attempt to confirm that there is a problem in your 
platelets and to use this information to help identify the gene or genes that cause this problem.  
More information on platelets and what the study aims to achieve is given below: 
What are platelets? 
Platelets are small cells within the blood that are involved in the clotting mechanism. 
Following injury, platelets ‘stick’ to each other and block (or plug) the site of injury.  Patients 
with too few platelets or with platelets that are less sticky may bleed more than we would 
expect, and in combination with other factors such as medications or injury may cause the 
loss of a great deal of blood.  By carrying out certain tests on platelets, it is possible to find 
out whether somebody has a problem with their platelets and whether this is likely to explain 
their bleeding problem. 
The testing of platelet function 
Platelet tests are routinely performed in the Haematology Clinic to investigate whether a 
patient has a platelet problem.  In many cases, however, the tests do not give a clear answer 
on whether the patient has a platelet problem or on the cause of the problem.  The present 
study will use a range of more specialist platelet tests to establish whether the patient has a 
platelet problem and to gain further information on the nature of the defect.  This will require 
analysis of platelet function in freshly donated blood.  Work will be carried out by the 
Birmingham Platelet Group who have a large amount of experience in this field. 
The search for defects in genes that could cause the platelet problem 
The most likely explanation for a platelet problem is a defect (or problem) in one or more of 
the genes that you have been passed down (or inherited) from your mother and/or father.  
Genes can be described as the set of “instructions” that tell the body how to develop and 
work.  A problem in one or more genes could cause the bleeding problem. 
The results from the study of platelet function will have provided important clues on genes 
that may have caused the bleeding problem. The present study will look for errors in these 
genes using techniques that have been developed to identify gene defects.   These studies 
require a small amount of blood that can be stored frozen for many years. 
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Is it possible that the gene defect will not be identified? 
Yes. There is no guarantee that we will detect a change in either the platelet tests or in your 
gene. If we are unable to find a problem, we will tell you. If we fail to identify a problem, it 
does not mean you do not have a platelet or gene disorder – it is just that we have not been 
able to identify a problem with the techniques that we have used. 
Are my family members likely to have the same gene defects and will they participate in the 
study? 
Your mother, father and other family members may have a bleeding problem caused by a 
defect in the same gene or genes.  Alternatively, your mother, father and other family 
members may have (or ‘carry’) one or more of the genes that is responsible for the bleeding 
problem, but may not have a bleeding problem.   
If we are able to identify one or more gene defects that cause your platelet problem, we may 
wish to investigate, with their consent, other members of your family to see if they have a 
problem with their platelets and whether they have a defect in the same gene or genes.  A 
separate information sheet is available for members of your family explaining these studies.  
Will my blood be analysed for gene defects other than those which could cause the bleeding 
problem? 
No.  We are only interested in identifying defects that could cause your bleeding problem and 
we will target our search for abnormal genes to those involved in the way that platelets work 
under normal circumstances. 
In patients with low platelet counts, we will need your consent to also look for mutations in 
the RUNX1 gene.  Mutations in this gene have been shown to cause low platelet numbers and 
may also predispose to several types of leukemia.  You are free to decline your permission for 
this testing without compromising your participation in this study.  This testing will not be 
carried out in the other participants in this study. 
 
4. Why have I been chosen? 
You have been chosen due to one of the following factors: 
1. Your hospital doctor suspects that you have a problem with your platelets, but does 
not know the cause of the problem. 
2. You have been identified as a suitable “control” or healthy volunteer. 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part.  If you decide to take part you will be 
given this information sheet to keep and be asked to sign an agreement (or consent) form.  By 
signing the consent form you are saying that you are happy to take part in the study and that 
you understand what has been explained to you.  If you choose not to take part, the clinical 
care you receive will not be affected in any way. 
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6. What will happen to me if I take part? 
If you agree to take part you will be asked some questions about your medical history 
including questions to complete a bleeding questionnaire. 
You will also be asked to give a sample of blood (between 10–50 ml, which is about the same 
volume as that of 2–10 teaspoonfuls).  The blood will usually be taken at a local Haematology 
Clinic at a time that is suitable for your yourself and the Haematology Clinic, ideally early in 
the day so that the analyses can be carried out on the same day. 
Depending on the results of the tests, we may ask you to give blood on up to three 
further occasions.  This is to enable us to carry out different types of tests on your platelets 
and therefore find out more information on the problem.  We will again ask for between 10–
50 ml of blood, and this again can be taken either during a ‘regular’ visit to the Haematology 
Clinic / surgery or through a specific appointment.   There will be a minimum of one month 
between the dates that the blood is taken and no upper time limit on the gap between the 
donations. 
What will happen to my blood? 
Your blood samples will be sent to research laboratories in Birmingham, Bristol and/or 
Sheffield for analysis of your platelets. We will also keep a frozen sample for a maximum of 
10 years, which may be used to look for gene defects that could cause the platelet problem or 
changes in blood proteins that may increase your chance of bleeding.  The sample will be 
destroyed at this time, or earlier if you request.    
We may wish to keep the sample for this length of time in the event that we are unable 
to find a problem with your genes in our first set of investigations.  It is possible that, as we 
gain more knowledge, that we will wish to investigate the sample at later times to see if we 
can find a gene defect that may be the cause of the bleeding problem. 
Please note that a frozen sample will not be stored for “control” individuals. 
 
7. What are the possible disadvantages and risks of taking part? 
You may experience a little pain and bruising around the vein where the blood sample is 
taken from.  The needle used to take the blood will be identical to what has been used on you 
previously to take blood samples. 
 
8. What are the possible benefits of taking part? 
The study will generate important information on possible defects in your platelets and may 
also identify the genes that are responsible for the defects.   The identification of a defect in 
your platelets may influence your clinical treatment. 
Appendix 1 – Patient Information Sheet and Consent Form 
 
XVII 
 
If a gene defect is found, it will be possible to investigate whether one or more 
members of your family have the same gene defect, should they wish.  You will not receive 
any money for taking part in this study. 
 
9. When will the study be completed? 
Recruitment of patients will end in February 2015.  Because we anticipate receiving many 
samples from throughout the UK, it may be many months before we can let you know if we 
have found a gene defect in your blood.  
The nature of the gene defect will not be identified in all patients. However, 
developments may take place over the next few years that will provide important, new 
information on the likely cause of platelet bleeding disorders.  We will therefore continue to 
follow developments in the field and, if appropriate, use this information to direct our efforts 
to identify the defective gene(s) in your frozen blood sample, which will be kept frozen for up 
to ten years, unless you ask for it to be destroyed.  We will contact you as soon as we have 
identified a genetic defect in the sample. 
 
10. Will my taking part in this study be kept confidential? 
Yes.  All information which is collected about you during the course of the research will be 
kept strictly confidential. 
 
11. What will happen if I don’t want to carry on with the study? 
If you decide that you do not want to be in the study at any time after you have had your 
blood sample taken, you can ask for us to destroy your stored sample. 
 
12. Further information on genetic testing 
If we find a genetic defect related to bleeding, we will let you know of this.  You will have the 
right to choose not to access this information.   We may refer you for retesting by genetic 
services outside of this study for confirmation of the gene analysis. 
We will discuss the full implications of the genetic studies with you with regard to 
your own children, having children in the future, insurance status and available counselling, 
as appropriate.  Stored samples will not be used for other genetic studies without additional 
consent and presentation to an ethics committee for consideration.   
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13.  Further tests that may be undertaken on your blood sample 
In some circumstances, we will pursue more detailed testing of your blood samples.  The 
types of detailed tests include, for example, using the stem cells from your blood sample to 
look at platelet production or examining the proteins in your platelets.  Only tests for which 
permission has been formally granted to the Birmingham Platelet Group from the Research 
Ethics Committee (REC) will be performed.  The purpose of the REC is to protect the rights, 
safety, dignity and well-being of research participants, and to facilitate and promote ethical 
research that is of potential benefit to participants, science and society. 
 
14. Contact for further information 
Further information about this study can be obtained by contacting one of our group on 
telephone number   You will be able to leave a message if there is no-one in 
the office and we will get back to you.  The members of the group are Mrs Gayle Halford 
(general enquires), Dr Marie Lordkipanidzé, Dr Gillian Lowe and Ms Rachael Taylor. 
The study co-ordinator is a British Heart Foundation Professor, Stephen Watson 
(Centre for Cardiovascular Sciences, School of Clinical and Experimental Medicine, Institute 
of Biomedical Research, College of Medical and Dental Sciences, Wolfson Drive, University 
of Birmingham, Edgbaston, Birmingham, B15 2TT). 
 
This completes Part 1 of the information sheet.  If the information in Part 1 has interested you 
and you are considering participation, please continue to read the additional information in 
Part 2 before making any decisions. 
 
PART 2 
 
15. Who is funding this study? 
The work is supported by the British Heart Foundation Research Charity. 
 
16. Will I get paid for taking part? 
You will not be paid for taking part. 
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17. Who has reviewed this study? 
This study has been reviewed and approved by the West Midlands Multi-Centre Research 
Ethics Committee and by the Local Research Ethics Committee for your hospital.   
 
18. What if something goes wrong? 
If you are hurt by taking part in this research project, there are no special compensation 
arrangements.   
If you are harmed due to someone’s negligence, then you may have grounds for a 
legal action but you may have to pay for it.  Regardless of this, if you wish to complain, or 
have any concerns about any aspect of the way you have been approached or treated during 
the course of this study, the normal National Health Service complaints mechanisms should 
be available to you.  At present this would be via PALS (Patient Advice and Liaison Service) 
at your local hospital, or www.pals.nhs.uk 
 
19. What will happen to the results of this study? 
Your results will be passed on to your haematology doctor who will be asked to give them to 
you and to answer any questions you may have.   
The collective results from all of the patients in the study may be presented in a 
scientific report to help other doctors who are treating patients with these bleeding disorders.  
No patient names will be used and it will not be possible to identify you from any report of 
the results of the study. 
 
20. What if I wish to complain about the way in which the study has been conducted? 
If you have any cause to complain about any aspect of the way in which you have been 
approached or treated during the course of the study, the normal National Health Service 
complaints mechanisms are available to you and are not compromised in any way because 
you have taken part in a research study.  Complaints should be dealt with by an independent 
body such as PALS.   To use the normal hospital complaints procedure, you should contact 
the PALS officer at your hospital or get more information at www.pals.nhs.uk 
 
 
Thank you very much for reading through this information sheet. 
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INFORMED CONSENT FORM 
PATIENT / FAMILY MEMBER 
 
Thank you for reading the information about our research project.  If you would like to take 
part, please read and sign this form. 
 
Patient Identification Code for this study: 
 
Title of Project:  Mild bleeding disorders caused by platelet defects 
 
Contact details for research team:  
 
Your referring doctor / research nurse      ……..……………………………………………….. 
 
or 
 
The study team: Mrs Gayle Halford (general enquiries), Dr Marie Lordkipanidzé and Dr 
Gillian Lowe  
 
Birmingham Platelet Group, Institute for Biomedical Research, School of Clinical and 
Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, 
Birmingham B15 2TT,    Please leave a message if no-one is in the office 
and we will get back to you. 
 
Please initial all boxes 
 
 
1.  I have read the attached information sheet on this project, and have been given a copy to 
keep.  I have been able to ask questions about the project and I understand why the research is 
being done and any risks involved. 
 
 
2.  I agree to give a sample of blood for research in this project.  I understand how the sample 
will be collected, that giving a sample for this research is voluntary and that I am free to 
withdraw my approval for the use of the sample at any time without giving a reason and 
without my medical treatment or legal rights being affected. 
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3.  I give permission for someone from the local research team to look at my medical records 
to get information on my bleeding history.  I understand that the information will be kept 
confidential. 
 
 
4.  I agree to answering some questions about my medical history including those needed to 
complete a bleeding assessment by questionnaire. 
 
 
5.  I understand that my referring doctor and I will be informed if any of the results of the 
medical tests done as a part of the research are important for my health. 
 
 
6.  I understand that I will not benefit financially if this research leads to the development of a 
new treatment or medical test. 
 
 
7.  I know how to contact the research team if I need to, and how to get information about the 
results of the research. 
 
 
8.  Consent for storage of sample  
I agree that the sample I have given and the information gathered about me can be stored in 
the Medical Schools of the Universities of Birmingham, Bristol and Sheffield for the purpose 
of analysing platelets, bleeding tendency and detection of the gene change responsible for the 
platelet disorder in myself or a family member, for a maximum of 10 years, after which it will 
be destroyed.   
If I wish I may request the return of the sample after analysis has been completed. 
 
 
9.    Consent for genetic research.  
I give permission for genetic analysis to be carried out on the sample I give, as part of this 
project.  I have received written information about this test and I understand what the result 
could mean to me and/or members of my family.  
 
 
10.    Consent for stem cell studies 
I give permission for the stem cells in my blood sample to be used to understand how my 
platelets are produced. 
          YES 
 
          NO 
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11.    Consent for RUNX1 mutation testing (ONLY FOR PARTICIPANTS WITH LOW 
PLATELET COUNTS).  
I give permission for genetic analysis to be carried out on the sample I give to specifically 
look at the RUNX1 gene.  I understand that this mutation is associated with low platelet 
counts and can in some cases predispose to certain types of leukemia.  
          YES 
 
          NO 
 
12.   I want to be told the results of the tests undertaken in this study.  I understand I can 
change my mind about this later. 
          YES 
 
          NO 
 
 
 
……………………………… ……………………… …………………………... 
Name of patient   Date    Signature 
(BLOCK CAPITALS) 
 
 
……………………………….. ……………………… …………………………... 
Name of person taking consent Date    Signature 
(if different from researcher) 
 
 
……………………………….. ……………………… …………………………... 
Name of researcher   Date    Signature 
 
 
Thank you for agreeing to participate in this research  
1 copy for patient, 1 for hospital notes, 1 for researcher 
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Appendix 3 – Assessment of receptor expression changes as a result of the R122C 
mutation (results) – Stuart Mundell and colleagues (40) 
Surface expression of this receptor was found to be reduced in cell lines (Figure A2.1), with a 
significant intracellular pool of the R122C variant (Figure A2.2).  Minimal agonist-dependent 
internalization was seen with the mutant receptor (Figure A2.2).    In addition, wild type 
receptor co-localized with the early and endosomal recycling marker transferrin whilst the 
R122C variant was predominantly found to colocalize with the lysosomal marker lysotracker 
blue (Figure A2.2). Therefore unlike the wild type receptor which could recycle back to the 
cell surface, the R122C variant would be targeted for degradation.  
 
 
 
 
 
 
 
 
 
 
Appendix 3 – Assessment of receptor expression changes as a result of the R122C mutation 
 
XLIV 
 
 
Figure A2.1 P2Y receptor expression in index case and family members. P2Y1 (A) and P2Y12 (B) 
surface receptor levels were measured in fixed platelets in index case (P1) and healthy volunteer (HD) 
by displacement of [
3
H]2MeS-ADP (1nM – 1 μM) by receptor antagonists for P2Y1 (A3P5P; 1 mM) 
and P2Y12 (AR-C69931MX; 1 μM) respectively. Data are expressed as [3H]2MeS-ADP binding 
(DPM) and represent means ± S.E.M. of three independent experiments.   Work performed by Stuart 
Mundell and colleagues (40). 
 
 
 
 
 
 
 
 
 
 
Appendix 3 – Assessment of receptor expression changes as a result of the R122C mutation 
 
XLV 
 
 
Figure A2.2 The R122C variant is poorly expressed at the cell surface as a result of rapid agonist-
independent internalization followed by subsequent intracellular retention and sorting to lysosomes 
(A) Membrane and cellular localization of wild type and R122C variant in 1321N1 cells. 1321N1 cells 
stably expressing HA-tagged wild type or R122C variant receptor constructs were fixed,  
permeabilized and incubated with a monoclonal anti-HA antibody at 37
o
 C for 1h. Receptor 
localization was determined by immunofluorescence using a monoclonal fluorescein-conjugated 
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(green) secondary antibody.  There was a clear reduction of the R122C variant expression at the cell 
surface and significant intracellular accumulation  (B) Agonist-dependent internalization is 
significantly impaired in the R122C variant receptor. 1321N1 cells stably expressing HA-tagged wild 
type or R122C variant receptor constructs were challenged with ADP (10 µM; 0-60 min) to induce 
receptor internalization and surface receptor loss was subsequently assessed by ELISA. The data 
represent means  S.E.M. of five independent experiments. (C) The R122C variant receptor is 
preferentially targeted to lysosomes following agonist-independent internalization. 1321N1 cells 
stably expressing HA-tagged receptor constructs were preincubated with a monoclonal anti-HA at 4
o
 C 
for 1h. Subsequently cells were incubated at 37
o
 C for 60 min in the absence of ADP. Receptor 
localization was determined by immunofluorescence in fixed cells and visualised using a monoclonal 
fluorescein-conjugated (green). Receptor colocalization with either rhodamine-conjugated transferrin 
(red) or lysotracker blue (blue) which label early and recycling endosomes or lysosomes respectively 
is shown.  Data shown are representative of three independent experiments.  Work performed by 
Stuart Mundell and colleagues (40).
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PLATELETS AND THROMBOPOIESIS      
 
 
Evaluation of participants with suspected heritable platelet function disorders 
including recommendation and validation of a streamlined agonist panel 
Ban B. Dawood,1 Gillian C. Lowe,1 Marie Lordkipanidze´ ,1 Danai Bem,1 Martina E. Daly,2 Mike Makris,2 Andrew Mumford,3 
Jonathan T. Wilde,4 and Steve P. Watson1 
1Department of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom; 2Department of 
Cardiovascular Science, University of Sheffield, Sheffield, United Kingdom; 3Bristol Heart Institute, University of Bristol, Bristol Royal Infirmary, Bristol, United 
Kingdom; and 4Adult Haemophilia Centre, Queen Elizabeth Hospital, Birmingham, United Kingdom 
 
Light transmission aggregometry (LTA) is 
used worldwide for the investigation of 
heritable platelet function disorders 
(PFDs), but interpretation of results is 
complicated by the feedback effects of 
ADP and thromboxane A2 (TxA2) and by 
the overlap with the response of healthy 
volunteers. Over 5 years, we have per- 
formed lumi-aggregometry on 9 platelet 
agonists in 111 unrelated research partici- 
pants  with  suspected  PFDs   and   in 
70 healthy volunteers. Abnormal LTA or 
ATP secretion test results were identified 
in 58% of participants. In 84% of these, 
the patterns of response were consistent 
with defects in Gi receptor signaling, the 
TxA2 pathway, and dense granule secre- 
tion. Participants with defects in signal- 
ing to Gq-coupled receptor agonists and 
to collagen were also identified. Targeted 
genotyping identified 3 participants with 
function-disrupting mutations in the P2Y12 
ADP and TxA2 receptors. The results of 
the present study illustrate that detailed 
phenotypic analysis using LTA and ATP 
secretion is a powerful tool for the diagno- 
sis of PFDs. Our data also enable subdivi- 
sion at the level of platelet-signaling path- 
ways and in some cases to individual 
receptors. We further demonstrate that 
most PFDs can be reliably diagnosed 
using a streamlined panel of key platelet 
agonists and specified concentrations 
suitable for testing in most clinical diag- 
nostic laboratories. (Blood. 2012;120(25): 
5041-5049) 
 
BLOOD, 13 DECEMBER 2012 · VOLUME 120, NUMBER 25 
 
5041 
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Dear Sirs, 
Hermansky-Pudlak syndrome (HPS) is an autosomal recessive disorder characterised by 
oculocutaneous hypopigmentation and a bleeding diathesis caused by a lack of dense granules 
in platelets. HPS is genetically heterogeneous with variable skin, hair, and iris 
hypopigmentation, and visual impairment. In addition, some forms of HPS give rise to 
granulomatous colitis and pulmonary fibrosis (1). HPS has been associated with mutations in 
nine human genes: HPS1 (mouse model pale ear), AP3B1/HPS2 (pearl), HPS3 (cocoa), HPS4 
(light ear), HPS5 (ruby-eye 2), HPS6 (ruby-eye), HPS7/dysbindin (sandy), HPS8/reduced 
pigmentation and HPS9/pallid (2,3). In addition, genes have been identified for a further six 
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mouse models of HPS (mocha, gunmetal, ashen, muted, buff, and subtle gray) (2). In general, 
HPS is a rare disorder, but HPS1 has a high prevalence in northwest Puerto Rico (1/1,800) 
due to a founder mutation (4). 
The large numbers of potential HPS culprit genes (>118 coding exons), together with 
minimal guidance offered by the genotype-phenotype correlations between HPS genes, 
provides a significant challenge for the molecular diagnosis of these disorders. In cases with 
suspected consanguinity, autozygosity mapping can be used as a high speed tool to prioritise 
mutation screening for a specific HPS gene (5). Further, this can be facilitated using 
microsatellite markers flanking the HPS genes to exclude genes in the case of heterozygous 
markers/haplotypes and prioritise direct sequencing of specific genes where autozygosity is 
noted. We illustrate the proof of principle of this approach in the identification of the second 
case of a mutation in the HPS7 (encoding Dysbindin) gene in a patient with a bleeding history 
and hypopigmentation. 
A 77-year-old Caucasian female was referred to the bleeding disorder clinic with a lifelong 
bleeding tendency (▶Figure 1 A). There was no history of a bleeding disorder in this 
participant’s half siblings, parents or children. Her parents were first cousins. She had pale 
skin and hair and had reduced visual acuity and nystagmus throughout life. She also had 
spontaneous epistaxes as a teenager which lasted for several hours and required medical 
attention, and several episodes of prolonged bleeding from minor injuries that required 
surgical haemostasis. She bled for several days after dental extractions in her twenties and 
thirties and required packing of the tooth sockets to control the bleeding. She had menorrhagia 
from menarche which eventually necessitated a hysterectomy at the age of 37. She 
experienced heavy post partum bleeding after all of her three vaginal deliveries. Surgical 
procedures in this patient, including surgery for an ectopic pregnancy in the 1960s, abdominal 
hysterectomy and salpingo-oophrectomy in 1971 and excision of a lipoma from her back in 
2002, were followed by prolonged bleeding requiring blood product transfusion. She had two 
episodes of severe per-rectal bleeding. The first one occurred in 1979 and was attributed to a 
rectal polyp which was surgically removed. She bled significantly after this procedure and 
required a platelet transfusion. A further episode occurred in 2009 which was attributed to 
Crohn’s disease. During this episode the patient required red cell and platelet transfusions and 
tranexamic acid and was being considered for a right hemicolectomy at the time of her 
haematology referral. Colonic biopsies showed florid granulomatous inflammation with no 
co-existing infection (▶Figure 1 B). Acid fast bacilli were absent. She was reviewed by a 
respiratory physician in 2010 and had no evidence of any respiratory disease, with normal 
lung function tests (FEV1 100% predicted, FVC 95% predicted, TLC 80% predicted and 
KCO 105% predicted, all within normal ranges). A chest radiograph showed no active lung 
disease, and a computed tomography scan of the thorax with contrast showed no convincing 
features of fibrosis. 
The patient gave informed consent and was recruited to the GAPP (Genotyping and 
Phenotyping of Platelets, NIHR ID 9858, Regional Ethics Committee reference 
06/MRE07/36) study. Platelet function testing was performed on platelet-rich plasma (PRP) 
by lumiaggregometry using Chronolume® to assess secretion. The response to intermediate 
concentrations of PAR-1 peptide (30 μM) and collagen (1 μg/ml) was reduced relative to the 
control on the day and also a panel of over 70 healthy volunteers. Normal aggregation was 
observed at higher concentrations of these agonists (not shown). A lack of dense granule 
secretion with the entire panel of agonists tested (6) was noted, as illustrated for PAR-1 and 
PAR-4 peptides in ▶Figure 1C and D. The lack of platelet ATP secretion was consistent with 
an absence of platelet dense granules, and in combination with the patient’s clinical features 
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were diagnostic of HPS. Such platelet function testing has previously been shown to be 
successful in diagnosing other HPS patients with complete lack of secretion from platelet 
dense granules (5, 6). 
DNA was extracted from peripheral blood, and genetic studies were undertaken. As the 
patient’s parents were related by blood, we were able to apply autozygosity linkage mapping 
by genotyping several microsatellite markers flanking all of the known human HPS genes 
(see Suppl. Table 1, available online at www.thrombosis-online.com). This was carried out to 
prioritise a limited number of HPS genes for direct sequencing. Strikingly the only HPS locus 
that displayed autozygosity for both flanking markers and over an extended region of genetic 
distance was the HPS7 locus. Therefore the most likely candidate HPS gene was 
HPS7/Dysbindin on chromosome 6p22.3. The 10 coding exons of DTNBP1 (encoding 
dysbindin) including exon-intron boundaries were PCR-amplified and sequenced. Sequencing 
of DTNBP1 revealed a homozygous nonsense mutation in exon 4 (c.177 G>A; p.Trp59Stop) 
confirming a diagnosis of HPS type 7 (Fig 1E). 
Dysbindin is important for normal platelet-dense granule and melanosome biogenesis and is 
mutated in the sandy (sdy) mouse (7). Dysbindin is a component of the biogenesis of 
lysosome-related organelles complex 1 (BLOC-1) which regulates trafficking to lysosome-
related organelles. The BLOC-1 complex is ubiquitously expressed and along with Dysbindin 
contains seven predicted coiled-coil-forming proteins (pallidin, muted, cappuccino, snapin, 
BLOC1S1, BLOC1S2 and BLOC1S3) (8), all of which are associated with Hermansky-
Pudlak syndrome in mice. 
The only previously reported HPS7 mutation in humans was a homozygous nonsense 
mutation (p.Q103X) found in a 48-year-old Portuguese woman with oculocutaneous 
hypopigmentation, ease of bruising and a bleeding tendency. She had mild shortness of breath 
on exertion and reduced lung compliance but otherwise normal pulmonary function (8). 
Although the patient described here has been diagnosed with Crohn’s disease, it is likely that 
this represents granulomatous colitis given the histological findings reported on colonic 
biopsy. She has no evidence of pulmonary fibrosis. Colitis has been reported in HPS1, HPS3 
and HPS4, and pulmonary fibrosis in HPS1, HPS4 and HPS2 (9, 10, 11). 
In conclusion, we report a novel mutation in the HPS7 (Dysbindin) gene causing a 
premature stop codon which was rapidly identified following autozygosity mapping using 
microsatellite markers. This high-speed technique provides a rapid approach to identify 
candidate HPS genes for Sanger sequencing in order to identify a disease causing mutation. 
An alternative method to identify the genetic defect in this patient would have been to utilise 
second generation sequencing strategies such as whole exome sequencing or custom built 
arrays; however, this would have been far more costly and time consuming given the 
consanguinity in this family which we exploited to narrow down the culprit gene. Despite 
having had numerous hospital visits and lifelong excessive bleeding, the cause of this 
patient’s bleeding was not elucidated until she was in her eighth decade. Mild inherited 
platelet disorders should therefore be considered in patients presenting with excessive 
bleeding later in life. 
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Figure 1: Identification of the second HPS7 mutation in a patient with Hermansky-Pudlak 
syndrome presenting late in life. A) Pedigree of a consanguineous family with Hermansky-Pudlak 
syndrome. The affected individual is represented by a solid symbol. B) Images of a colonic biopsy 
from the patient in low power (upper panel) and high power (lower panel). Both images show 
inflammatory infiltrates and granulomata with numerous giant cells, alongside normal bowel 
mucinous glands. No caseous necrosis is seen, and special stains showed no evidence of micro-
organisms (including mycobacteria). C and D) Absence of secretion (black trace) to high doses of 
PAR-1 peptide 100 µM (C) and PAR-4 peptide 500 µM (D) in this patient. Left-sided Y axis depicts 
percentage aggregation, and right-sided Y axis represents platelet ATP secretion assessed using 
Chronolume®. 1.6 nmol of ATP standard were added to each cuvette in order to calculate absolute 
secretion and secretion normalised to platelet count in PRP for both patient and control. E) 
Identification of a homozygous single base substitution (c.177 G>A) in Dysbindin leading to a 
premature stop codon (p.Trp59Stop). Sanger sequencing showing wild-type and mutant DTNBP1 
sequence traces. The position of the mutation is indicated by the boxed regions. 
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Summary 
A small number of thromboxane receptor variants have been described in patients with a 
bleeding history that result in platelet dysfunction. We have identified a patient with a history 
of significant bleeding, who expresses a novel heterozygous thromboxane receptor variant 
that predicts an asparagine to serine substitution (N42S). This asparagine is conserved across 
all class A GPCRs, suggesting a vital role for receptor structure and function. We investigated 
the functional consequences of the TP receptor heterozygous N42S substitution by 
performing platelet function studies on platelet-rich plasma taken from the patient and healthy 
controls. We investigated the N42S mutation by expressing the wild-type (WT) and mutant 
receptor in human embryonic kidney (HEK) cells. Aggregation studies showed an ablation of 
arachidonic acid responses in the patient, whilst there was right-ward shift of the U46619 
concentration response curve (CRC). Thromboxane generation was unaffected. Calcium 
mobilisation studies in cells lines showed a rightward shift of the U46619 CRC in N42S-
expressing cells compared to WT. Radioligand binding studies revealed a reduction in BMax 
in platelets taken from the patient and in N42S-expressing cells, whilst cell studies confirmed 
poor surface expression. We have identified a novel thromboxane receptor variant, N42S, 
which results in platelet dysfunction due to reduced surface expression. It is associated with a 
significant bleeding history in the patient in whom it was identified. This is the first 
description of a naturally occurring variant that results in the substitution of this highly 
conserved residue and confirms the importance of this residue for correct GPCR function.  
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Introduction 
Platelet activation is a tightly regulated process that is required for haemostasis, dysregulation 
of which can result in thrombosis and vessel occlusion. Platelet activity is regulated by a 
number of cell surface receptors, including several G-protein coupled receptors (GPCRs). The 
thromboxane receptor (TP-α isoform) is a GPCR expressed on platelets in addition to a 
variety of other cell types including macrophages, vascular endothelial cells and smooth 
muscle cells (1). 
Thromboxane A2 (TXA2) generated by platelets acts in an autocrine manner on TP-
receptors which signal via phospholipase A2 and Rho to cause platelet activation. This 
pathway is currently targeted by aspirin, which exerts its antiplatelet effects by inhibition of 
cyclooxygenase enzymes (COX-1); however, there is considerable interest in developing 
direct TP receptor antagonists in order to preserve the beneficial effects of prostaglandins 
(such as gastric mucosal protection) that are lost upon global COX inhibition (2, 3). 
As with most GPCRs, a large number of mutagenesis studies have been carried out with the 
TP receptor in order to further understand structure-function relationships. However, studying 
the impact of such mutations on platelet function is not possible; therefore an alternative 
approach is to study patients with naturally occurring mutations within platelet receptors, such 
as TP-α. Thromboxane receptor deficiency (MIM #614009) is inherited in an autosomal 
dominant manner and is associated with mild mucocutaneous bleeding (4). To date one 
quantitative defect causing reduced TP receptor expression (4) and three qualitative defects 
caused by TP receptor amino acid substitutions have been reported (5-7). Importantly, the 
naturally occurring variants that resulted in amino acid substitutions all provided important 
insights into structure-function of the endogenous TP receptor. For example the R60L variant 
resulted in reduced G protein coupling (5), whereas the D304N substitution caused an 
impairment in ligand binding (6). More recently, characterisation of the W29C variant 
showed that this tryptophan residue in TMD1 is critical for efficient receptor expression at the 
cell surface (7). 
As part of the UK Genotyping and Phenotyping of Platelets (GAPP) consortium we have 
identified a number of mutations in receptor genes in patients with a bleeding tendency (8, 9). 
Here we used this approach to identify a novel thromboxane receptor defect in a patient with a 
bleeding history. The patient was heterozygous for an asparagine to serine substitution at 
position 42 (N42S) of the TP receptor that resulted in impaired receptor surface expression 
and platelet dysfunction. This is the first description of a naturally occurring variant that 
causes substitution of this highly conserved asparagine residue and validates findings from 
crystallography studies with other GPCRs (10, 11). 
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Methods 
Materials 
Dulbecco’s modified Eagle’s medium (DMEM), Lipofectamine 2000 and fetal bovine serum 
(FBS), anti-HA-monoclonal antibody (HA-11), goat anti-mouse rhodamine, FITC and 
rhodamine-conjugated secondary antibodies and Fura-2 AM were purchased from Invitrogen 
(Carlsbad, CA, USA). Complete protease inhibitor tablets were from Roche. Arachidonic acid 
(AA) and rabbit polyclonal TP receptor antibody was purchased from Cayman Chemical 
(Ann Arbor, MI, USA). U46619 was purchased from Sigma Aldrich (St. Louis, MO, USA). 
PAR-1 receptor specific peptide (SFLLRN) was from Alta Biosciences (Birmingham, UK), 
collagen was from Nycomed (Zurich, Switzerland). Ristocetin was from Helena Biosciences 
(Tyne and Wear, UK). Radiochemicals were from Perkin Elmer Life Sciences (Waltham, 
MA, USA). The ELISA alkaline phosphatase substrate kit was from BioRad (Hercules, CA, 
USA). All other reagents were from Sigma. 
 
Ethics 
This study was approved by the National Research Ethics Service Committee West 
Midlands–Edgbaston (REC reference: 06/MRE07/36, ISRCTN 77951167, UKCRN ID 9858), 
and participants and controls gave written informed consent in accordance with the 
Declaration of Helsinki. Relevant NHS permissions were obtained in all participating 
institutions. 
 
TBXA2R sequencing 
Genomic DNA was purified from EDTA-anticoagulated blood using the Maxwell 16 DNA 
purification system (Promega, Madison, WI, USA). The TBXA2R gene was PCR amplified 
from genomic DNA. PCR reactions were performed in 15µl volumes using OneTaq PCR 
master mix (New England Biolabs, Ipswich, MA, USA). PCR products were treated with 
ExoSAP-IT (Affymetrx, Santa Clara, CA, USA) and sent to DBS Genomics (University of 
Durham, UK) for Sanger Sequencing. 
 
Platelet function studies 
 
Blood was drawn by venipuncture through a 21-gauge needle into evacuated tubes containing 
3.8% sodium citrate. Platelet function was assessed using light transmission aggregometry as 
described previously (17). Platelet-rich plasma (PRP) was prepared by centrifugation of 
whole blood at 200g for 10 minutes (min) and platelet-poor plasma (PPP) by further 
centrifugation at 1,000g for 10 min. Platelet aggregation was measured in PRP using a dual 
Chronolog lumiaggregometer in response to ADP, adrenaline, arachidonic acid, PAR-1 
receptor specific peptide (SFLLRN), collagen, U46619 and ristocetin. ATP secretion was 
assessed using the Luciferin-Luciferase reagent (Chrono-Lume®, Chrono-log Corp., 
Columbia, MD, USA) and an ATP standard solution. 
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96-well plate aggregometry – Optimul assay  
Platelet aggregation in response to AA (0.03 – 1 mM), ADP (0.005 – 40 µM), and U46619 
(0.005 – 40 µM) was assessed by 96-well plate aggregometry. The method is based on light 
transmission through a 96-well plate pre-coated with increasing concentrations of the agonists 
and assesses platelet aggregation in PRP. 
 
Plasma thromboxane (Tx) B2 assay 
After aggregation, indomethacin (30 µM) was added in relevant wells to stop COX 
activity. The whole plate was then centrifuged (1,300 g for 10 min) at room temperature and 
the supernatants were frozen at -80ºC. TxB2 levels were determined by a competitive 
immunoassay (Cisbio Bioassays, Codolet, France). 
  
Radioligand binding 
TP and P2Y12 receptor ligand binding surface expression was determined by ligand binding in 
fixed platelets and human embryonic kidney (HEK) cells as previously described (6, 12). 
After incubation with [
3
H] SQ29548 (3 Ci mM
-1
, 0.01–2 µM) for 20 min at room temperature, 
either in the presence or in the absence of unlabelled ligand (10 µM), reactions were 
terminated with ice-cold binding buffer and rapid filtration through Whatman GF/C glass 
fiber filters under vacuum. Radioactivity bound to the filters was measured by scintillation 
counting. Control experiments were performed with the non-specific P2Y purinergic receptor 
ligand [
3
H] MeSADP (3 Ci [111 GBq mM]) in the absence or presence of the P2Y12 receptor 
antagonist AR C69931MX (10 µM), to determine P2Y12 receptor-specific radioligand 
binding. 
 
Generation of receptor constructs and mutagenesis 
N-terminally FLAG-tagged TP receptor constructs were generated by PCR. The N42S 
mutation was introduced using the primer-extension overlap PCR mutagenesis method and 
subcloned into the BamH1 and EcoR1 sites in pcDNA3.1+. 
 
Cell culture and transfection 
HEK293 cells were cultured in DMEM, 10% fetal calf serum, 100 units ml
−1
 penicillin, and 
100 μg ml−1streptomycin and maintained at 37°C, 5% CO2. Cells were transiently transfected 
with receptor DNA or pcDNA3 using LIPOFECTAMINE 2000 (Life Technologies, Paisley, 
UK) according to manufacturer’s instructions. All assays were performed 48 hours (h) post-
transfection.  
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Measurement of cytosolic Ca
2+
 concentration ([Ca2+]i) 
HEK293 cells were grown in clear bottom, black 96-well plates (Costar). Cells were washed 
with HEPES-buffered saline buffer (HBBS; 130 mM NaCl, 3 mM KCl, 10 mM HEPES, 1 
mM MgCl2, 2 mM CaCl2, and 30 mM D-glucose, pH 7.3) and loaded with the 3 µM Fura-2 
calcium sensitive dye for 1 h at 37°C. Cells were washed with HBBS and maintained at room 
temperature. Changes in intracellular calcium upon agonist stimulation were measured using a 
Flexstation III microplate reader (Molecular Devices, Sunnyvale, CA, USA). 
 
ELISA 
Surface receptor loss was assessed by immunosorbent assay (ELISA) as described previously 
(13, 14). Cells were split into 24-well tissue culture dishes coated with 0.1 mg/ml poly-L-
lysine. Twenty-four hours later, cells were fixed with paraformaldehyde (4%). Surface 
receptor assessed using a monoclonal anti-HA (HA-11 1:1,000) antibody or monoclonal anti-
FLAG (1:500) antibody. Receptor levels were subsequently determined by ELISA and 
expressed as % surface receptor with the background signal from pcDNA3-transfected 
controls subtracted from all receptor-transfected values. 
 
Immunofluorescence microscopy 
Cellular distribution of tagged receptors in HEK cells was assessed by immunofluorescence 
microscopy (13). Briefly cells were grown on poly-L-lysine coated coverslips. Twenty-four 
hours later, receptor distribution was assessed using a primary anti-FLAG antibody or anti-
HA- polyclonal antibody (1:200) and the appropriate fluorescent-conjugated secondary 
antibody (1:200). For experiments where surface and total where visualised in the same cells, 
anti-FLAG antibody and FITC-conjugated secondary antibody were first added to non-
permeabilsed cells to label surface receptor, and total receptor was stained with anti-FLAG 
antibody and Rhodamine-conjugated secondary antibody following permeabilisation. 
Confocal microscopy was carried out on a Leica SP5-AOBS confocal laser scanning 
microscope attached to a Leica DM I6000 inverted epifluorescence microscope with phase-
contrast and a Plan-Apo 63 x 1.40 NA oil immersion objective. All images were collected on 
Leica TCS-NT software for 2D and 3D image analysis and processed using Adobe Photoshop 
CS3. 
 
Immunoblotting 
Washed platelets were lysed and subjected to SDS-PAGE, as previously described (15). 
Immunoblotting was carried out as using a TP-receptor antibody (1:1,000). 
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Clinical history 
The patient was a 64-year-old female who had a history of menorrhagia from menarche that 
ultimately necessitated hysterectomy, excessive post-operative and post dental surgery 
bleeding, prolonged bleeding from minor cuts and a tendency to bruise easily. She had a 
raised ISTH bleeding assessment score of 13 (95
th
 centile of score in previously tested healthy 
volunteers in the GAPP study = score of 4) (16). She had not experienced any life-threatening 
bleeding episodes and had no co-morbidities. The patient had a daughter with menorrhagia 
and a sister with a history of easy bruising; however, both these family members were 
unfortunately unavailable for further study. There was no obvious history of excessive 
bleeding in either of the patient’s parents. This history was indicative of a platelet function 
disorder as initial coagulation screening laboratory investigations were normal and the patient 
was recruited to the GAPP study, in which detailed platelet function testing was performed as 
previously described (17). 
 
Results 
Platelet phenotyping 
Platelet aggregation and secretion in PRP was assessed by lumi-aggregometry and a luciferase 
assay, respectively, at three distinct time points over three years. The platelet count in PRP 
was within the normal range. Platelet aggregation and secretion to 1 mM and 1.5 mM 
arachidonic acid was consistently absent in the patient whereas these concentrations caused 
full aggregation of platelets collected from a healthy volunteer on the same day, and in 
previously tested healthy volunteers (▶Figure 1A, B and D). Aggregation in response to 3 µM 
U46619 (synthetic thromboxane analogue) was also markedly reduced and reversible in the 
patient, whereas it elicited full aggregation in the control on the same day as well as in a bank 
of local controls (▶Figure 1C). Secretion in response to these agonists was also abrogated in 
the patient (▶Figure 1A-C). Aggregation in response to a range of other agonists was also 
tested (▶Figure 1D). There was also a reduction in platelet responsiveness to ADP, adrenaline 
and intermediate concentrations of collagen and PAR-1 peptide, consistent with the 
amplification role of TxA2 in platelet activation. 
These findings were consistent with 96-well plate aggregometry data (Optimul assay) 
which also showed absent aggregation in the patient at a range of arachidonic acid 
concentrations (▶Figure 1E) and a significantly right-shifted U46619 CRC (▶Figure 1G; 10-
fold shift, EC50 0.22 µM vs 2.95 µM in healthy volunteers and the patient, respectively). 
Interestingly, the Optimul assay showed no difference in ADP responsiveness (▶Figure 1F), 
whereas there the patient showed reduced responsiveness to adrenaline and collagen (data not 
shown). 
To rule out the possibility of a defect in arachidonic acid metabolism, thromboxane 
generation was measured. The plasma TxB2 levels in the patient were 40.7 ng / 1 x 10
8
 
platelets, which is within the normal range and not significantly different from mean data 
previously collected from healthy controls (▶Figure 2). The normal COX activity in the 
patient, combined with reduced responsiveness to the direct-acting agonist, U46619 suggested 
a defect at the level of the thromboxane receptor. The reduced responses to other 
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thromboxane-dependent agonists, such as adrenaline and intermediate dose collagen 
concentrations can also be explained by incomplete activation of the thromboxane receptor 
resulting in reduced amplification and secondary mediator generation. 
 
Identification of the TBXA2R N42S mutation 
In light of the platelet phenotyping data, we sequenced the TP receptor gene TBXA2R. All 
three exons of TBXA2R were PCR amplified and sequenced, covering the entire 343 amino 
acid coding region. The patient was found to harbour a c.125 A>G transversion in exon 2 of 
TBXA2R that predicted a novel heterozygous missense mutation resulting in an asparagine to 
serine substitution at position 42 in TMD1 of the receptor. Interestingly, this asparagine 
residue (1.50 Ballesteros-Weinstein numbering) is the most highly conserved residue across 
class A GPCRs and crystallographic structure of rhodopsin suggests it is involved in a series 
of stabilising interactions (10). Furthermore, an asparagine to serine change in the 
thromboxane receptor at this position was predicted to be damaging using the PolyPhen-2 tool 
(18) (using both HumDiv and HumVar training datasets) and deleterious using the 
PROVEAN tool (19). 
 
Heterologous expression of variant N42S TxA2R 
In order to test the functional impact of the N42S mutation, FLAG-tagged constructs of wild-
type (WT) or N42S TP receptor were generated and transiently transfected into HEK293 
cells. The ability of the WT and N42S receptor to signal was examined by measuring changes 
in cytosolic Ca
2+
 concentration in response to U46619. The CRC for N42S-expressing cells 
was right-shifted compared to WT (EC50 WT 29 nM vs N42S 0.1 µM) without any decrease 
in the maximal response reached (▶Figure 3A). These findings were consistent with the 
reduced U46619-induced aggregation seen in the patient (▶Figure 1). 
To further investigate why there was a reduction in the ability of the N42S variant to 
function both in platelets and in cell lines, we measured binding of the TP receptor antagonist 
[3H]- SQ29548 to HEK293 cells expressing the WT or variant N42S receptor. Binding of 
[3H]-SQ29548 to transfected HEK293 cells was saturable and maximal at a ligand 
concentration of 0.6 µM (▶Figure 3B). Maximum binding of [3H]-SQ29548 to cells 
expressing N42S TP receptor was reduced by more than 60% compared with those expressing 
WT receptor (Bmax N42S 235 ± 12 dpm/mg protein; WT 628 ± 27 dpm/mg protein; ▶Figure 
3B). Furthermore, there was almost a three-fold shift in the binding affinity of [3H]-SQ29548 
to HEK293 cells expressing N42S compared to WT (Kd WT 74 ± 16 nM; N42S 200 ± 40 
nM). 
To investigate whether there were changes in maximal ligand binding in the patient 
harbouring the N42S variant, we carried out radioligand binding studies on washed platelets 
taken from the patient and four healthy controls. Interestingly, there was a 63% (Bmax control 
355 ± 18 dpm/mg protein; patient 130 ± 15 dpm/mg protein) loss of TP receptor surface 
binding sites in the patient, as compared to healthy controls (▶Figure 3C), higher than might 
be predicted given that the patient is heterozygous for the N42S change. There was no change 
in total receptor expression (▶Figure 3E). There was no difference in P2Y12 receptor surface 
binding sites between the patient and the control (▶Figure 3D). These data suggest surface 
expression of the N42S variant receptor is significantly reduced compared to WT. 
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N42S results in reduced receptor surface expression in cells lines 
To further confirm whether the reduction in N42S TP receptor function was due to a loss of 
surface expression, a cell surface ELISA approach was used to quantify receptor levels. These 
data showed a dramatic reduction in cell surface expression of the N42S variant in HEK293 
cells (3.6 ± 7.3% of WT controls; ▶Figure 4A). These data were reproducible in Chinese 
hamster ovary (CHO) cells (data not shown) suggesting the lack of surface expression was 
due to the mutation and not to a cell line-specific effect. Immunofluoresence experiments 
were carried out to visualise localisation of the WT and N42S TP receptors. Sequential 
staining with an anti-FLAG antibody was carried out in non-permeabilised and permeabilised 
cells to label surface and total receptor, respectively. WT receptor was localised to the cell 
surface whereas, in agreement with the ELISA data, there was neglible surface expression of 
the N42S variant (green staining, ▶Figure 4B). Total receptor expression was not affected. 
 
Co-expression of WT receptor does not rescue surface expression of Asn42Ser 
Since the patient is heterozygous for the N42S variant receptor, it is predicted that she will 
express both the WT and N42S receptor in equal proportions. In an attempt to replicate this in 
cell lines, tagged WT and N42S constructs were co-transfected into the same cells. 
Interestingly, in HEK293 cells, co-expression of HA-tagged WT receptor with the FLAG-
tagged N42S TP receptor did not rescue expression of the N42S variant (▶Figure 5A). 
Furthermore, surface expression of the WT receptor was significantly reduced in presence of 
N42S (▶Figure 5B). Imaging of both the WT and N42S receptors in co-transfected cells 
revealed that the receptors were co-localised intracellularly (▶Figure 5C). Taken together, 
these data suggest that in addition to poorly expressing at the cell surface, the N42S receptor 
also causes intracellular retention of the WT receptor. These observations may explain why 
there was a larger than expected reduction in TP receptor surface expression in the 
heterozygous patient. 
 
Discussion 
Using the GAPP approach, we have identified a number of rare function-disrupting mutations 
in GPCRs, including two TP receptor variants (6, 17). We now report a further novel 
heterozygous TP receptor variant, N42S which results in reduced surface expression and thus 
reduced receptor function. Platelet phenotyping data showed loss of platelet responsiveness to 
arachidonic acid and U46619 with normal COX activity, which was consistent with a TP 
receptor defect. This report takes the number of TP receptor variants identified in patients 
with abnormal bleeding to a total of five, indicating that these remain rare contributors to 
bleeding risk even in selected populations. It is possible that this patient had other 
unidentified factors which also contributed to her bleeding phenotype, consistent with a 
multifactorial model for individual bleeding risk. 
The patient described here had a history of significant post-operative and mucocutaneous 
bleeding. Three of the previously identified TP variants (c.167dupG, R60L & D304N) were 
also identified in patients with mucocutaneous bleeding (4-6), whereas the W29C patient had 
abnormal post-operative bleeding without a history of mucocutaneous bleeding (20). 
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However, similarly to reported P2Y12R mutations, these patients had family members who 
harboured the same heterozygous change in the TBXA2R gene, but did not have any bleeding 
symptoms (6, 20). In the absence of a family study, which would be recommended wherever 
possible in all patients with excessive bleeding and a potential causative genetic lesion, it is 
impossible to confirm whether the N42S mutation is causing the significant bleeding seen in 
the patient. Interestingly, however, the patient did have family members with menorrhagia 
and a history of easy bruising, although unfortunately these were unavailable for further 
study. It is possible that there are other unidentified factors that are contributing to bleeding 
symptoms. In the platelet function studies we were unable to detect any responses to the 
endogenous agonist, arachidonic acid in either the LTA or in the Optimul assay, which is in 
line with a “all-or-none” type of response seen with this agonist. Specific assessment of the 
TP receptor with the synthetic agonist, U46619, showed that platelet responses were strongly 
impaired in response to low and intermediate concentrations, whereas very high 
concentrations were able to elicit full aggregation in the patient despite a significant reduction 
in surface expression, a finding which is likely explained by receptor reserve. As 
thromboxane is involved in the amplification of other platelet responses (21), it is possible 
that loss of TP receptor function could have a more profound effect in vivo. Reduced platelet 
activation could also result in reduced thrombin generation, which may also contribute to 
impaired global haemostasis. 
This study also provides important insights into endogenous TP receptor structure and 
function. Asparagine 42 (1.50 Ballesteros-Weinstein numbering) is the most highly conserved 
residue in class A GPCRs and has been shown to be involved in hydrogen bonding with 
Gly51, Ala299, Asp83 in bovine rhodopsin (10, 11), all of which are conserved in human TP-
α. Crystallographic studies suggest that this network of hydrogen-bonding stabilizes the 
packing of TMD1, 2 and 7. Furthermore, mutagenesis studies with the thyrotropin-releasing 
hormone receptor showed that substitution of this asparagine residue results in reductions in 
maximal ligand binding and affinity, in addition to an increased EC50 (22), observations 
which are consistent with the findings reported here. This is the first report of a naturally 
occurring mutation which results in the substitution of this highly conserved asparagine in 
TMD1 and demonstrates the importance of this residue to structure and function of an 
endogenously expressed GPCR. 
Cell line studies show that the N42S mutant receptor was retained intracellularly, likely in a 
Trans Golgi Network (TGN)/ER compartment (data not shown). Furthermore, the 
thromboxane receptor sequence also contains a potential arginine based-ER retention motif 
(RxR) within intracellular loop 3 (ICL3) of the receptor. These motifs have been shown to 
regulate anterograde traffic of proteins including GPCRs (23, 24). The notable intracellular 
localisation of this N42S variant and the ability of this site to interact with other residues 
through hydrogen bonding mean that this substitution has the potential to impact 
conformational rearrangement of the receptor. Such rearrangement may give rise to exposure 
to motifs such as the RxR motif, which may otherwise be masked in native WT form. This 
may result in impaired ER-to-plasma membrane export, although this remains to be explored 
in further detail. 
We recently described the characterisation of another TP receptor variant, W29C, which 
also resulted in reduced surface expression in platelets taken from a heterozygous patient and 
in cell lines expressing the mutant. Like the asparagine 42 residue, tryptophan 29 is also 
located in TMD1. Recent mutagenesis studies have also demonstrated the importance of 
TMD1 in the formation of TP receptor dimer formation at the cell surface (25). Interestingly, 
studies with the 5HT2C receptor also demonstrated that residues within TMD1 (N55 and W56) 
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played an important role in dimer formation (26). Therefore the reduction of N42S cell 
surface expression maybe, in part, due to disruption of interactions required for homodimer 
assembly at the cell surface. 
Here we show that in addition to reduced surface expression, N42S also causes intracellular 
retention of WT receptor. Efficient traffic of any protein through intracellular compartments 
such as the ER/Golgi apparatus can be directed through interaction with ER chaperone 
proteins such as calnexin (27). Calnexin targets N-linked glycoproteins and can direct the ER 
export of proteins or target misfolded proteins for intracellular retention through a glycan-
independent mechanism. Whilst the TP mutant described here results in a loss of an 
asparagine residue, the transmembrane positioning of this mutation makes it unlikely to be a 
residue for N-glycan addition due to its inaccessibillty within the ER lumen. The chaperone 
ANKRD13C has been implicated in biogenesis and ER exit of GPCRs, including TP-α (28). 
A possible explanation for the retention of the WT receptor may be the inability of WT-N42S 
heterodimers to interact efficiently with molecular chaperones in the ER. Taken together with 
previous studies, the description of the N42S variant provides further evidence for the role of 
TMD1 in regulating TP receptor surface expression. 
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What is known about this topic? 
Rare thromboxane (TP) receptor mutations associated with platelet dysfunction have previously been 
described in four index cases with bleeding symptoms. 
Mutagenesis studies together with the recently reported W29C variant suggest that transmembrane 
domain 1 (TMD1) of the TP receptor is important for cell surface expression. 
Asparagine 42 in TMD1 is a highly conserved residue across class A GPCRs and crystallography 
studies suggest it interacts with a number of other residues. 
 
What does this paper add? 
This is the first report of a naturally occurring receptor variant that results in substitution of this highly 
conserved asparagine and confirms its importance for function of an endogenously expressed GPCR. 
This study confirms the importance of the TMD1 for TP surface expression. 
The intracellular retention of WT receptors with the N42S variant may explain larger than expected 
platelet dysfunction in a heterozygous patient with a significant bleeding history. 
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Figure 1: Agonist-induced platelet activation in the patient. Light transmission aggregation and secretion of platelets in 
PRP from a healthy control or patient in response to A) A.A (1 mM), B) A.A (1.5 mM) or C) U46619 (3 µM). Key: Control 
aggregation (black), patient aggregation (blue), control secretion (green), patient secretion (black). (D) Quantification of all 
aggregation responses for patient, control and healthy volunteers. X axis shows agonist used (ADP = adenosine diphosphate, 
Adr = adrenaline, A.A.= arachidonic acid, U46619 is a direct TP receptor agonist, PAR-1=PAR-1 peptide (thrombin receptor 
agonist), Coll=collagen. Y axis shows aggregation. For all agonists other than adrenaline, this was measured at 5 min after 
agonist addition. Adrenaline-dependent aggregation was measured at 10 min post agonist addition. Ristocetin responses 
represent agglutination rather than aggregation. Data from healthy volunteers collected from responses of 68 individuals. E-
G) 96-well Optimul aggregometry. Aggregation dose-response curves to E) A.A, F) ADP and G) U46619 presented as 
median and interquartile range. Open squares represent healthy volunteers (n=50), black triangles represent the patient. 
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Figure 2: Thromboxane generation in the patient. TxB2 concentration in plasma supernatants from healthy volunteers and 
the participant with a thromboxane receptor mutation. The circles represent healthy volunteers, the triangles represent the 
participant with a thromboxane receptor mutation. Line and whiskers represent median and interquartile range; the grey band 
represents the normal range derived from a bank of healthy volunteers. 
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Figure 3: N42S mutant displays reduced ligand binding and signalling. A-B) HEK293 cells were transiently transfected 
with FLAG-tagged WT TP-α (black circles) or N42S (open circles). A) Changes in cytoplasmic calcium concentration 
[Ca2+]i were measured in fura-2/AM loaded cells before addition of U46619. (Data are mean ± SEM, n=3). B) TP receptor 
levels were measured with the use of TP receptor antagonist [3H]-SQ29548 (3 Ci/mmol, 0.01–2 ìM) in the presence of 
unlabelled ligand (10 ìM) to determine specific binding. Data are expressed as [3H]-SQ29548 binding (dpm) and represent 
means ± SEM of three independent experiments. C-D) Surface TP receptor (C) and P2Y12 purinergic receptor expression 
(D) was studied by measuring binding of the specific receptor ligands [3H]SQ29548 and [3H]MeSADP, respectively, in 
washed fixed platelets in the absence and the presence of unlabelled ligand to assess receptor-specific radioligand binding. 
Patient (open circles); healthy control (black circles). E) Total receptor expression was assessed in platelet lysates by SDS-
PAGE and immunoblotting with a TP-receptor antibody (Cayman).  
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Figure 4: Reduction in expression of N42S variant at the 
cell surface. Surface receptor levels were assessed in 
HEK293 cells were transiently transfected with FLAG-
tagged WT TP-α or N42S. A) FLAG tagged surface receptor 
was measured in fixed cells using an ELISA-based assay. 
Data are expressed as percentage of WT surface expression 
and represent mean ± SEM (n=3). B) WT and N42S 
expressing cells were stained for surface (green) and total 
receptor (red) using an anti FLAG antibody under non-
permeabilising and permeabilising conditions, respectively. 
Cells were imaged by confocal microscopy and are 
representative of three independent experiments. 
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Figure 5: Co-
expression of N42S 
with the WT receptor 
causes intracellular 
retention of WT TP 
receptor. HEK cells 
were transiently co-
transfected with HA-
WT TP-α and FLAG-
N42S. Surface 
expression of N42S 
(A) and WT (B) was 
assessed using anti-
FLAG and anti-HA 
antibodies, 
respectively, by cell 
surface ELISA (mean 
± SEM) (n=3). C) WT 
(green) and TP-α (red) 
were visualised in the 
same cells by staining 
with anti-HA and anti-
FLAG, respectively. 
Colocalisation in the 
merged images is 
shown in yellow. Cells 
were imaged by 
confocal microscopy 
and are representative 
of three independent 
experiments. 
 
 
 
